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Abstract 
Chelation therapy is widely used for metal-unbalance related diseases, namely those 
due to disorders on metal metabolism, such as beta-thalassemia, hemochromatosis 
(Fe), and neurodegenerative diseases (Cu, Fe, Zn and Al). The study of metal chelators 
for clinical applications, either as chelating therapeutics able to target specific metal 
ions in the body, or as metal-carriers for therapeutic or imaging purposes, is a topical 
research area which faces up to urgent medical problems. Metal-chelating drugs are 
used in many ways for the prevention, diagnosis and treatment of cancer, since cancer 
cells, like normal cells, require essential metal ions such as iron, copper and zinc for 
growth and proliferation. Chelators can target the metabolic pathways of cancer cells 
through the control of proteins involved in the regulation of these metals and also of 
other molecules involved in cell cycle control, angiogenesis and metastatic 
suppression. The thermodynamic aspects regarding the complexation of metal ions of 
medical interest are of primary importance for a correct understanding of the role of 
metals in human diseases in order to rationalize the design of new molecules for 
diagnostic and therapeutic purposes. A typical case is the treatment of metal overload 
diseases where the highest thermodynamic stability and largest selectivity of the 
complexes are crucial factors in the ligand design.  
This thesis is focused on the development and study of new compounds which, as a 
result of their strong interaction with specific metal ions, can be potentially used as 
pharmaceutical drugs for diagnosis or therapy. The work was performed with a 
multidisciplinary approach regarding mostly chemistry, but including also biochemistry 
and biology. 
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The work presented in this thesis is devoted to reach the following aims: 
 Design and synthesis of new multivalent ligands in order to enhance the 
efficiency and selectivity of both metal-interaction and biomolecular 
recognition of available ligands (or metal complexes), as well as the 
targeting for drug delivery; 
 Assessment of the most important physical and chemical properties of 
metal related compounds, namely metal-chelating efficacy and selectivity 
(thermodynamic and kinetic) with respect to other biometals or biological 
molecules, mostly in solution but also in silico; 
 Bioevoluation, in vitro and in vivo, for the most promising compounds. 
 
This thesis is divided in two chapters. Chapter I is dedicated to a description of 
Chelation Therapy for treating metal intoxication in humans. The importance of 
chelating agents in neurodegenerative diseases like Alzheimer disease, is introduced. 
The main aspects of Fe, Al, and Cu metabolism in humans are presented. The papers I, 
II, III and IV relative to this chapter has been appended. 
Chapter II describes the synthesis of the new studied ligands, and the experimental 
methods and techniques that were used for the investigation of the ligands and of 
their complexes with a number of metal ions. Important features of the used 
techniques are briefly described including basic principles, advantages and limitations. 
The papers V, VI, and VII explain in detail the developed work. 
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The main conclusions of this work are: 
 A new family of hydroxypyrone ligands (L4, L5, L6, L7, L8, and L9) has been 
synthesized and fully characterized. These ligands are easy and cheap to 
produce; 
 Complex formation equilibria showed good efficiency and selectivity for 
iron and aluminium. With Fe3+ various protonated 2:3 Fe:L species have 
been detected (with exception for L7). Experimental data give evidence of 
a strong chelating ability for L8 and, in order of decreasing ability, for 
ligands L5 > L4 > L9 = L6 > L7. Al3+ also forms 2:3 Al:L complexes with the 
ligands L4, L5, L6, and L9. The ligand with a shorter linker, L8, forms the 
most stable complexes of stoichiometry 2:2 (Al:L). Also Al3+ forms with L8 
the strongest complexes, and in order of decreasing stabilities with the 
ligands L6 > L5 > L4 > L9 > L7. 
 Studies in mice confirmed the high in vivo metal scavenging ability of the 
tetradentate ligands (L4, L5, L6, L8, and L9) in comparison with the 
corresponding bidentate (L7). The excellent chelating properties 
recommend further toxicological and pharmacological research on these 
new promising ligands. 
 
Keywords 
Chelation therapy, speciation, metal complexes, ligands, iron, aluminium, copper, 
hydroxypyrones, kojic acid  
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Chapter 1 
Chelation Therapy 
1.1. Introduction 
Chelation therapy is the process of removing from the body undesirable metal ions by 
administration of a drug, by injection or orally, that has suitable chelating properties. 
The concept of chelation derives from the Greek word “chele” that means claw of a 
lobster. 
The chelation therapy transforms the toxic metal ion in less dangerous species that can 
be excreted from the organism. Three different categories of metal toxicity can be 
distinguished, according to their sources and effects: 
 Acute ingestion of toxic metal ions, that can be accidental, as frequently 
happens to children, or caused by a voluntary homicidal or suicidal 
attempt; 
 Chronic intoxication, which may depend on environmental, 
occupational or iatrogenic causes; 
 Metal overload due to genetic diseases. 
The new chelating agents proposed in this thesis (see Chapter 2) are suitable for the 
third point.  
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The use of chelation therapy to treat metal intoxication was developed during the 20th 
century, initially to moderate the toxicity of arsenic compounds used to treat syphilis. 
British Anti Lewisite, BAL (2,3 dimercaptopropan-1-ol, see Fig. 1.1), was first 
synthesized at Oxford by Sir Rudolph Peters as an antidote for war chemical agents [1]. 
For security reasons it was declared to the scientific community only after the end of 
the war in 1945 [2]. It was the first antidote for metal intoxication. The use of citrate 
for the treatment of lead poisoning was also investigated, but with limited success. The 
polyamine carboxylic acids (EDTA) and, more effectively, diethylenetriaminepenta-
acetic acid (DPTA) were used to treat lead intoxication (see Fig. 1.1). These two 
compounds are administered by slow intravenous infusion and are poorly absorbed by 
the gastrointestinal tract. They distribute into extracellular regions and are rapidly 
excreted in urine. Toxic effects can arise from their ability to sequester essential metal 
ions such as Ca2+ and Zn2+, but these can be moderated by the use of CaNa2(EDTA), 
Ca2(EDTA),Zn2(EDTA) or ZnNa3(DPTA) instead of simple sodium salts. In the 1950s 
meso-2,3-dimercaptosuccinic acid (DMSA) and D,L-2,3-dimercaptopropane-1-sulfonic 
acid (DMPS) were used as metal sequestering agents (see Fig. 1.1). These chelators 
surpassed the unstable biologically and more toxic BAL. Also they have a stronger 
ability to access the intracellular metals [3].  
Sequestering agents specific to iron and copper were also developed to treat chronic 
diseases, that originate toxic effects due to metal imbalance. Such ligands are 
discussed in more detail in the Section 1.8. 
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EDTA DPTA 
   
BAL DMSA DMPS 
Figure 1.1. Structures of the various chelating agents used to treat cases of heavy metal 
poisoning. 
 
1.2. Metals as Essential Elements 
Essential elements are commonly classified as essential, inert, and toxic. The essential 
needs for the functioning of prokaryotic and eukaryotic cells require 17 metals of the 
30 essential elements. Many metal ions play a dual role in organisms physiology in 
function of the concentration range considered. Toxic compounds can be tolerated in 
low doses, and essential elements can become toxic at high concentrations (Fig. 1.2, 
see also the Bertrand diagram in paper I). 
Essential metals include copper, that is an essential cofactor for many oxidative 
enzymes, such as catalase and peroxidase, iron that is implied in hundred enzymatic 
reactions and is an essential component of hemoglobin (the oxygen carrier in red 
blood cells), and zinc that takes a role on enzymatic functions of more than three 
hundred proteins. Zinc deficiency that has been frequently identified in developing 
countries may lead to dwarfism, an adolescent nutritional deficiency. Cobalt is an 
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essential cofactor for vitamin B12 vital in protein formation and DNA regulation; 
manganese is a cofactor r in many enzymatic reactions involving phosphorylation, 
cholesterol and fatty acid synthesis; selenium is essential for a variety of enzymes, 
including several anti-oxidants. Contrary to animals, plants do not require selenium for 
their survival, but they absorb it and for this reason selenium poisoning can occur from 
eating plants grown in selenium rich soils. Molybdenum, an essential cofactor for 
xanthine oxidase and aldehyde oxidase, is also an essential element to plants 
functioning, required to fix nitrogen through bacteria [4].  
 
 
Figure 1.2. Essential and toxic metal ions. 
 
Metals and metal compounds (mercury and organometallic compounds) can be 
absorbed by ingestion, inhalation and absorption through the skin. Metals and metal 
compounds taken orally are mainly absorbed in the intestinal tract and absorption 
occurs through diffusion processes due to gradient concentrations. In particular, for 
essential metal elements such as iron there are special transport mechanisms. When 
inhaled, the water-soluble gases and vapors are dissolved in the mucous membranes 
of the tracheobronchial and nasopharyngeal regions, while those less soluble reach the 
end zones of the airways and the alveoli of the lungs, and then take the bloodstream 
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and lymphatic system. Once absorbed into the bloodstream, the metal ions and their 
compounds are linked to blood plasma proteins. Metals are distributed in the 
organism through the blood circle [5]. The behavior of a metal in physiological 
conditions depends essentially from its "chemical speciation", that means the different 
forms in which it is located in a given environment. From thermodynamic equilibria 
studies in solution and the values of the formation constants obtained for complexes, 
various species present in solution and their concentrations can be determined. 
Therefore, the thermodynamic approach can be applied for the study of ligands that 
interact with metal ions, essential for living organisms or toxic due to accumulation. 
These ligands are interesting for the biomedical point of view as they can be used as a 
therapy to remove toxic metals from the human body in diseases due to accumulation 
of heavy metals (chelation therapy). 
Chelation therapy occupies a central place in modern medicine and pharmacology, as 
continuous studies in laboratory and extensive clinical trials demonstrate that acute or 
chronic intoxication with a variety of metals (essential or non-essential) may be  
considerably improved by administration of a suitable chelating agent [6].  
 
1.3. Chelating Agents 
Chelating agents are organic or inorganic compounds capable of binding metal ions 
and form a complex ring-like structure called “chelates”. A chelating agent has ligand 
binding atoms that form either two covalent linkages, or one covalent and one co-
ordinate, or two co-ordinate linkages in the case of bidentate chelates. Mainly atoms 
like S, N and O act as ligand atoms in the form of chemical groups like –SH, –S-S, –NH2, 
=NH, –OH, –OPO3H, or >C=O. Bidentate or multidentate ligands form ring structures 
that include the metal ion and two-ligand atoms attached to the metal (Fig. 1.3). 
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Monodentate Ligand 
 
Bidentate Ligand 
 
 
Polydentate Ligand 
 
 
Figure 1.3. Formation of metal ligand complex using mono, bi, and 
polydentate ligands. 
 
Many donors act as bidentate ligands. Five-membered chelate rings are specially 
stable. There are also examples of inorganic chelate ligands which form five-
membered rings with metal ions. The stability of  the complex  respects the trend: 
monodentate < bidentate < tridentate…< hexadentate [3], due to chelate effect, that 
depends on entropic parameters. In order to explain this effect, consider the following 
equilibrium constants: 
Ni2+ (aq) + 6NH3 (aq)  [Ni(NH3)6]2+ (aq)  log = 8.61  (1.1) 
Ni2+ (aq) + 3en (aq)  [Ni en3]2+ (aq)   log = 18.28  (1.2) 
The system [Ni en3]
2+ (en = ethylenediamine, NH2CH2NH2) in which three chelate rings 
are formed is nearly 1010 times more stable than that without the formation of a ring.  
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Although the effect is not always so pronounced, this example can be considered as a 
general trend of the chelate effect. Taking into consideration the thermodynamic 
relationships: 
G ° = - RT ln         (1.3) 
G ° = H ° - TS °         (1.4) 
where G ° is the Gibbs free energy, R is the gas constant (1.987 cal mol–1 K–1), and T is 
the temperature. Thus,  increases as G ° becomes more negative (due to more 
negative H ° or more positive S °). As a very simple case, consider the following 
reactions (1.5 and 1.6) and the pertinent thermodynamic data for them, given in  
Table 1.1.  
Cd2+ (aq) + 4CH3NH2 (aq)  [Cd(NH2CH3)4]2+ (aq) log = 6.52  (1.5) 
Cd2+ (aq) + 2en (aq)  [Cd(en)2+] (aq)   log = 10.6  (1.6) 
Table 1.1. Thermodynamic data of a purely entropy-based chelate effect 
Ligands H° (kJ mol–1) S° (J mol–1 deg–1) -TS° (kJ mol–1) G° (kJ mol–1) 
4CH3NH2 -57.3 -67.3 20.1 -37.2 
2 en -56.5 +14.1 -4.2 -60.7 
 
In this case enthalpies are similar for the two reactions, and therefore the chelate 
effect can be attributed entirely to the entropy difference. Probably, the main cause 
for the large entropy increase in the two cases is the net increase in the number of  
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unbound water molecules. Thus, although 6NH3 displace 6H2O, with no net change in 
the number of independent molecules, it takes only 3en molecules to displace  
6H2O [7]. 
 
1.4. Principle of Hard-Soft Acid and Bases 
In recent years there has been a considerable progress in the design and synthesis of 
molecular systems able to selectively recognize metal ions. Several useful concepts 
have been developed for the design of these new ligands. The starting point to 
produce potential ligands is the study of the electronic and steric characteristics 
(inorganic chemistry research) of the various metal atoms from the periodic table. 
Secondly, the appropriate properties of the ligands, that have to match those of the 
metal, are searched. 
For this purpose the classification of acids and bases in hard and soft, that is the 
principle of HSAB (hard-soft acid and bases), defined by Pearson (Table 1.2) is useful 
for determining the type of donor atoms to coordinate the relative cation [8]. 
According to HSAB classification the small metal atoms with high charge density, which 
are not easily polarizable, are called hard. These metals have the tendency to form 
ionic bonds with hard bases, while bigger and more polarizable atoms, belonging to 
the soft category, form mostly covalent bonds with the bases complementary to them 
(soft bases). Considering these principles it has been possible to make useful general 
predictions on the stability of metal complexes with various ligands. However, some 
uncertainties remain for the prediction of borderline cases such as Zn2+, Pb2+ and Fe2+, 
which can form stable complexes both with hard and soft bases.  
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In this thesis the ligands we propose (see Chapter 2) are formed by two hydroxypyrone 
units (hard bases), and they are selective to Fe3+ and Al3+ (hard acids) as described by 
Pearson’s. Furthermore, the strength of coordination of negatively charged groups 
(like OH-) is related to their basicity. For example, the selectivity of a ligand towards a 
more acid metal, like Fe3+ and Al3+ in comparison to a less acid metal, such as Cu2+ and 
Zn2+, increases with the number and basicity of the negatively charged groups [8-9]. 
 
Table 1.2. Acid and basic classification according to the HSAB principle of Pearson 
Acids 
Hard Soft 
H+, Li+, Na+, K+, Be2+, Mg2+, Ca2+, Sr2+, 
Ba2+, Al3+, Sc3+, Ga3+, In3+, La3+,Gd3+, 
Lu3+, Cr3+, Co3+, Fe3+, As3+, Si4+, Ti4+, 
Zr4+, Hf4+, Th4+, U4+, Pu4+, Ce4+, WO4+, 
Sn4+, UO2+, VO2+, MoO3+ 
Cu+, Ag+, Au+, Ti+, Hg+, Pd2+, Cd2+, 
Pt2+, Hg2+, CH3Hg+, Co(CN)52-, Pt4+, 
Te4+, Br+, I+ 
Borderline 
Fe2+, Co2+, Ni2+, Cu2+, Zn2+, Pb2+, Sn2+, Sb3+, Bi3+, Rh3+, Ir3+, B(CH3)3 
Bases 
Hard Soft 
H2O, OH-, F-, CH3CO2-, PO43-, SO42-, Cl-, 
CO32-, ClO4-, NO3-, ROH, RO-, R2O, NH3, 
RNH2, NH2NH2 
R2S, RSH, RS-, I-, SCN-, S2O32-, R3P, R3As, 
CO, (RO)3P, CN-, RNC, C2H4, H-, R- 
Borderline 
C5H5NH2, C5H5N, N3-, Br-, NO2-, N2, SO32- 
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1.5. Ideal Chelator 
To synthesize an ideal chelating agent it is necessary to consider the chemical and 
biomedical properties of the molecule (see paper I): 
 Low toxicity of the chelating agent and formed complexes; 
 Rapid elimination of the toxic complex-metal ion; 
 High stability of the formed complexes, in competition with the stability 
of endogenous natural ligands in the body; 
 High selectivity towards the target metal ion (good value of pM [10]); 
 Biochemical metabolism of the chelating agent once entered into the 
body; 
 Kinetic and mechanism of exchange with endogenous ligands; 
 Factors affecting absorption and bioavailability. 
Regarding the last point, the chelators have to be sufficiently absorbed through the cell 
membranes, but it is important that the metal ion complex do not cross the blood-
brain-barrier (BBB) to prevent unexpected neurological damages. Three key 
parameters should be taken into account when considering diffusion through the 
biological membranes, namely molecular size, lipophilicity, and net charge. 
Lipinski suggest very useful parameters to predict the membrane permeability. For a 
molecule to be absorbed it has to respect the following characteristics: 
 Molecular weight < 500 g/mol; 
 Log P < 5 (with P being the octanol-water partition coefficient); 
 Less than 10 hydrogen bond donors in the molecule (expressed as a 
sum of OH and NH groups); 
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 Less than 10 hydrogen bond acceptors present in the molecule 
(expressed as the sum of O and N atoms). 
The stability of the complex depends on the denticity of the ligand. Bidentate and 
tridentate ligands form complexes with lower stoichiometry than hexadentate ones. 
This can be potentially dangerous, because these complexes can be more toxic than 
the parent metal ion. However, not all hexadentate chelators can protect adequately 
the metal ion from deleterious reactions, as for example, ethylenediamine-tetraacetic 
acid (EDTA) that is not able to shield the surface of the Fe3+ ion, but it forms an open 
complex (Fig. 1.4 A, basket complex). The exposition of the molecule to the biological 
environment facilitates the interactions with the metal, and consequently originates 
Fenton reactions with reactive oxygen species (ROS). On the contrary, the iron chelator  
desferrioxamine (DFO) showed in Fig. 1.13, completely covers the surface of iron 
during complex formation, preventing iron-catalyzed free radical reactions (Fig. 1.4 B, 
stable complex) [3]. 
 
 
A) Basket complex B) Stable complex 
 
Figure 1.4. Structures of two different metal complexes with a 
chelating agent (in red); A) Basket complex enhances interaction of the 
metal with biomolecules (in purple); B) The stable complex prevents 
interaction of the metal with biomolecules. 
Biomolecule–Metal Interactions
Chapter 1 
 
 
38 
1.6. Metal Ions in Neurodegenerative Diseases  
As the population gets older, there is an increased prevalence of neurodegenerative 
diseases. These diseases can be hereditary or, in very special cases, can result from 
sporadic infection, and very often develop in individuals with more than 65 years old. 
This is the case of Parkinson (PD), Alzheimer (AD) and transmissible spongiform 
encephalopathy (TSE) diseases. These clinically different diseases have similar 
progressive and chronic nature. They are developed by the accumulation of a specific 
protein in the cells of tissues, called “amyloid”, and recent evidences show that metal 
ion homeostasis may be involved in the progression of the disease. The hypothesis of 
the involvement of metal ions in neurodegenerative diseases has attracted a renewed 
attention to chelation therapy in the attempt to fight the neurological disorders.  
Metals may have an effect on neurodegenerative diseases including, oxidative stress 
and signaling involvement, and protein aggregation. Evidences show that the binding 
of metal ions to proteins promotes folding and stabilizes folded or partially folded 
states, thus accelerating protein aggregation. 
Amyloid is a general term that describes different types of protein aggregates, having 
some physico-chemical characteristics in common: a fibrillar morphology, a 
predominance of β-sheet secondary structure, resistance to proteolysis, insolubility in 
common solvents and detergents, and possibility of degradation after the reaction 
with the dye Congo red [11]. 
The formation of the so-called fibrills has been intensively studied. It was shown that 
fibrillization phenomenon has similarities with the classical increase of the size of 
crystals, being associated to the presence of small aggregates, called "seeds" or 
"nuclei", that increase in size for the incorporation of other molecules  
(nucleation) [11]. 
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The involvement of particular proteins in the amyloid diseases was believed to be 
caused by specific conformational features. Recent observations have shown that in 
non-physiological conditions, many proteins form a fibrous gel very similar to 
amyloids. The ability to form amyloids appears to be a generic property of polypeptide 
chains, common to all proteins, and resulting from intermolecular interactions that 
stabilize the aggregate [12]. 
Amyloids are very stable under physiological conditions due to the number of 
hydrogen bonds present. Biological systems have developed various protective 
mechanisms to prevent aggregation. For example, the globular shape makes the main 
chain inaccessible to the formation of hydrogen bonds, except when the protein is 
exposed to denaturing conditions. Proteins with a high disorder can have a change in 
conformation, a variation of the secondary and tertiary structure, without alteration of 
the primary structure, which occurs for example in the case of AD [12]. This variation 
can be caused by a direct toxic activity and the absence of normal biological functions 
in the formation of proteins. 
Normally, the protein associated with the neurodegenerative disease is found in the 
human body in equilibrium between normal and toxic forms; with the formation of the 
"misfolded" protein equilibrium is lost, and onset the disease: the protein aggregates 
in various organs and becomes amyloid. Antibodies, present in the body, do not 
intervene probably because they fail to distinguish between the two forms. 
 
1.6.1. Alzheimer’s Disease 
AD is characterized by memory loss, confusion, irritability, language breakdown, and 
social withdrawal. It constitutes a dramatic health, social and economic problem, for 
all countries, as patients stop being self-sufficient. The problem is the worldwide rapid 
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increase of affected people. There are currently about 36 million people affected with 
this disease, and forecasts say that in the next 20 years will be 66 million, and 115 
million in 2050 [13]. AD can be defined as a disarrangement of the cellular control 
system responsible for the correct protein folding (misfolding), in particular 
neurofibrillary tangles (NFTs) inside the neuron and neuritic senile plaques (SPs) in the 
extracellular space between neurons are produced, are these are two distinctive traits 
that define the disease. The main constituent of SPs is -amyloid (A), a proteolytic 
cleavage by-product of the precursor protein (-APP) [14]. NFTs are mainly composed 
of hyperphosphorylated tau protein. Studies on plaques show that they contain many 
copies of the A peptide in a soluble oligomeric -sheet aggregate with high amounts 
of Cu2+, Fe3+, and Zn2+ (see Table 1.3).  
 
Table 1.3. Metal levels in patients with Alzheimer's disease compared to healthy 
individuals [15-16] 
Location Copper (μg g−1) Iron (μg g−1)  Zinc (μg g−1) 
Plaque rim 23a 52a 67a 
Plaque core 30b 53a 87a 
Total senile plaque 25a 52a 69a 
Alzheimer's neuropil 19b 39b 51c 
Control neuropil 4 19 23 
a P < 0.05 (plaque values versus with Alzheimer's neuropils). 
b P ≤ 0.08 (Alzheimer's neuropils versus with control neuropil). 
c P < 0.05 (Alzheimer's neuropils versus control neuropil). 
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Al3+ was found at elevated levels in NFTs, indicating that it may promote protein 
aggregation [17]. After that, it was proposed a hypothetical interaction between Al3+ 
and phosphate groups of the hyper-phosphorylated tau proteins [18] (see Fig. 1.5).  
 
 
                                              
Figure 1.5. A) Hypothetical interaction between Al3+ and phosphate groups of the hyper-
phosphorylated tau proteins in AD [18].  B), C), D) and E) aluminium, iron, copper and zinc 
differentially alter Aβ aggregation, respectively. Al3+ promotes the formation of highly 
hydrophobic Aβ oligomers; Fe3+ promotes Aβ deposition into amorphous structures; Cu2+ 
leads to the formation of disordered/amorphous structures; and Zn2+ triggers the formation 
of amorphous aggregates [19]. 
 
The brain is an highly oxidative organ, and the presence of transition metals may lead 
to the generation of highly toxic free radicals. It was found in vitro that A can 
efficiently generate ROS in presence of copper and iron transition metals [20]. ROS in 
biological systems is the hydroxyl free radical, OH
.
, which can be formed by homolityc 
fission of the H2O2 molecule. This OH
.
 radical can be also produced according to the 
Al ZnFe Cu
Aβ
A CB D E
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Fenton reaction (1.7) in the presence of metals (for instance Fe2+):   
Fe2+ + H2O2   → Fe3+ + OH- + OH.
     (1.7) 
while the Fe3+ ion can be reduced by superoxide to give Fe2+ and molecular oxygen: 
Fe3+ + O2.-    →  Fe2+ + O2         (1.8) 
The sum of the last two reactions is known as Haber-Weiss reaction (1.8). The 
presence of iron catalyzes the formation of the hydroxyl radical, and the reaction 
becomes thermodynamically favorable in biologic systems. 
Haber-Weiss reaction:     O2.-  + H2O2   →  O2 + OH- + OH.   (1.9)  
ROS generated by metals may in turn lead to toxic cellular events, such as DNA 
damage, protein and lipid oxidation. For this reason in our body there are complex 
pathways which ensure metal intake, distribution, utilization and excretion that 
contrast its toxicity (see paper IV). 
Although there several studies in the literature concerning the role of A and its 
interaction with metals, the mechanism is not completely clarified. It has been 
proposed that the metal can encourage the formation of  protein aggregates, or can 
affect the protection from the redox-active metal ions (ROS): “Amyloid paradox” [21]. 
In paper III we introduced the concept of “metal paradox”, meaning that traces of 
endogenous metal ions, putatively being neurotoxic can, under many circumstances be 
neuroprotective [22].  One thing is for sure, the introduction of metals in our lives 
must be reduced, because it is changing the regular metal homeostasis of our body. 
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1.6.2. Parkinson’s Disease 
The second neurodegenerative disease for number of incidence is PD. From 1-2% of 
people over sixties are affected. The disease was described by James Parkinson in 1817 
and from then it is still not clear the causes and cure. 
PD is a slowly progressive disorder that affects movement, muscle control, and 
balance. There are two the main hallmarks of the disease: firstly, the accumulation of a 
protein (alpha-synuclein) into inclusions called Lewy bodies in neurons, and secondly 
the selective degeneration of neuromelanin-containing dopaminergic neurons in the 
substantia nigra (SN) and locus coeruleus occurs. 
Metals, such as manganese, iron, copper and zinc are thought to be involved in PD. 
Metals can induce both an increase in oxidative stress and facilitate protein 
aggregation. Recent studies have shown that alpha-synuclein is able to interact with 
zinc, copper, and iron and these interactions lead to protein aggregation and 
crosslinking [23]. In patients affected with PD, a change in the homeostasis of metal 
ions occurs. Zinc and iron increase, while copper decreases in the SN [24]. Interesting 
work developed by I. Paris et al., has shown that these metals are able to induce 
neurotoxicity by reacting with the neurotransmitter dopamine. Mn3+ is able to oxidize 
dopamine to aminochrome (see Fig. 1.6), and Cu2+ and Fe3+ form complexes with 
dopamine (see Fig. 1.7) [25].  
 
 
Figure 1.6. Dopamine oxidation to amminochrome catalyzed by manganese. 
 
Cyclization
Dopamine Dopamineo-quinone Leukoaminochrome Aminochrome
2Mn3+ 2Mn2+ 2Mn3+ 2Mn2+
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Figure 1.7. Cu2+ and Fe3+ abilities to form complexes with dopamine, based on ionic 
binding between the positive charges of metal ions and negative charges of 
dissociated hydroxyl groups. 
 
1.6.3. Prion’s Disease 
Prion’s disease also known as TSE's are a group of progressive neurodegenerative 
diseases. The term "prion" was introduced in 1982 by Stanley B. Prusiner that received 
a Nobel Prize in Physiology and Medicine in 1997 for this discovery. The term prion 
comes from the fusion of proteinaceous and infectious. Prion is in fact an infectious 
pathogen agent that causes a number of fatal neurodegenerative diseases through a 
new mechanism of action, not yet fully understood. 
Prion is defined as proteinaceous because it appears to be without nucleic acid and 
exclusively constituted by a structural modification of the prion protein (PrP), which is 
a normal constituent of the living cells [26]. Prusiner, showed for the first time that the 
infectious agent was resistant to the treatments that destroy nucleic acids (which are 
based on virus), and was instead sensitive to agents that denaturate proteins. The 
normal PrP protein, called PrPc is then converted to PrPSc through a process in which 
Fe3+
Cu2+
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there is a variation of the secondary and tertiary structures of the protein: a portion of 
-helix is converted to a β-sheet (see Fig. 1.8), and this structural transition is 
accompanied by profound changes in the chemical-physical characteristics, such as 
insolubility and resistance to proteolysis. Prion diseases are transmissible genetic and 
sporadic, and can affect both men and animals. The forms that affect men include: 
Creutzfeldt-Jakob disease (CJD), Gertsman-Straussler-Schenker (GSS), Kuru and fatal 
insomnia. The disease can also affect different types of animals, including sheep 
(scrapie) and cattle (bovine spongiform encephalopathy, BSE). "Scrapie” that affect 
sheep’s, is characterized not only by brain degeneration, but also by itching, causing 
injury to the woolly fleece. 
The infectiousness of the disease was demonstrated, by inoculation of extracted 
contaminated brain to healthy animals. The first experiments were made on rodents 
that showed the disease after the injection of material from infected sheep. These and 
other studies showed that PrPc is easily converted into the toxic form PrPSc, in the 
presence of another protein PrPSc [26]. In the 60s it was demonstrated the relationship 
between the scrapie disease and a disease found in populations that practiced 
cannibalism in New Guinea, called Kuru. Since that time, several diseases were found 
to have the same symptoms of the neurodegenerative diseases due to PrP [26]. Prion 
diseases have attracted a general interest when occurred the epidemic BSE (“mad cow 
disease”) in England in 1986 and with the discovery of the possibility of the 
transmission to humans via food. 
PrP is a glycoprotein, the primary structure is constituted by a polypeptide of 253 
residues with a mass of about 34 kDa [27]. In the structure is present a characteristic 
domain 51-91 amino acid, in which is located a nonapeptide PQGGGGWGQ, followed 
by an octapeptide repeated for four times PHGGGWGQ. This region and the areas 
containing the histidine at position 96 and 111 are very important for the formation of 
bonds with metals, particularly with copper [27-28]. 
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PrPC PrPSc 
 
 
 
 
Figure 1.8. Molecular models of the conversion of PrPcPrPSc. Adapted from [29]. 
 
Affinity chromatography and circular dichroism (CD) measurements have 
demonstrated that the prion protein has higher affinity for metal ions, special copper 
and others (iron and manganese). A substantial difference between the two forms of 
PrP (normal and scrapie) is the affinity for copper; PrPSc prefers to bind manganese and 
zinc. It has been hypothesized a possible role of metal ions in the change of 
conformation of the PrP and thus in the onset of neurodegenerative diseases. The 
binding to copper has a direct consequence on the conformation of the terminal amino 
group of the molecule. Instead of a transition from -helix to β-sheet, rotation and 
structuring occurs. It was hypothesized a relationship between PrPc and PrPSc with 
metal ions in the onset of the disease (see Fig. 1.9) [27].  
Human 
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Figure 1.9. Hypothesis of the relationship between PrPc, PrPSc 
with metal ions. 
 
From the contact of PrPc with copper (PrPcCu) an abnormal form of PrP can be 
generated, called PrP*Cu/Mn/Zn that it is not toxic, but has different properties compared 
to the normal PrPc, as high insolubility and partial resistance to proteases. By the other 
hand, the toxic form PrPScCu can derive directly from the native form by a mechanism 
not yet clearly understood. Changes in the protein conformation may change the 
affinity for metal ions, leading to the formation of new molecular species containing 
different metal ions, called PrPScCu/Mn/Zn. Metal ions may also act directly on the 
intermediate form PrPc*Cu/Mn/Zn which becomes the toxic PrP
Sc
Cu/Mn/Zn. In conclusion, it 
is still necessary to verify the presence or absence of an intermediate in the conversion 
of PrP, and thus the possible involvement of metal ions in the conversion of the normal 
protein to the toxic form. 
PrPCCu
PrPC*Cu/Mn/Zn
PrPScCu/Mn/Zn
PrPScCu
a)b)
c) d)
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1.7. Diseases Caused by Metal Overload 
1.7.1. Thalassemia 
Thalassemia is a group of inherited disorders of globin synthesis due to defective or 
absent production of one of the globin chains (alpha, beta, gamma, delta) which 
constitute the molecules of human hemoglobin. The defective production of the globin 
chain determines a relative excess of the other, originating an imbalance which is the 
basis of the disease. Depending on the type of globin involved, two varieties of 
thalassemia can be distinguished, the beta- and alfa-thalassemia (β- and  
-thalassemia, respectively). Due to its high frequency and gravity, β-thalassemia 
represents a significant health problem in many areas of the world, special in the 
Middle East, the Indian subcontinent, the Far East and in the Mediterranean area. In 
particular, in Italy the most affected regions are Sicily, Sardinia and near the river  
Po [30]. There is a strong correlation between these areas and the presence of 
Falciparum malaria in the past, because the natural selection has favoured the survival 
of people with the mutated gene that causes the disease. WHO has estimated that 
about 1-5% of the world’s population might be healthy carriers of β-thalassemia and 
that about 60000 severely affected infants are born every year [31].  β-thalassemia 
occurs when the mutated genes are involved in the composition of the β-chains (on 
chromosome 11). There are two genes that can be affected. The mutation of a single 
gene, causes thalassemia minor, in which the patient has no relevant symptoms (see 
Fig. 1.10). The involvement of both genes constituting the β-chains of hemoglobin 
causes β-thalassemia major (Cooley's anemia), a severe symptomatology [32]. 
The conventional treatment of thalassemia includes transfusion therapy and iron 
chelation therapy. Transfusion therapy is used to correct anemia preventing the onset 
of cardiomyopathy and assuring the patient a regular growth, a good quality of life and 
normal resistance to infection. 
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Figure 1.10. Inheritance of β-thalassemia. Unaffected carrier parents 
have 25% of probably to have a sick child (illustrated in red). 
 
The transfusion regimen commonly adopted provides a blood transfusion every 2-4 
weeks, maintaining the hemoglobin levels at about 110 g/L. To achieve this level, 1-3 
units containing 200-250 mL of packed red cells (totaling about 200-250 mg of iron), 
are transfused. However, frequent transfusions cause iron deposition in the body 
(about 15-20 mg/day). Chelation therapy is therefore used to remove the excess of 
iron in order to maintain the right balance in the organism [33]. The most widely used 
chelating agent is DFO (see Fig. 1.13), which was introduced in the late 70's. From that 
date, mortality and complications related to the accumulation of iron have been 
drastically decreased. Nevertheless, DFO has various drawbacks; it is expensive, is 
poorly absorbed from the gut and it has short plasma half-life. For this reason, it has to 
be administered by slow subcutaneous infusions, leading to a very poor patient 
compliance. This explains why in the last 25 years, the chelation therapy research has 
been directed to the development of iron chelators orally administrable [30]. 
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1.7.2. Wilson’s Disease 
Wilson's disease (WD), also known as hepatolenticular degeneration, was described for 
the first time in 1912 by Kinnear Wilson as a “progressive lenticular degeneration". It is 
an hereditary lethal neurological disease, that is connected to a chronic liver disturb 
which leads to cirrhosis [34]. Only a few decades after its initial description, the role of 
copper in the pathogenesis of WD was determined, and the cause of hereditary was 
showed to be autosomal recessive [35]. In 1993, the abnormal gene in WD has been 
identified. This gene encodes the P-type adenosine triphosphatase (ATP7B), it is 
present in the hepatocytes and works in the transmembrane transport of copper to 
hepatocytes. The absence, or reduction of the functionality, of the ATP7B protein leads 
to a hepatocellular reduction, excretion of copper into bile, resulting in hepatic 
accumulation of copper. Finally, copper is released into the bloodstream and 
deposited in other organs, particularly in the brain, kidneys and cornea (called “Kayser-
Fleischer rings”, showed in Fig. 1.11) [36-37].  
 
 
 
Figure 1.11. Bilateral Kayser–Fleischer rings (panel A, within arrows). 
Five years after the initiation of copper-chelating treatment, the 
Kayser–Fleischer ring has almost disappeared (panel B) [37]. 
 
The failure to incorporate copper into ceruloplasmin (CP) is a further consequence of 
the loss of the function of ATP7B protein [38]. In WD the loss of ATP7B functionality 
leads to the synthesis of apoceruloplasmin, which is rapidly degraded in plasma. 
A B 
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Consequently, the concentration of serum CP is a very useful diagnostic parameter for 
WD [39]. About half of the patients with WD have signs and symptoms of 
neuropsychiatric disorders [40]. Often the neurological symptoms are initially 
undetectable. Patients not treated with chelation therapy have additional PD 
symptoms, due to the accumulation of copper in the basal ganglia [41]. The worldwide 
frequency of WD is estimated to be one for 35000-100000 people. However, in 
Sardinia, the disease has a higher frequency, with an incidence of one to 7000  
people [42]. 
 
1.8. Chelators for Metals 
1.8.1. Iron Chelators 
Iron is one of the most important metals in our organism, and is critically fundamental 
for a variety of cellular events. In fact, no life form is possible without the presence of 
this element. Human metabolism is highly conservative with the majority of iron being 
recycled within the body. In a normal case, iron levels are under extremely tight 
control and practically iron-catalysed reactions that generate free radicals do not 
occur. However, this delicate equilibrium between iron uptake and iron loss can be 
broken, and this is the case of patients that suffer from iron overload. One of the most 
serious disease where iron overload plays an important role is β-thalassemia major. In 
order to protect patients from iron toxicity, iron chelating agents have been 
introduced in clinical practices. Unfortunately, an ideal chelator for treating iron 
overload in humans has not been identified yet. 
Iron(III) is a spherically symmetrical tripositive cation of radius 0.65 Å, and is classified 
as a hard Lewis acid by virtue of its high charge density. It forms stable bonds with hard 
ligands which contain oxyanions as functional groups, such as catechols, 
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hydroxamates, aminocarboxylates, hydroxycarboxylates, hydroxypyridinones (HPOs) 
and hydroxypyrones. 
 
1.8.1.1. Catechols 
Catechol, as a functional group, is found in Enterobactin (see Fig. 1.12), 
a siderophore that acquires iron for microbial systems. It is primarily found in Gram-
negative bacteria, such as Escherichia coli and Salmonella typhimurium [43]. In order to 
mimic the natural siderophore molecule, MECAM (1,3,5-N,N',N''-tris-(2,3-
dihydroxybenzoyl)triaminomethylbenzene, see Fig. 1.12), was synthesized.  
 
 
 
Enterobactin MECAM 
Figure 1.12. Hexadentate catechols. 
 
MECAM binds strongly to iron with a pFe value of about 28 [44]. Considering only the 
catechol moiety, it has high electron density on both oxygen atoms. However, this high 
charge density is also associated with the high affinity for protons (pKa values of 12.1 
and 8.4) [45]. Thus, the binding of cations by catechol has marked pH sensitivity. On 
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the other hand, the ligand, at physiological (pH 7.4), is in the totally protonated form 
and consequently having a net charge equal to zero it is able to penetrate the cell 
membranes more efficiently than a charged molecule. 
 
1.8.1.2. Hydroxamates 
Another important natural hexadentate ligand is DFO (see Fig. 1.13). DFO is the only 
iron chelating agent discovered for more than 40 years, and still continues to be 
extensively used. It is a siderophore produced by Streptomyces pilosus [46], and 
consists in three hydroxamate moieties. Compounds containing only a hydroxamate 
moiety are bidentate, (see Fig. 1.13) and can form 1:3 metal:ligand complexes at pH 
7.4 and sufficient ligand concentration. The protonation constant (pKa ~ 9), lower than 
that of the cathecol moiety, allows the formation of stronger iron-ligand complexes. 
However, the affinity of the simple bidentate hydroxamate ligand for iron is 
insufficient to solubilize iron(III) at pH 7.4 at clinical concentrations. For this reason, 
only tetradentate and hexadentate ligands are considered as possible iron(III) 
scavengers under such conditions [44]. 
 
 
 
DFO L-lysinehydroxamic acid 
Figure 1.13. Hexadentate (DFO) and bidentate (L-lysinehydroxamic acid) hydroxamates.  
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1.8.1.3. Aminocarboxylates 
This category includes EDTA and DPTA (see above Fig. 1.1) that are both able to 
chelate strongly to iron. However, they are not selective for iron and remove also 
other essential metals from the body like zinc. This ability is useful in certain plants like 
wheat, barley, rye, and oat: plants secrete phytosiderophores such as mugineic acid, 
shown in Fig. 1.14, from their roots which are capable of complexing iron(III) and  
zinc [47]. Moreover, the complexes formed with iron can catalyze redox reactions 
producing free radicals. Indeed, the redox potential of Fe3+/EDTA complex (+0.12 
V/NHE) allows its reduction by physiological reductans [48].  
 
 
Mugineic acid 
Figure 1.14. Aminocarboxylates. 
 
1.8.1.4. Hydroxycarboxylates 
Hydroxycarboxylates only have oxygen coordinating atoms, and they are more 
selective for iron than aminocarboxylates. This category includes rhizoferrin and its 
precursor citrate (see Fig. 1.15). Rhizoferrin was firstly isolated from Rhizopus 
rnicrosporus var. rhizopodifonnis, and it is able to form 1:1 iron-ligand complexes, 
similarly to DFO [49]. 
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Citrate Rhizoferrin 
Figure 1.15. Hydroxycarboxylates. 
 
1.8.1.5. Hydroxypyridinones 
Hydroxypyridinones (HPOs) are a family of N-heterocyclic core chelators which 
combine the characteristics of the functional groups hydroxamates and catechols. 
They are the most studied class of compounds, due to the higher chelating capacity 
and selectivity for iron. The carbonyl and the phenolic oxygen coordinate iron, forming 
a stable 5-membered ring.  
There are three main families of HPOs, namely, 1-hydroxypyridin-2-one (1,2-HP),  
3-hydroxypyridin-2-one (3,2-HP), and 3-hydroxypyridin-4-one (3,4-HP), see Fig.1.16. At 
the last family takes part the 1,2-dimethyl-3-hydroxypyridin-4-one, called deferiprone 
(DFP or L1), which has the highest value of pFe 20.67 [48]. It is the most important oral 
chelator currently in use. Many derivatives have been synthesized by combining two or 
three units of HPOs [50-53] (see Fig. 1.16), due to the particular structure of the 6-
membered ring scaffold that offers many possibilities of functionalization at different 
ring-positions, enabling the modulation of bioavailability and possibility of the 
interaction with several biological targets.  
Tren(3,4-HP)3 has an extremely high pFe value of 30.5 [52]. Unfortunately, tris-
compounds have molecular weights too high to be absorbed in the gastrointestinal 
tract, and consequently they cannot be orally administered. 
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1,2-HP  3,2HP  3,4HP or DFP 
 
 
Tren(3,4-HP)3 
Figure 1.16. Bidentate and hexadentate HPOs.  
 
1.8.1.6. Hydroxypyrones 
In resemblance to HPOs, hydroxypyrones chelate iron forming stable five-membered 
rings. Hydroxypyrones differ for the oxygen in the ring which gives less affinity to the 
proton and consequently the pKa values are lower than that of HPOs, for more than 
two orders of magnitudes. For instance DFP has pka 9.8 [48] and kojic acid  
pka 7.7 [54].  
Kojic acid (see Fig.1.17) is one of the most studied hydroxypyrones in the literature. It 
contains a polyfunctional heterocyclic ring, with several important centers enabling the 
occurrence of additional reactions like oxidation and reduction, alkylation and 
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acylation, nucleophilic and electrophilic substitution reactions. Kojic acid is a promising 
molecule for the development of more potent derivatives. Indeed, considering the 
ligands recently studied in our research group, namely L1, L2, and L3 (see Fig. 1.17), 
that are formed by two units of kojic acid joined by different linkers, the pFe values 
found were 23.1, 18.9 and 22.2, respectively [54-55], that are several orders of 
magnitude higher than that of the precursor. One of the most important advantages of 
these molecules is that they are easy and inexpensive to produce. 
 
      Kojic acid 
 
 
 
Figure 1.17. Kojic acid derivatives. 
 
1.8.2. Aluminium chelators 
Aluminium is the third most abundant element in earth's crust, after oxygen and 
silicon, and it is the most abundant metal. Due to its versatility, in the last century has 
been widely used in industry, for instance in automotive, and space aeronautics 
industries [56]. Also, it is used in the production of paper and textiles, in many 
cosmetics [57], in pharmaceutical drugs for human and veterinary medicine [58], in 
antiperspirants and in a variety of products that are in close contact with our skin. 
Aluminium salts are utilized in alimentary industry [59]. Additionally, aluminium salts 
are used in water purification, as well as in brewing and sugar refining [60].  
R
L1
L2
L3
H
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Aluminium is not a essential metal for the human body [56], and its abuse can produce 
dangerous effects on our health. Since 1970, aluminium was recognized to cause 
serious diseases, such as osteodistrophy and dialysis dementia in patients with renal 
failure under dialysis treatment. The awareness of aluminium toxicity has led several 
research groups to study new possibilities for chelating agents, some of them being 
already used for iron chelation. Both iron and aluminium, due to their short ionic 
radius and their high charge, are hard metals. As seen for iron, also aluminium prefers 
to coordinate with hard bases containing oxygen atoms, as hydroxamates, 
catecholates, bisphosphonates, salicylates, HPOs and hydroxypyrones [61]. 
The first aluminium chelator, introduced in clinical practice, for osteomalacia was DFO 
(Fig. 1.13) [62]. In recent years, various chelating agents were synthesized. In 
particular, HPOs derivatives have been extensively studied (see Fig. 1.18).  
Different polydentate 3,4-HP chelators have been proposed by the group of M. A. 
Santos: the tetradentate iminodiacetic acid  bis-(3,4-HP) and derivatives called 
IDAPr(3,4-HP)2 [63]; a ternary system composed by an arylpiperazine-containing bis-
hydroxypyridone [51]; two hexadentate ligands, the tris-hydroxypyridinone-based  
compounds KEMPPr(3,4-HP)3 and KEMPBu(3,4-HP)3, derived from KEMP acid scaffold 
to which three 3,4-HP chelating moieties are attached via different size spacers [52]; 
two new tripodal tris(3,4-HP) hexadentate chelators NTA(BuHP)3 and NTP(PrHP)3 (NTA 
= nitrilotriacetic acid, NTP = nitrilotripropionic acid) [64-65]. The last hexadentate 
ligands present extremely high pAl values, 22.0 for NTA(BuHP)3 and 22.4 for 
NTP(PrHP)3. Other ligands with good pAl values are tripodal O-TRENSOX and the 
similar triscatechol derivative TRENCAMS, with values of pAl 20.0 and 26.2, 
respectively [66]. Bisphosphonate ligands were found to be very efficient chelating 
agents for Al3+. The stabilities of the complexes formed are higher than that found for 
DFP (pAl 16.05) and very close to DFO (pAl 19.43) [67-69]. Hydroxypyrone ligands  
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KEMPPr(3,4-HP)3 n = 3 
KEMPBu(3,4-HP)3 n = 4 
IDAPr(3,4-HP)2 
  
NTA(BuHP)3 p=1, n=2 
NTP(PrHP)3 p=2, n=1 
TRENCAMS 
 
 
O-trensox Bisphosphonate (1L) 
Figure 1.18. Aluminium chelators. 
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studied in our group of research (see Fig. 1.17), formed by two units of kojic acid linked  
by a methyl group (L1), orto-vanillin (L2), and vanillin (L3), are capable to chelate 
aluminium. From these, L3 has the highest value of pAl= 13.9 [55].  
 
1.8.3. Copper Chelators 
Copper was the first metal discovered by man and is still today extensively used. 
Copper production has lifted over the last decades and continues to increase, meaning 
that more copper ends up in the environment. World refined copper consumption 
amounts to 20.5 million tons in 2011 (16.7 million tons were achieved in 2005) [70]. 
Copper is a transition metal ion essential for human health. It acts as catalytic or 
structural cofactor of many enzymes. It is required for the development and function 
of nervous and cardiovascular systems and it is fundamental for skin, bone, 
reproductive and immune systems. Many body functions such as collagen production, 
formation of red blood cells, regulation of cholesterol level, iron adsorption, oxidation 
of fatty acids, melanin production and intracellular energy level control are all 
dependent on copper. The treatment for copper overloading or intoxication is 
chelation therapy. Different molecules are already in clinical use as chelators or under 
study in clinical trials. The three most important chelators used for the treatment of 
WD are D-penicillamine (D-pen), triethylenetetramine (trentine, Trien) and ammonium 
tetrathiomolibdate (TTM), whose structures are reported in Fig. 1.19.  
The very first chelator used for WD was BAL (Fig. 1.1), originally developed during the 
World War II as an antidote for lewisite, a chemical warfare agent, which was later 
employed to treat metal intoxications [71]. After, it was replaced by the less toxic and 
orally available D-pen that it is still used today, although Trien revealed to be better 
tolerated [72]. TTM showed a remarkable efficacy in the treatment of patients with 
neurological symptoms [73], but unfortunately is not yet allowed for chemical 
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treatment. Other potentially efficient ligands, with higher specificity for certain tissues, 
are the sulfurated polydentate chelators as  Pc  (see Fig. 1.20) [74]. Pc has a very high 
selectivity for Cu+ versus Zn2+ (ca. 10 orders of magnitude) [75].  
 
 
 2 NH4
+ 
Trien D-pen TTM 
Figure 1.19. Main copper chelators for the treatment of WD. 
 
Interesting examples of tripodal Cys-rich chelators have been reported (HnLx, see  
Fig. 1.20) [76-77], which has been suggested to act as potential Cu+ chelators in vivo. L1 
and L2 forms very stable mononuclear and polynuclear Cu+ complexes and they are 
selective for Cu+ versus Zn2+; whereas the ligand L3 gives polynuclear Cu+ complexes of 
lower stability. An additional chelating agent for copper is Clioquinol (5-chloro-7-iodo-
8-hydroxyquinoline, CQ, see Fig. 1.20) is an aromatic chelator which coordinates metal 
ions through its (N,O-) donor set [78]. CQ has been used in the past as an antibiotic 
[79], and more recently, as antiproliferative agents against tumor cell lines, in the form 
of copper complexes [78]. CQ was also found to reduce the formation of amyloid 
plaques [80], being able to partially disaggregate Cu-triggered Aβ aggregates by virtue 
of its high affinity for Cu2+ [81]. Two CQ analogs have been reported in the literature, 
consisting of two 8-hydroxyquinoline moieties linked through a spacer (C1, C2, showed 
in Fig. 1.20) [82-84]. These tetradentate ligands, C1 and C2, showed higher copper 
binding affinities and remarkable capacity to reduce the production of ROS. 
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                                     Pc 
  
 
 
 
CQ C1 C2 
 
Figure 1.20. Copper chelators. 
 
In recent years several bifunctional (BF) chelators for AD have been synthesized. BF are 
ligands that, beside the presence of a metal ion binding site, are designed to have a 
second function. This additional function can originate, for instance, the presence of a 
reducing moiety capable to inhibit the formation of ROS, or a group that may favor 
mechanisms of active transport of the chelator across membranes. Additional 
functions have also been introduced to prepare prodrugs, in which an 
activatable/cleavable protecting group allows the chelator to be inactive until it 
reaches specific tissues. Here, the protecting group is removed by enzymes or by ROS 
species making the chelator available for metal complexation. The general idea is that 
the introduction of a second function allows the chelator to work only under specific 
H3L
1: X = OEt 
H3L
2: X=  NH2 
H3L
3: X= OH 
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conditions, in specific tissues, or in the presence of specific biomolecules [85]. There 
are three types of approaches used to synthesize BFs for AD:  
 the incorporation of a chelating moiety into a scaffold known to interact 
with Aβ, for instance K0 ligand (Fig. 1.22), has been designed by merging the 
structural feature of CQ and the scaffold IMPY (see Fig. 1.21) [86-87]; 
 the linkage of a chelating group to a molecule that interacts with Aβ, as XH1 
(see Fig.1.22) formed by two units of Tht (see Fig. 1.21) linked to DTPA [88]; 
 the peptide approach, as example Cyc-KLVFF (see Fig. 1.22) a cyclen moiety 
attached to a N-terminus of the KLVFF fragment (see Fig.1.21) [89], this 
oligopeptide is a β-sheet breaker which inhibits Aβ aggregation [90-93].  
 
  
IMPY Tht 
 
KLVFF 
Figure 1.21. Molecules capable to interact with Aβ. 
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K0 
 
 
XH1 
 
Cyc-KLVFF 
Figure 1.22. Example of incorporation (K0), linkage (XH1) and peptide (Cyc-KLVFF) approach. 
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2.1. Reagents 
Kojic acid, iron chloride FeCl3, aluminium chloride AlCl3, copper chloride CuCl2, and 
ethanol were purchased from Sigma-Aldrich. N,N-diethyl-ethylenediamine 
benzylamine hydrochloride, piperazine, methylamine hydrochloride were purchased 
from TCI Europe. N-benzylmethylamine was purchased from Alfa Aesar. Formaldehyde 
was purchased from Merck, HCl from Fluka, KCl and ZnCl2 from Carlo Erba (Milan, 
Italy). Desferal (DFO) was obtained from Biofutura Pharma products. All the products 
were used without any further purification. 
Fe3+, Al3+, Cu2+ and Zn2+ solutions were prepared by dissolving the respective amount 
of FeCl3, AlCl3, CuCl2 and ZnCl2 in pure bidistilled water. A stoichiometric amount of HCl 
was added to prevent hydrolysis. The Fe3+ solution was standardized by 
spectrophotometric titration with DFO; Al3+ solution was standardized with EDTA 
titration; Cu2+ and Zn2+ was standardized with KOH titration. In NMR experiments H2O–
D2O or D2O were used.  
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2.2. Synthesis 
In the framework of the collaboration between our research group and the group of 
professor Amelia Santos of the Technical Institute of Lisbon, 5 new ligands were 
synthesized (Fig. 2.1). The ligand L8 was previously synthesized in our group. The 
chelating properties of these ligands are described in papers V, VI and VII. In particular, 
paper V describes the equilibria in solution of the ligands L4, L5, L6, L7, and L8 with 
iron. These ligands are studied in paper VI with aluminium. Furthermore, in paper VII 
not only were investigated the chelating properties of L9 with aluminium and iron, but 
the selectivity properties were also evaluated for the ligand. The values of pM for 
other two fundamental metals of the human organism, copper and zinc, were 
determined. 
 
 
Figure 2.1. Synthesized ligands L4, L5, L6, L7, L8, and L9. 
Sintesi
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The ligands showed in Fig. 2.1 were obtained by a Mannich reaction in position six of 
kojic acid. These ligands are tetradentate and are formed by two units of kojic acid 
joined by different linkers that confer different properties, with the exception of L7 
that is bidentate and formed by a single unit of kojic acid. In the Table 2.1 are 
described the reaction conditions for the synthesized ligands. 
 
Table 2.1. Reaction conditions of the synthesized ligandsa 
Ligand Starting materials 
Proportions 
(eq.) 
T  
(°C) 
Time 
(h) 
Yield 
(%) 
L4 
Kojic acid 2 
40/50 1.5 92 Formaldehyde 2 
Methylamine hydrochloride + NaOH 1 
L5 
Kojic acid 2 
40/50 3.5 52 Formaldehyde 2 
Benzylamine hydrochloride + NaOH 1 
L6 
Kojic acid 2 
RT 5 97 Formaldehyde 2 
Piperazine 1 
L7 
Kojic acid 2 
RT 5 87 Formaldehyde 2 
N-Benzylmethylamine 1 
L8 
Kojic acid 2 
60 3 68 Acetaldehyde 1 
Ammonium hydroxide excess 
L9 
Kojic acid 2 
RT 5 67 Formaldehyde 2 
N,N-diethyl-ethylenediamine 1 
a In all reactions ethanol was used as a solvent 
RT means room temperature 
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The synthesized intermediates and other bidentate ligands obtained are described in 
appendix 1. The reactions that were tested before obtaining the desired products are 
described in appendix 2. 
 
2.3. Tetradentate Ligands 
In comparison with bidentate and hexadentate ligands, tetradentate ligands have 
intermediate characteristics, namely: 
 The complex formation is favored entropically in the following order 
hexadentate > tetradentate > bidentate (Chapter 1, section 1.3); 
 Generally, the molecular weight of tetradentate ligands is lower than 
500 g/mol, that is one important parameter for potential oral chelators, 
as defined by Lipinski rules; 
 They can efficiently scavenge iron(III) at low metal concentrations.  
Considering the dissociation of bidentate (Lb), tetradentate (Lt) and  
hexadentate (Lh) ligands, we have the equilibrium equations: 
Fe(Lb)3     Fe3+ + 3Lb  k’d  = [Fe3+][Lb]3/[Fe(Lb)3]  (2.1) 
Fe(Lt)3/2   Fe3+ + 3/2Lt  k’’d  = [Fe3+][Lt]3/2/[Fe(Lt)3/2] (2.2) 
FeLh              Fe3+ + 3Lh  k’’’d  = [Fe3+][Lh]/[FeLh]  (2.3)   
Where K’d, K’’d, and K’’’d are the equilibrium constants of dissociation. The degree of 
dissociation for bidentate ligand-metal complexes depends on [Ligand]3, for 
tetradentate on [ligand]3/2 and for hexadentate only on [ligand], hence the diluition 
dependance of complex dissociation follow the order hexadentate < tetradentate < 
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bidentate [1-2]. The tetradentate ligands L4, L5, L6, L8 and L9 are able to form stable 
metal complexes (M2L3Hx) metal to ligand M:L= 2:3 ratios at pH 7.4 [3-4], see Fig. 2.2 A 
and B and speciation plot reported in papers V, VI and VII. In these complexes each 
iron atom is fully coordinated in an octahedral configuration.  
A similar behavior has been proposed for the complex Fe2(IDAPr(3,4-HP)2)3, where 
each iron atom coordinates a tetradentate ligand (IDAPr(3,4-HP)2) and the third forms 
a bridge to complete the octahedral coordination sphere of iron [5]. 
 
 
 
 
 
 
 
 
 
Figure 2.2. A) Fe2L3 model for the ligands L4, L5, L6, L8 and L9; B) Crystal of the complex 
Fe2(L6)3; C) Fe2L3 model proposed for the complex Fe2(IDAPr((3,4-HP)2)3; D) Structural diagram 
for the complex Fe2(IDAPr((3,4-HP)2)3. 
Fe Fe
Fe Fe
B A 
C D 
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2.4. Analytical Methods in Solution 
2.4.1. Balance of Complex Formation in Solution: Definitions 
The parameters necessary for the characterization of a system with simultaneous 
equilibria of complex-formation in solution are contained in the “model of speciation”. 
This model provides the stoichiometry of the formed species and the relative complex 
formation constants under known and controlled conditions of temperature and ionic 
strength. This allows to calculate the composition of the system in different conditions 
of pH, absolute concentrations of the components, and M:L ratios. Also, it is possible 
to describe a system in terms of the distribution diagram of species changing a given 
parameter, such as pH, concentration of metal, of ligand, and others. 
The stoichiometric composition and the stability constant for a generic system 
consisting of a metal ion M, a ligand L and a proton H, are described by the following 
equations: 
pM + qL + rH    MpLqHr        (2.4) 
pqr = [MpLqHr] / [M]p[L]q[H]r 
      (2.5) 
The terms in the square brackets of equation (2.5) represent the concentrations of the 
different species present at equilibrium (2.4). The charges and the solvent molecules 
are omitted for simplicity. 
pqr is the global (or cumulative) constant of formation and provides quantitative 
information on the interaction between metal ion M and ligand L. The stoichiometry 
coefficient r, relative to proton, is negative when the number of protons lost by the 
ligand are greater than the maximum number of protons lost in the absence of the 
metal ion, i.e. when hydroxylated species are formed. 
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The species MpLqHr is often indicated simply by the relative stoichiometric index; for 
example, if pqr is equal to 111 the specie is MLH. 
The protonation constants X, and the step complex formation constants k, are used to 
describe the equilibria in solution: 
1) Ligand protonation: 
L + H  HL   X1 = [HL]/([H][L])     (2.6)                 
L + 2H  H2L  X2 = [H2L]/([H]2[L])     (2.7)                                             
In subsequence:                   
L + pH  HpL  Xp = [HpL]/([H]p[L])    (2.8) 
Where Xp is the global or cumulative protonation constant. 
 
2) Complex formation between metal and ligand: 
M + L  ML  K1 = [ML]/([M][L])    (2.9)                         
ML + L  ML2   K2 = [ML2]/([ML][L])   (2.10) 
For n ligands (L) we obtain: 
MLn-1 + L  MLn  Kn = [MLn]/([ML n-1][L])   (2.11) 
The partial K and cumulative β constants satisfy the following relations: 
110 = K1 = [ML]/([M][L])        (2.12) 
120 = K1K2 = [ML2]/([M][L]2)       (2.13) 
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And for n K we obtain: 
1n0  =K1K2 .... Kn = [MLn]/([M][L]n)      (2.14) 
 
2.4.1.1. Solutions of a System with Multiple Equilibria 
The components of the system (metal, ligand and proton) can be described by the 
following equations: 
• n mass balances of the n components; 
• charge balance; 
• N  constants of formation of the present species. 
The three mass balances for a binary system are the following: 
cM = [M] + [ML] + [ML2] + ...+ [MLn] = [M] +      n [M] [L]n   (2.15) 
cL = [L] +[HL] + [H2L] + ... +[HpL] + [ML] + 2[ML2] + n[MLn] = [L] + 
+  
 
   p [H]
p [L] +      n [M] [L]n     (2.16) 
cH = [H] -[OH] + [HL] + 2[H2L] + ... + p[HpL] = [H] - Kw[H]-1 +  
+   
 
   p [H]
p [L]        (2.17) 
 
where cM, cL and cH are the analytical concentrations of M, L, H, and [M], [L], [H] are 
the corresponding free concentrations. 
The system consists of these three equations containing 3+N unknown factors, namely 
the free concentration of the components and global constants of formation. 
Experimental methods for the study of these systems are based on the determination 
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of the free concentration of at least one component, measured on systems at variable 
concentration of components (temperature and ionic strength must be constant). 
In the case of  labile complexes, those in which the ligands are not linked irreversibly to 
the metal and may be replaced by other metals with fast kinetics, there is a 
competition between the metal and proton for donor sites of the ligand. In this case, 
the investigation can be conducted through an acid-base titration, followed 
potentiometrically. Each point of the titration can thus measure the value of the 
concentration of the free proton. For each Np point of the titration it is possible to 
write a system with three mass balances. This system has a total of 3∙Np equations 
with (3-1)∙Np+N unknown, there are (3-1) free concentrations unknown while the N 
formation constants are the same for all points. The system can be solved if the 
number of unknown terms is the same of the number of equations, namely the 
number of experimental points. 
Normally, the exact analytical solution of these systems can only be achieved in very 
simple cases. For high order equations, non-linear least squares methods are used. In 
this case, the number of points needed is at least double than that of the parameters 
to be determined [6]. 
Currently, there are several programs available that allows to process hundreds of 
experimental points for multi-metal and multi-ligand systems which have a large 
number of simultaneous equilibria. The goodness of the fit allows to evaluate the 
reliability of the model and results. Although potentiometry is the technique most 
widely used for this purpose, for its simplicity and accuracy, the method may be 
coupled to any analytical technique that is capable of measuring the free 
concentration of at least one component of the system in variable experimental 
conditions. 
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In general, the methods for determining the concentration of a component are based 
on the measurement of a physical quantity x, which is related to the unknown 
concentration. Depending on the relationship between the physical quantity x and 
concentration, the methods of analysis can be divided into: 
a) methods in which the quantity x is related with the concentration of single 
species present in the system. For example, in potentiometry the potential 
of glass electrode or electrodes sensitive to the metal ion, is given by the 
equation: 
               
  
  
            (2.18) 
b) methods in which the relation between concentration x is complex. For 
example, the absorbance in spectrophotometry depends on all present 
species, and with calorimetry the measured heat comes from the 
contribution of all species and from  non-chemical factors. 
c) methods based on colligative properties of the solution. 
 
2.4.2. Potentiometry  
The methods referred in group a) can be very simple to apply. The most widely used 
technique for the determination of free component concentration of a system is the 
potentiometric titration, which uses a glass electrode. This method is applicable both 
for the determination of the protonation and complex formation constants. 
The technique can be used whenever the ligand involved in the equilibrium of complex 
formation is also involved in a acid/base type balance. In this system there is a 
competition between the proton and metal ion for the ligand. 
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The potential   of the system measured with a glass electrode is correlated with the 
activity of hydrogen ions, through an equation analogous to that of Nernst: 
         
  
 
        
    
  
 
         
  
 
         (2.19) 
   is the standard or asymmetry potential,   is an experimental parameter  that takes 
into account the deviation from the theoretical Nernst slope (is typically slightly less 
than 1),     is the activity coefficient of the ion H+
 and     is the activity of proton 
and       its concentration. 
In solutions at constant temperature and ionic strength, the coefficient     remains 
constant and can be incorporated in the standard potential   : 
     
 
   
  
 
               (2.20) 
where: 
  
 
       
  
 
              (2.21) 
  
 
and   can be obtained through an appropriate calibration procedure, which is 
generally a titration of a strong acid with a strong base. The values of the measured 
potential can then be correlated with the concentration     , and the equilibrium 
constants obtained can be expressed in terms of concentration.  
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2.4.2.1. Glass Electrode Calibration 
Calibration of the glass electrod must be performed daily before starting the 
measurements. The calibration of glass electrodes, in terms of hydrogen ion 
concentration, may be processed by: 
1. Following IUPAC recommendations [7], which are based on the use of 
either one or two designated buffer solutions, or by using a regression 
procedure performed with data from more than two buffer solutions [8-9]. 
2. Titration of a strong acid with a strong base, with known acidic 
concentration [10]. 
The second procedure satisfies the normal conditions used in the determination of the 
stability constants (high ionic strength). GLEE (Glass Electrode Evaluation) [11] is the 
program used for the calculation of the slope and standard electrode potential  of the 
glass electrode. The program was developed as part of Hyperquad, that is a program 
for determining the stability constants [12]. It uses a (non-linear) least-squares 
refinement to fit a modified Nerst equation: 
                       (2.22) 
where   is the measured electrode potential,    and   are parameters of the 
refinement and represent the standard electrode potential and slope, and      
represents the hydrogen ion concentration.    and   are used in Hyperquad data 
input. Equation (2.22) is an excellent approximation with the exception of the regions 
with high acidity or basicity, where junction potentials may be not negligible. GLEE 
allows to linearize the titration curve (Fig. 2.3). 
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Figure 2.3. Gran plot obtained with GLEE program. 
 
The points are plotted using the method of Gran that is useful to check the presence of 
impurities in the titrant (carbonate in the base). The graph is formed by two lines (acid 
and basic). The intersection of the two lines gives an estimate of the equivalent 
volume (  ) acid and basic, (in this point the Gran function is equal to zero). Ideally, 
without experimental errors the two    must be equal. In reality, the alkaline solution 
is impure and           is higher. The alkalinity level can be used to evaluate this 
error: 
  k                   
                  
         
         (2.23) 
In our laboratory the strong basic solution (KOH) is substituted when the alkalinity 
level is greater than 2%. 
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2.4.3. Spectrophotometric Method 
Spectrophotometry is an important technique for the determination of stability of 
complexes in solution. This technique is very powerful, because measures 
quantitatively the absorption without perturbing the equilibrium. 
Spectrophotometry is based on the Beer-Lambert law: 
               (2.24) 
where A is the absorbance, ε is the absorptivity (characteristic of each substance at 
each wavelength), c is the molar concentration of the absorbing species and   is the 
optical path length in cm. When considering systems with more than one component, 
each point of the spectrum is a sum of the contributions of each individual species: 
                                   (2.25) 
 
2.4.3.1. Decomposition of Spectral Gaussian  
To describe an experimental signal of Gaussian shape the easily handled form is used: 
     
  
       
 
  
 
         (2.26) 
where H is the height of the peak,    the abscissa of the maximum, W the width of the 
band at half height (half-bandwidth) and the proportionality factor k = 2.7725. The UV-
VIS spectrum of a single species is composed by several analytical signals, and can be 
expressed as the sum of Npks Gaussian peaks: 
        
    
   
      
              (2.27)             
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In many situations (as in equilibrium and kinetic studies or in analytical procedures) 
spectra from     different solutions are recorded. The spectra are the sum of the 
contributions of two or more species, whose concentration varies among the 
solutions. These     spectra can be expressed by a set of     equations similar to 
equation 2.27, all of which have the same   
  and    values, while the Npks intensive 
factors      assume a definite value in each spectrum. The experimental absorbance 
values from     solutions at    wavelengths are stored in a matrix   [      ] with 
indexes   and   respectively, where each column represents a single spectrum:  
   
          
   
            
         (2.28) 
Summing equation 2.26 with 2.27 is possible to describe each element: 
           
  
       
  
 
  
      
           (2.29) 
Taking this equation into account, the matrix of calculated absorbances can be 
expressed as a product of a matrix            of the exponential terms by a matrix of 
heights           :  
                (2.30) 
The intent of any least-squares procedure is to find in the above equation the values of 
the parameters which minimize    
   
   , namely the sum of the squares of residuals 
             extended to    wavelengths and     solutions. In equation 2.30 the 
matrix A is linearly depent on , while it is a non-linear function of    and . The least 
square procedure can be studied by to different types of calculation: i) a linear one for 
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the determination of the peaks height, and ii) non-linear for the determination of the 
position and width of the band. The decomposition of the bands is performed with the 
program SPECPEAK [13]. 
 
2.4.4. Simultaneous Potentiometric and Spectrophotometric Titrations 
Potentiometric titrations were performed with an automatic titrator Dosimats 
Metrohm 665, connected to a Metrohm 691 pH-meter. All titrations were carried out 
at a temperature of 25.00±0.02 °C. The solutions have been maintained under inert 
atmosphere by flushing with ultrapure argon in the cell. To keep the system in 
constant agitation magnetic stirring was used. A daily electrode calibration was 
performed. 
The UV-Visible spectra were measured with a Varian Cary50 spectrophotometer with a 
fiber optical system using two different optical paths (0.2 cm for the pure ligands and  
1 cm to analyze the ligands with metals). The immersion of the fiber on the titration 
cell allows the simultaneous determination of potentiometric and spectrophotometric 
data. The ability to record directly the spectrum in the cell eliminates some drawbacks 
associated with the use of cuvettes, in particular: 
 Changes in temperature due to the transfer of the solution; 
 Loss of substance by transfer into the cuvette; 
 Formation of air bubbles in the cuvette. 
The great advantage is that is possible to automate the entire process by synchronizing 
the titrator, the pH-meter and the spectrometer. This allows to perform titrations with 
a high number of experimental points.  
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The collected spectral data were analyzed with the programs SPECFIT and  
SPEAKPEAK [13], and the potentiometric data with the program HYPERQUAD [12]. 
Simultaneous spectrophotometric and potentiometric titrations were used for all the 
new ligands reported in this thesis (see papers V, VI and VII), firstly, to study and 
determine the dissociation constants pK of ligands (see Fig. 2.4), and secondly to 
determine the complex formation constants of the ligands with the metal ions. 
 
 
 
Figure 2.4. A) Potentiometric curve of ligand L9; B) Spectra collected during the 
potentiometric titration of the ligand L9, the red spectra was collected at pH acid, and the 
blue one at basic pH; C) Speciation plot of the ligand L9. 
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For iron and copper combined potentiometry with spectrophotometric analysis was 
performed. In the case of the colorless alluminium and zinc complexes only 
potentiometry was used. After obtaining the refined data, was possible with HySS 
(Hyperquad Simulation and Speciation) [14], to simulate the speciation plots of pure 
ligands and in the presence of metal. These data are reported in papers V, VI and VII. 
 
2.4.5. Nuclear Magnetic Ressonance 
In 1945 two physical groups of the Stanford University and Harvard University headed 
by Felix Bloch and Edward Mills Purcell, respectively, observed independently the first 
signals of nuclear magnetic resonance (NMR). Since that date, the enormous 
development of the technique has led to the design of extremely refined and precise 
instruments. The NMR technique is one of the most versatile methods of investigation 
for the different fields of scientific research, being particularly used in chemistry, 
biology and medicine. NMR spectroscopy studies the magnetic properties of the 
nucleus allowing detailed information about the molecules structure, nature of the 
atoms, their number, and also the type of molecular surroundings in which the atom is 
located. By the other hand, not all atoms can be observed with this technique, but only 
those with suitable magnetic characteristics.  
The nucleus magnetic properties are represented by its nuclear magnetic moment μ, 
defined as: 
    
   
  
          (2.31)        
where, γ is a proportionality constant called gyromagnetic ratio (different for each 
type of nucleus), I is a fundamental property of the nucleus, called nuclear spin angular 
momentum (with values of 0, 1/2, 1, ... in units of h/2π), and h is the plank constant. 
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The effective value of I, for each nuclei, depends on the mass and atomic number. 
Nucleus with I ≠ 0, can be studied by NMR spectroscopy, whereas the nuclei with an 
even number of protons, neutrons or both (such as, 12C, 16O and 32S, I = 0) cannot be 
studied. 
Hydrogen is the most important magnetic element. It is present in almost all organic 
compounds, and this explains why the 1H-NMR technique was the first to be 
developed. Another widely studied nucleus is the isotope carbon 13 (13C), which is 
present in the nature in about 1.1%. These are the two nucleus studied in this 
dissertation and they have both spin I = 1/2. 
When a sample is introduced in magnetic field, the movement of the electrons creates 
small local magnetic fields, which shield the nucleus from the applied magnetic field. 
When an external magnetic field B is applied to an atom, the electron cloud that 
surrounds the nucleus, generates a small magnetic field with opposite direction to B, 
shielding the nucleus itself. Each nucleus of the sample is immersed in an effective 
field (Beff) different than B: 
                    (2.32) 
where σ is the shielding constant. The value of σ depends on the nucleus chemical 
vicinity, and it is generally higher for nuclei surrounded by a dense electron cloud. 
Nuclei of the same element in a different chemical surrounding resonate at slightly 
different frequencies, originating different signals in the NMR spectrum. The NMR 
spectrum is divided in two parts (see examples reported in Fig. 2.5), where the right 
part (upfield) resonate shielded nuclei and the left part (downfield) resonate less 
shielded nuclei. 
Normally, NMR spectra are made with constant    (frequency), and varying the 
magnetic field from higher to lowest values. The separation in units of the magnetic 
field between two spectral peaks depends on the type of spectrometer used, being 
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directly proportional to its operating frequency. In a spectrometer operating at         
360 MHz, the separation signals of two chemically different nucleus is six times higher 
than one that operates at 60 MHz. In order to make comparable spectra, recorded 
with instruments operating at different frequencies and magnetic fields, it has been 
introduced a dimensionless unit, which allows to measure in absolute the position of 
the spectral lines. This measure is called chemical shift δ, 
    
                 
  
           (2.33) 
where δ is defined as the resonance frequency difference of a particular signal         
from the trimethylsilane signal TMS           expressed in Hz, divided by the 
operating frequency of the instrument expressed in MHz (  ) [15]. 
 
 
Figure 2.5. 1H-NMR spectra of L4 in D2O at pH 3.5 (in black), and Kojic acid in D2O at 
pH = 7 (in red). 
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In this dissertation, the 1H-NMR technique with operating frequencies of 300 or        
400 MHz was used to follow the synthesis of the ligands L4, L5, L6, L7, L8, and L9, and 
to analyze the reaction intermediates and final products. Furthermore, for all ligands 
the HSQC (Heteronuclear Single Quantum Correlation) technique was also used, which 
allows to assign the NMR signal with certainty to the corresponding nucleus (see  
Fig. 2.6). 
 
 
 
Figure 2.6. 1H-13C HSQC of L4 in MeOD. 
 
1H-NMR titration of all ligands, at different pH values, was a useful method not only to 
evaluate the protonation constants, specially in acidic pH, where it was not possible to 
use the potentiometric method, but mainly to correctly attribute the different 
protonation steps at the various basic groups on the ligand. All data (chemical shifts) 
were analyzed with HypNMR [16-17] program, leading to the optimized value of log β.  
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Also, 1H-NMR titrations of the ligands with Zn and Al for different M:L ratios were 
performed. In the case of Al, the slow exchange of ligand between its free and 
complexed forms determines the appearance of separate NMR signals; due to this 
property, in the study of the ligand L4 with Al with the ratio M:L = 2:3 the first evidence 
of the formation of Al2(L4)3 complex was obtained (see paper VI). 
 
2.4.6. Electrospray Ionization Mass Spectroscopy 
Mass spectrometry (MS) is based on the generation of gaseous ions from analyte 
molecules, with subsequent separation of these ions according to their mass/charge 
(m/z) ratio, and the detection of these ions. MS is applied analytically in a great variety 
of qualitative and quantitative studies. Qualitative applications comprise 
determination of the structure of unknown compounds such as natural substances, 
metabolites of drugs and synthetic compounds. MS is used for the determination of 
molecular mass, molecular formula and elemental composition. Compared to other 
spectrometric techniques, MS is the most sensitive spectrometric technique for 
molecular analysis, like NMR and infrared spectrometry. In quantitative analysis, MS is 
applied for developing definitive and reference methods.  
The mass spectrometer is a highly sophisticated and computerized instrument. It 
consists of five major components: a vacuum system, an ion source, a mass analyzer, 
an ion detector, and a data recording system, as shown in Fig. 2.7. There are several 
ion sources, which can be classify in hard and soft. Electrospray Ionization (ESI) is a soft 
ionization technique extensively used for production of gas phase ions (without 
fragmentation) of thermally labile large molecules. The process of electrospray 
ionization includes both the nebulization of the liquid stream into an aerosol of highly  
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charged droplets and the ionization of the analyte molecules after desolvation of the  
charged droplets. ESI is subsumed under the atmospheric pressure ionization (API) 
interfaces. The sample is introduced, after an appropriate split through the 
chromatographic column or by direct insertion via infusion apparatus through a 
stainless steel hypodermic needle into the atmospheric pressure desolvation chamber. 
While the needle is at ground potential, a strong electric field (2-5 kV) is applied to the 
cylindrical counter electrode which charges the surface of the liquid emerging from the 
needle, creating a fine spray of charged droplets. Driven by the electric field, the 
droplets pass through a curtain of nitrogen drying gas. The gas curtain has the function 
of supporting evaporation of the solvent and preventing the uncharged material from 
entering into the ion source. By expansion of the curtain gas, the ions are carried 
through a capillary into the vacuum of the first pumping stage, and then pass through 
the pumping stages and the lens system, finally into the mass analyser [18-19]. 
The compounds studied in this dissertation were pure solids and they were introduced 
into the ion source by direct insertion. ESI-MS was used with qualitative purposes, 
analyzing both the pure L4, L5, L6, L7, L8, and L9 ligands and in presence of several 
metals: Fe3+, Al3+, Cu2+, and Zn2+. ESI-MS was a useful method to investigate the 
stoichiometric of the formed complexes, see the example showed in Fig. 2.7 of the 
mass spectrum of L9 with Fe3+, and papers V, VI for other ligands and paper VII for L9 
with different metals. 
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Figure 2.7. Schematic representation of a mass spectrometer. 
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Appendix 1 
Intermediates and other Ligands Synthesized 
3-hydroxy-6-(hydroxymethyl)-2-((4-phenylpiperazin-1-yl)methyl)-4H-pyran- 
4-one 
Kojic acid (100 mg, 0.7 mmol) was stirred in aqueous ethanol (96%, 10 mL) at room 
temperature. Phenylpiperazine (107.5 µL, 0.7 mmol) and aqueous formaldehyde (37%, 
57 µL, 0.7 mmol) were mixed whit ethanol (2 mL) for 30 minutes and then added drop 
wise to the ethanolic mixture previously prepared. Stirring at room temperature was 
maintained for 18h and during this time a fine white precipitate appeared. Upon 
refrigeration for 2h, the reaction mixture was filtered and the resultant solid washed 
whit cold ethanol. The reaction was followed by TLC, using CH2Cl2:MeOH (6:0.5) 
mixture as eluent. The final product was obtained as a white solid (η = 79%) soluble in 
basic water. Melting point: 191-192 °C. 1H-NMR (300 MHz, D2O + KOD, pH = 11):  
δ 7.2165(5H, Ph), 6.391(1H,S), 4.460(2H, s), 3.728(2H, s), 3.189(4H, s), 2.776(4H, s). 
C17H20N2O4, Mass spectrum (ESS-MS (+)): MH
+ (317.2). 
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Figure A.1.1. 3-hydroxy-6-(hydroxymethyl)-2-((4-phenylpiperazine-1-yl) 
methyl)-4H-pyran-4-one (MW = 316.2). 
 
 
Figure A.1.2. 1H-NMR spectrum of 3-hydroxy-6-(hydroxymethyl)-2-((4-phenylpiperazine-1-
yl) methyl)-4H-pyran-4-one. 
 
 
 
 
 
 
 
W
at
er
 
Appendix 1 
 
 
107 
2-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-3-hydroxy-6-(hydroxymethyl)-4H-
pyran-4-one 
Kojic acid (40 mg, 0.28 mmol) was stirred in aqueous ethanol (96%, 8 mL) at room 
temperature. 1-(4-chlorophenyl)-piperazine dihydroclhoride (95%, 80 mg, 0.30 mmol) 
neutralised whit NaOH (1 M, 0.6 mL, 0.6 mmol) and aqueous formaldehyde (37%,  
25 µL, 0.31 mmol) were mixed in ethanol (2 mL) for 30 minutes and then added drop 
wise to the ethanolic mixture prepared above. Stirring at room temperature was 
maintained for 6h, and a fine white precipitate appeared. Upon refrigeration for 2h the 
reaction mixture was filtered and the resultant solid washed whit cold ethanol. The 
reaction was followed by TLC, using CH2Cl2:MeOH (6:0.7) mixture as eluent. The final 
product was obtained as a white solid (η = 51%), that is soluble in acid water. Melting 
point: 210 °C. 1H-NMR (300 MHz, D2O + DCl, pH = 3): δ 7.217(4H, Ph), 6.623(1H, S), 
4.560(2H, s), 4.544(2H, s), 3.581(4H, s), 3.514(4H, s). C17H19ClN2O4, Mass spectrum 
(ESS-MS (+)): MD+ (352.2). 
 
 
Figure A.1.3. 2-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-3-hydroxy-6-
(hydroxymethyl)-4H-pyran-4-one (MW = 350.1). 
 
 
 
Appendix 1 
 
 
108 
 
Figure A.1.4. 1H-NMR spectrum of 2-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-3-hydroxy-
6-(hydroxymethyl)-4H-pyran-4-one. 
 
2-((dibenzylamino) methyl)-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one 
Kojic acid (0.50 g, 3.5 mmol) was stirred in ethanol (96%, 20 mL) at room temperature. 
N-dibenzylamine (715 µL, 3.6 mmol) and aqueous formaldehyde (37%, 285 µL,  
3.5 mmol) were mixed whit ethanol (2 mL) for 30 minutes and then added drop wise to 
the ethanolic mixture prepared above. Stirring at room temperature was maintained 
for 36h. The reaction mixture was dried on a rotavapor, acetone was added to the 
dried product and the mixture was left on the refrigerator. After 2h acetone was 
separated and the oily product was dried. The reaction was followed by TLC, using 
CH2Cl2:MeOH (6:0.7) mixture as eluent.  A yellow oil was obtained (η = 82%), soluble in 
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basic water. 1H-NMR(300 MHz, D2O + KOD, pH  = 12 ): δ 7.282(10H,Ph), 6.190(1H,S), 
4.258(2H, s), 3.723(2H, s), 3.613(4H, s). C21H21NO4. 
 
 
Figure A.1.5. 2-((dibenzylamino) methyl)-3-hydroxy-6-(hydroxymethyl)-4H-
pyran-4-one (MW = 351.1). 
 
 
Figure A.1.6. 1H-NMR spectrum of 2-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-3-hydroxy-
6-(hydroxymethyl)-4H-pyran-4-one. 
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5-(benzyloxy)-2-(hydroxymethyl)-1-methylpyridin-4(1H)-one 
5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one (300 mg, 1.3 mmol) and 
methylamine hydrochloride (99%, 88 mg, 1.3 mmol) were mixed in ethanol (96%,  
15 mL). The reaction mixture was refluxed at 65 °C, and after one hour NaOH (7 M) 
was added until pH=12. The mixture was left under stirring further 1.5 hours, after that 
a precipitate appears. The precipitate was filtered and the resultant solid washed whit 
cold ethanol. The reaction was followed by TLC, using CH2Cl2:MeOH (6:0.7) mixture as 
eluent. The final product (η = 39%) is a solid soluble in acid water. 
 
 
Figure A.1.7. 5-(benzyloxy)-2-(hydroxymethyl)-1-methylpyridin-4(1H)-one 
(MW = 245.1). 
 
5-hydroxy-2-(hydroxymethyl)-1-methylpyridin-4(1H)-one 
To 5-(benzyloxy)-2-(hydroxymethyl)-1-methylpyridin-4(1H)-one (20 mg, 0.08 mmol) 
was added Pd/C catalyst (5 mg, 25% of starting material) and methanol (10 mL). The 
mixture was stirred for 1 hour under the pressure of two atmospheres. The final 
product was a white solid (η = 95%). 1H-NMR (300 MHz, D2O): δ 7.698(1H, s), 
6.768(1H,S), 4.639(2H, s), 3.789(3H, s). C7H9NO3. 
 
Appendix 1 
 
 
111 
 
Figure A.1.8. 5-hydroxy-2-(hydroxymethyl)-1-methylpyridin-4(1H)-one  
(MW = 155.1). 
 
 
Figure A.1.9. 1H-NMR spectrum of 5-hydroxy-2-(hydroxymethyl)-1-methylpyridin-4(1H)-
one. 
 
5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one 
To kojic acid (1.00 g, 7 mmol) was added benzylchloride (99%, 1.1 mL, 7.1 mmol), 
NaOH (7 M, 1.3 mL, 9 mmol) and ethanol (96%, 25 mL). The reaction mixture was 
refluxed at 65/70 °C for 12 hours; was evaporated whit a rotavapor and cold water was 
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added. A light brown precipitate appeared, filtered and the resultant solid washed 
whit ether. The reaction was followed by TLC, using CH2Cl2:MeOH (6:0.5) mixture as 
eluent. A light brown solid (η = 78%) was obtained, and is soluble in basic water. 1H-
NMR(300 MHz, MeOD): δ 7.932(1H, s) 7.310(5H,Ph), 6.431(1H,S), 4.949(2H, s), 
4.326(2H, s). Melting point: 125-126 °C. C13H12O4, Mass spectrum (ESS-MS (+)): 
[M+Na]+ (254.9). 
 
Figure A.1.6. 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one (MW = 232.1). 
 
 
Figure A.1.7. 1H-NMR spectrum of 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one. 
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5-(benzyloxy)-2-(hydroxymethyl)pyridin-4(1H)-one 
To 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one (1.00 g, 4.3 mmol) was added 
ammonia (16 mL) and ethanol (96%, 25 mL). The reaction mixture was refluxed at 
65/70 °C for 16h. The solvent was evaporated using a rotavapor and acetonitrile was 
added. A precipitate appeared, was filtered and the resultant solid was washed whit 
cold acetonitrile. The reaction was followed by TLC, using CH2Cl2:MeOH (6:0.7) mixture 
as eluent. The final product was a beige solid (η = 80%), soluble in basic water. 1H-
NMR(300 MHz, MeOD): δ 7.632(1H, s) 7.442(5H,Ph), 6.616(1H,S), 5.085(2H, s), 
4.422(2H, s). Melting point: 210-220 °C. C13H13NO3, Mass spectrum (ESS-MS(+)): [M + 
Na]+(254.0), [M + K]+(269.9). 
 
 
Figure A.1.8. 5-(benzyloxy)-2-(hydroxymethyl)pyridin-4(1H)-one  
(MW = 231.1). 
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Figure A.1.9. 1H-NMR spectrum of 5-(benzyloxy)-2-(hydroxymethyl)pyridin-4(1H)-one. 
 
5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one  
To 5-(benzyloxy)-2-(hydroxymethyl)pyridin-4(1H)-one (600 mg, 2.6 mmol) was added 
Pd/C catalyst (90 mg, 15% of starting material) and methanol (20 mL), the mixture was 
stirred 2h under the pressure of two atmospheres. A dark purple solid was obtained (η 
= 20 %). 
1H-NMR(300 MHz, D2O): δ 7.622(1H, s), 6.533(1H,S), 4.609(2H, s). Melting point: 239-
241 °C. C6H7NO3, Mass spectrum (ESS-MS (-)): MH
-(139.9). 
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Figure A.1.10. 5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one (MW = 141.0). 
 
 
Figure A.1.11. 1H-NMR spectrum of 5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one. 
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Appendix 2 
Unsuccessful Synthesis 
First Strategy 
Considering the higher affinity of deferiprone to iron compared with kojic acid, we tried to 
synthesize new hydroxypyridinones starting from kojic acid derivatives (see Fig. A.2.1.). The 
substitution of the oxygen in the hydroxypyrone ring with a nitrogen is possible only for the 
single unit of kojic acid but does not occur when two units of kojic are joined by a linker 
(Table 1). 
 
Figure A.2.1. Reaction scheme. 
 
We tried to change in the four reactions (listed in the table A.2.1.) the base, replacing 
ammonia with benzylamine, but we obtained again only the fragmented reagents. 
Furthermore, we tried the same four syntheses at room temperature by increasing the 
reaction times (till 20 days), but a partial decomposition of the reagents and the formation 
of 5-hydroxy-2-(hydroxymethyl) pyridin-4 (1H)-one occurs. 
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Table A.2. 1. Reactions with NH3 
Ligands reagents 
T 
(°C) 
Time 
(h) 
Comments 
L1 NH3 70/80 21 Decomposition reagents 
L2 NH3 70/80 26 Decomposition reagents 
L6 NH3 70/80 20 No reaction 
L8 NH3 70/80 46 Decomposition reagents 
a In all the reactions ethanol was used as a solvent 
 
Second Strategy 
We tried to obtain the kojic acid derivatives substituted with the nitrogen in the ring, 
starting from 5-hydroxy-2-(hydroxymethyl)pyridin-4 (1H)-one (R = H) and 5-(Benzyloxy)-2- 
(hydroxymethyl)pyridin-4 (1H)-one (R = Bn) (see Fig. A.2.2.). 
 
Figure A.2.2. Reaction scheme. 
 
In Tables A.2.2. and A.2.3. are reported the several trials for the different conditions tested, 
namely, change in temperature, time of reaction and reagents.  
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Table A. 2.2  Reactions starting from  5-(benzyloxy)-2-(hydroxymethyl)pyridin-4(1H)-onea 
 
 
 
 
Reagents 
T 
(°C) 
Time 
(h) 
Comments 
Formaldehyde  
+ NH3 
65/70 24 No reaction 
Acetaldehyde  
+ NH3 
65/70 36 No reaction 
Ortovanilin 
+ NH3 
65/70 24 
Decomposition 
reagents 
Formaldehyde  
+ dimethylamine 
RT RT No reaction 
Acetaldehyde  
+ dimethylamine 
RT RT No reaction 
Ortovanilin  
+ dimethylamine 
RT RT 
Decomposition 
reagents 
a In all the reactions ethanol was used as a solvent. 
 
Table A.2.3.  Reactions starting from  5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-onea 
 
 
 
 
Reagents 
T 
(°C) 
Time 
(h) 
Comments 
Formaldehyde 
+ NH3 
65/70 48 No reaction 
Acetaldehyde 
+ NH3 
65/70 48 No reaction 
Ortovanilin 
+ NH3 
65/70 48 No reaction 
Ortovanilin 
+ dimethylamine 
RT 68 
Decomposition 
reagents 
Formaldehyde 
+ Piperazin 
RT 6 No reaction 
a In all the reactions ethanol was used as a solvent. 
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Chelation Therapy for Metal Intoxication: Comments from a Thermodynamic 
Viewpoint 
Valeria Marina Nurchi, Miriam Crespo-Alonso, Leonardo Toso, Joanna Izabela Lachowicz and 
Guido Crisponi
* 
Dipartimento di Scienze Chimiche e Geologiche, Università di Cagliari, Cittadella Universitaria, 09042 Monserrato-
Cagliari, Italy  
Abstract: Chelation therapy plays a prominent role in the clinical treatment of metal intoxication. In this paper the 
principal causes of metal toxicity are exposed, and the chemical and biomedical requisites of a chelating agent are 
sketched. The chelating agents currently in use for scavenging toxic metal ions from humans belong to few categories: 
those characterized by coordinating mercapto groups, by oxygen groups, poliaminocarboxylic acids, and 
dithiocarbamates. Considering that the complex formation equilibria have been studied for less than 50% of chelators in 
use, some reflections on the utility of stability constants are presented, together with an evaluation of ligands under the 
stability profile. The competition between endogenous and toxic target metal ions for the same chelating agent is 
furthermore examined. A thorough examination of stability constant databases has allowed to select, for each toxic metal, 
the ligands distinguished by the best pMe values. Even though this selection does not consider the biomedical requisites of 
a chelating agent, it gives a clear picture both of the pMe values that can be attained, and of the most appropriate chelators 
for each metal ion.  
Keywords: Chelating agent, Chelation therapy, Heavy metal, Speciation, Stability constant, Toxic metal. 
INTRODUCTION 
 The poisoning action of toxic metal ions, originated by 
accidental, occupational/environmental and iatrogenic causes, 
represents one of important health and social problems both 
in developed and in emerging countries [1-12]. The research 
on this topic is nonetheless totally inadequate since the 
investments of pharma-industries are limited because of their 
poor profitability. The research on chelating agents to be 
used in clinical practice is based essentially on biology-
driven programs, paying no attention to the chemical 
knowledge of the mechanism involved in the complex 
formation. Actually the term “chelating agent” in common 
sense is a drug able to bind metal ions. In this way the 
chelating agents used for given metal ions are not necessarily 
the best, but the most common drugs. Specificity and 
stability, as well the knowledge of the length of the treatment 
(limited in time or lifelong) are extremely important in the 
choice of a chelator. A first intent of the present paper is to 
remark, based on the analysis of literature data, the large 
extent of chelators in use for which a deep chemical basis is 
lacking, and to propose a strategy for the future research in 
this field. A second aim is the selection from stability 
constant databases of the best possible families of ligands for 
each target toxic metal ion. Speciation plots and proper 
parameters (pM) will allow a preliminary evaluation of the 
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4478; E-mail: crisponi@unica.it 
attitude of these ligand families as chelators for clinical 
treatments. Finally, some aspects of wide importance, as the 
competition between toxic and endogenous metal ions 
toward the same metal chelator, have been deepened. 
METAL TOXICITY 
 Metal toxicity can be roughly sorted in three big different 
classes according to its sources and effects: 
• Acute intoxication, deriving from direct ingestion of 
toxic metal (accidental, as often occurs to children, 
or due to a voluntary homicidal or suicidal attempt); 
• Chronic intoxication, depending on environmental 
pollution, or related to work conditions, or to iatrogenic 
causes;  
• Metal overload due to genetic diseases (-thalassemia 
(iron)
1
 and Wilson’s disease (copper) [6, 13]).  
 This classification helps in managing clinical treatments, 
among which chelation therapy plays a prominent role. 
Chelation therapy has the intent of scavenging the toxic 
metal ion from the organism, or of attenuating its toxicity by 
converting it in a less toxic compound, or of relocating it 
from the position where its action is toxic to a compartment 
where the toxic action cannot be exploited, or of controlling 
its redox potential. 
 
                                                
1 -thalassemia, a genetic disease with a defect in haemoglobin synthesis, 
requires regular blood transfusions to prevent anaemia. 
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CHAPTER 11 
Metal Ions in the Pathogenesis of Alzheimer’s Disease: An Open 
Field 
Guido Crisponi1,*, Valeria M. Nurchi1, Daniela Fanni2, Clara Gerosa2, Sonia 
Nemolato2, Miriam Crespo-Alonso1, Leonardo Toso1, Joanna I. Lachowicz1 
and Gavino Faa2 
1Department of Chemistry and Geology, University Campus, 09042 Montserrat 
Cagliari, Italy and 2Department of Surgical Sciences, Sec., Pathology, Via 
Ospedale 46, 09124 Cagliari, Italy 
Abstract: Despite the large availability of data regarding the mechanisms at the basis of β-
amyloid production in Alzheimer’s disease (AD), the factors responsible for β-amyloid 
accumulation in neurons of AD patients until now have not been entirely clarified. Several 
metal ions have been indicated as possible triggers of the main conformational 
modifications of β-amyloid protein, and metal homeostasis disarrangement has been 
proposed as a relevant pathological cofactor of neurodegeneration. Epidemiological 
evidences suggest a possible association between exposure to increased amounts of 
multiple metals and onset and progression of AD. According to this hypothesis, metals 
could induce oxidative stress in neurons, developing neurodegenerative disease. In this 
chapter, the role of various trace metals as cofactors of a poor cognitive function and of an 
increased risk of dementia leading to AD will be discussed. In particular, this study is 
aimed to critically analyze the role played by copper, iron, zinc and aluminium in 
neurodegeneration. Based on the current evidences concerning the relationship between 
these metal ions and onset and progression of AD, no definitive recommendations are, at 
the best of our knowledge, possible. However, foods rich in metals such as iron and copper 
should be discouraged, as well as caution should be suggested in exposure to aluminium 
sources. Further studies on the relationship between metal overexposure and AD 
development hopefully will open new opportunities for the prevention and management of 
neurodegenerative diseases. 
Keywords: Alzheimer’s disease, neurodegenerative diseases, β-amyloid protein, 
oxidative stress, copper, iron, zinc, aluminium. 
INTRODUCTION 
Alzheimer’s disease (AD) may be defined as a disarrangement of the cellular  
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control system responsible for the correct folding of proteins during neuronal cell 
life. Misfolded proteins show a tendency to aggregate, leading to a series of 
severe pathological consequences and ultimately to AD, suggesting the inclusion 
of this disease among conformational diseases [1]. Two proteins are characterized 
by misfolding in AD: β-amyloid protein (Aβ), a proteolytic cleavage product of 
the Aβ precursor protein (APP), and tau protein, a microtubule-associated protein, 
prone to aggregation after hyperphosphorylation [2]. Despite a large amount of 
data available in the recent literature regarding the mechanisms at the basis of Aβ 
production and of its interactions with other cellular components, the factors 
responsible for Aβ accumulation in neurons are nowadays still not entirely 
clarified. Mounting evidences support the hypothesis that both endogenous and 
exogenous metal ions could be involved, as factors or cofactors, in the 
pathogenesis of AD [3]. A number of metal ions have been indicated as possible 
triggers of the main conformational modifications of Aβ, and metal 
dyshomeostasis has been suggested as a relevant pathological cofactor of 
neurodegeneration [4]. Gathered evidence suggests that Aβ precipitation could be 
caused by abnormal interactions with metal ions, including ZnII, CuII and FeIII. 
Moreover, in a mouse model of AD, compounds that interdict metal ion binding 
to Aβ have been reported to inhibit Aβ precipitation and deposition, opening a 
new field of research: the metallobiology of AD [5]. These data suggest a major 
role for trace metal ions in the generation of toxic Aβ oligomers in neurons, that 
are likely to be responsible for the synaptic dysfunction associated with AD. On 
this basis the so-called “metal protein attenuating compound” approach has been 
recently proposed as a novel therapy for AD [6]. 
Whereas the previous data indicate that metal ions - including iron, copper, zinc 
and aluminium – might increase the neurotoxicity of Aβ, other reports have 
demonstrated that Aβ could help to limit the toxicity on brain cells exerted by 
redox-active metal ions, thereby participating to the antioxidant defense of 
neurons against reactive oxygen species (ROS). These findings were at the basis 
of the hypothesis of the amyloid paradox, amyloid-beta-metal complexes 
putatively being neurotoxic and, under some circumstances, neuroprotective [7]. 
This review will try to report the main data from the recent literature on the role 
played by metal ions in the onset and development of AD, focusing on the role 
played by iron, copper, zinc and aluminium in neuronal toxicity and dementia. 
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METAL-INDUCED OXIDATIVE STRESS AND NEURO-
DEGENERATIVE DISEASE 
The brain is a highly oxidative organ, accounting for about 2% of total body 
weight but consuming 20% of the oxygen used by the whole body. Moreover, 
with normal ageing, human brain accumulates transition metal ions, including iron 
and copper, which may promote the generation of ROS via Fenton chemistry* [9]. 
Binding of Aβ to redox-reactive metals, which in turn generate free radicals, has 
been proposed among the several mechanisms recognized to be involved in the 
molecular pathways to neurodegeneration and, in particular, in the onset and 
development of AD [10]. Compelling evidences - based on results of studies on in 
vitro systems, experimental animals and humans - indicate that the etiology of AD 
involves oxidative stress. This implicates that redox active metal ions, such as 
copper and iron, and redox-inert zinc ions, play a central role in this process [11]. 
According to this hypothesis, trace metal dyshomeostasis and the consequent 
abnormal accumulation of transition metals, including iron and copper, in the 
ageing brain cells might elicit oxidative stress and macromolecular damage that 
could eventually impede neuronal function leading to neurodegeneration and to 
AD [12]. It has been claimed that the increased oxidative stress in brain cells of 
AD patients could be reflected by increased protein and DNA oxidation, enhanced 
lipid peroxidation, decreased levels of cytochrome c oxidase and increased brain 
content of transition metal ions iron and copper, both capable of stimulating free 
radical formation via Fenton reaction [13]. Redox active CuII and FeIII ions have 
been shown to be reduced in the presence of Aβ protein, with concomitant 
production of ROS, hydrogen peroxide (H2O2) and hydroxyl radical (OH.), 
leading directly to the widespread oxidation damages typical of AD brains [14]. 
The discovery of a functional iron-response element (IRE) in the 5’ untranslated 
region of APP, consistent with the biochemical evidence that it is a redox-active 
metalloprotein, is at the basis of the hypothesis that the redox interactions between 
Aβ protein and metal ions may be at the heart of a pathological positive feedback 
system, wherein Aβ amyloidosis and oxidative stress promote each other [14]. 
                                                            
* According to Alexander “…. a potential harmful chemical property of iron and its compounds is the ability to 
catalytically generate potent hydroxyl radicals that are oxidatively toxic to cells. This catalysis (Fenton reactions) occurs 
with activated oxygen species (superoxide and hydrogen peroxide) ….” [8]. 
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Abstract 
Copper is present in different concentrations and chemical forms throughout the earth crust, surface and deep water 
and even, in trace amounts, in the atmosphere itself. Copper is one of the first metals used by humans, the first 
artifacts dating back 10,000 years ago. Currently, the world production of refined copper exceeds 16,000 tons / year. 
Copper is a micro-element essential to life, principally for its red-ox properties that make it a necessary cofactor for 
many enzymes, such as superoxide dismutase and cytochrome-c oxidase. In some animal species (e.g. octopus, snails, 
spiders, oysters) copper-hemocyanins also act as carriers of oxygen instead of hemoglobin. However, these red-ox 
properties also make the pair Cu+/Cu2+ a formidable catalyst for the formation of Reactive Oxygen Species, when 
copper is present in excess in the body or in tissues. 
The treatment of choice in cases of copper overloading or intoxication is the chelation therapy. Different 
molecules are already in clinical use as chelators or under study or clinical trial. It is worth noting that chelation 
therapy has also been suggested to treat some neurodegenerative diseases or cardiovascular disorders. 
In this review, after a brief description of the homeostasis and some cases of dyshomeostasis of copper, the main 
(used or potential) chelators are described; their properties in solution, even in relation to the presence of metal or 
ligand competitors, under physiological conditions, are discussed. The legislation of the most important Western 
countries, regarding both the use of chelating agents and the limits of copper in foods, drugs and cosmetics, is also 
outlined. 
 
1. INTRODUCTION 
1.1 Copper in environmental compartments 
Copper was the first metal discovered by man and is still 
extensively used today. In fact, copper production has 
lifted over the last decades and continues increasing, 
meaning that more copper ends up in the environment. 
The World consumption of refined copper amounted to 
20.5 million tons in 2012 (16.7 million tons were 
achieved in 2005) [1]. Copper is the material of choice for 
many industrial and commercial uses due to its 
versatility, malleability, resistance to corrosion and good 
thermal and electrical proprieties. It is extensively used 
to make electrical wiring, motors and magnets, tubing 
and valves, fittings, munitions, alloys (stainless steel, 
brass, bronze), coins, cooking utensils, coatings and 
building materials. Copper derivatives are used as 
fungicides, algicides, insecticides or preservatives for 
wood, leather and fabrics. For example, chromated 
copper arsenate (CCA) was extensively used in the past 
 
 
2 
 
to treat wood. After January 2004 the US Environmental 
Protection Agency (EPA) has banned its use for building 
construction, especially for children’s structures [2]. 
Copper is used as a fertilizer for plants and is given to 
animals as a nutrient to support growth. It is also used to 
prevent diseases in livestock and poultry production and 
to increase the intake of food by animals. One 
consequence of this is the accumulation of copper in 
manure that is thrown to the fields and contaminates 
soils. In 1999, the European Commission proposed limits 
for the use of copper in animal feed. According to size 
and age of the animal, copper values can range from 
170–25 mg/kg–1 for pigs, 15 mg/kg–1 for cattle and 25 
mg/kg–1 for chickens, sheep and goats. No regulation is 
adopted in China for copper use in animal feed, and its 
use is often excessive.  
Copper is essential for the normal functioning of 
plants, animals and microorganisms, but at elevate 
concentrations it becomes toxic. Therefore its levels in 
the natural environment and its biological availability are 
a very important issues. When copper is released into 
the environment, the metal is exposed to different 
conditions (pH, redox potential, and organic content) 
that influence its bioavailability. It is well knows that the 
concentration and type of dissolved organic carbon [3-5] 
and the presence of competing cations such as Ca2+, 
Mg2+, H+, Na+ or K+ [6, 7] can modify the bioavailability of 
copper.  
Natural discharges of copper to air and water occur, 
as a result of windblown dust and volcanic eruptions, but 
the main contribution for copper accumulation in the 
environment results from industrial activity. Copper 
enters in the air, mainly during the combustion of fuel 
and motor oil and during copper and other metals 
production. In air, copper persists for about 13 days [8], 
and remains there before it settles in the soil or water 
with rain. In Europe, the mean copper emission to 
atmosphere from road transport was estimated to be 
4.0–5.5 ktonnes/year [9]. Brake lining material from 
vehicles is also an important source of particulate copper 
emissions to the atmosphere, particularly in Western 
Europe where is responsible for 50–75% of the total 
copper emissions to air [9].  
The accumulation of copper in the soils is a result of 
the extensive use of copper-based fungicides and 
fertilizers. Particularly, the use of fungicides to fight vine 
diseases has led to accumulation in vineyard soils all over 
the world [10]. Copper has been detected at 
concentrations above 100 mg/kg in soils of France [11], 
Italy [12] and other European countries [10, 13], in the 
American continent [14] and in Australia [15]. As a result 
soils contain large quantities of copper, predominantly in 
the Cu2+ state complexed or bonded to the organic 
matter. The level of free copper in the soils is controlled 
by a combination of complexation, adsorption, and 
precipitation processes. 
The release of copper into rivers, lakes, and oceans 
results mainly from waste discharges, like those from 
mines and industries, leaching of antifouling marine 
paints and wood preservatives. In aquatic environments, 
copper is extremely toxic to fish, invertebrates, 
amphibians, algae and aquatic microorganisms [16]. Its 
toxicity is proportional to the concentration of inorganic 
Cu2+ species. In addition, the free hydrated Cu2+ ion 
blocks the uptake of essential micronutrients Mn2+ and 
Zn2+ [17]. 
Copper contaminated sediments may contain a wide 
range of copper concentrations that increase the degree 
of exposure to the metal [18, 19]. Copper bioavailability 
and toxicity is controlled by its adsorption, complexation 
and precipitation with other ligands, like sulfide. 
Unfortunately, the enormous heterogeneity of sediment 
composition makes it extremely difficult to predict the 
correlation of sediment toxicity due to a specific 
contaminant like copper. New guidelines to determine 
copper values in marine sediments, were proposed 
recently by Simpson et al. [19].  
1.2 Copper in food and drinking water 
Copper is an essential nutrient required for adequate 
growth, cardiovascular integrity, lung elasticity, 
neovascularization, neuroendocrine function, and iron 
metabolism. The average intake of copper by human 
adults varies from 0.6 to 1.6 mg/day, and about half is 
absorbed from food [20-23]. The main sources of copper 
intake are seeds, grains, nuts, beans, potatoes, tomatoes, 
shellfish and liver [23]. Copper in food is bound to 
organic molecules and is processed safely by the liver 
and distributed to copper-requiring proteins [24]. Excess 
of copper is excreted through bile and this is the main 
factor controlling homeostasis. 
Copper in drinking water contribute less to copper 
intake (<0.001 mg/day) [25, 26], but depending on water 
characteristics, like pH and hardness, and the availability 
of copper in the distribution system, the concentrations 
of copper can vary significantly. Several studies 
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performed in Europe, Canada and in the USA indicate 
that copper levels in drinking water can range from 
≤0.005 to ≥30 mg/L [27].  
The exact value for copper recommended intake is 
difficult to precise, because there are several parameters 
to consider, like age, sex, dietary intake, and region of 
origin. Most of the studies concerning copper deficiency 
and excess in humans have been performed in USA. 
Regarding this, in 2001 the recommended dietary intake 
(RDA) of copper has been reported to be 0.9 mg/day for 
human adults specified by the Institute of Medicine 
(IOM) [28]. More recently, in 2004 ministries of health of 
Australia set their own recommendations to 1.7 mg/day 
for adult man and 1.2 mg/day for adult woman [29]. 
1.3 Copper in drugs and cosmetics 
Throughout history, copper compounds have been used 
in medicine, either topically or ingested. More than 2000 
years ago, the ancient Egyptians and Chinese people 
used copper salts as antiseptics and to sterilize drinking 
water [30]. In the 19th century, the medical use of copper 
became widespread with a variety of inorganic copper 
preparations that were used to treat chronic adenitis, 
eczema, impetigo, scrofulosis, tubercular infections, 
lupus, syphilis, anemia, chorea, and facial neuralgia. 
Nowadays, copper continues to be an important 
component of a great number of pharmaceutical agents. 
For example, copper intrauterine devices for the 
prevention of inception are widespread used for very 
prolonged periods of time by millions of women 
worldwide. Another example, although controversial, is 
the use of copper bracelets to treat arthritis and to help 
reduce pain [31-35]. Further studies report the 
effectiveness of magnet therapy on rheumatoid arthritis 
and chronic pain [36].  
Copper has long been used as antifungal and 
antibacterial agent. Although the exact mechanism by 
which the metal acts is not fully understood, its benefits 
have long been recognized (for recent reviews see 
references [37-39]). In addition, its strong biocidal 
properties are routinely used in healthcare areas as in 
the control of legionella [40, 41] and other bacteria [42] 
and in hospital water distribution systems using the 
method of copper and silver ionization. 
Recently, the use of copper as anticancer agents has 
attracted much attention. First of all, being an essential 
element, copper complexes are believed to be less toxic 
than cisplatin compunds, currently used in cancer 
therapy (reviewed by [43]). Even though the precise 
action of copper is not always known, it is believed that a 
big contribution to its toxicity comes from its ability to 
produce reactive oxygen species (ROS), to displace other 
metal ions, to peroxidize lipids, and to cleave DNA or 
RNA. In addition, copper-based semiconductors are also 
attractive alternatives to cadmium-contrasting agents for 
in vivo cancer imaging [44, 45], because their chemistry is 
dominated by only two oxidation states and its 
coordination chemistry remains relatively simple 
compared to other transition elements. 
Copper derivatives are also used in cosmetics. The 
copper complexes formed with the tripeptide (glycyl-
histidyl-lysine, GHK) [46], isolated from human plasma, 
have been extensively studied as anti-aging cosmetics 
[47] and wound healing drugs [48]. They stimulate the 
synthesis of collagen, elastin and glycosaminoglycans and 
promote the formation of the extracellular cement 
between cells [48]. A series of studies have 
demonstrated that cosmetics containing GHK are more 
effective than the traditionally used treatments 
containing Vitamin C, or retinoic acid [47]. The creams 
with GHK were shown to improve strength and elasticity 
of the skin. 
2. COPPER IN THE HUMAN BODY  
Copper is a transition metal ion essential to human 
health. It acts as catalytic or structural cofactor of many 
enzymes, it is required for the development and function 
of nervous and cardiovascular systems and it is 
fundamental for the skin, bone, reproductive and 
immune systems. Many body functions such as collagen 
production, formation of red blood cells, regulation of 
cholesterol levels, iron adsorption, oxidation of fatty 
acids, melanin production and intracellular energy levels 
control are all dependent on copper.  
The amount of copper contained in human organisms 
is about 80-100 mg [49]. However, it is believed that this 
number is dependent on age and gender [50]. The 
highest concentrations of copper are present in the brain 
and the liver, but the central nervous system and the 
heart contain high levels of copper as well [49].  
In human body, most of copper is bound to biological 
macromolecules, under both its main oxidation states: 
Cu
+
 is mainly present in the intracellular space (reducing 
environments), while Cu2+ is dominant in the 
extracellular space (oxidizing environment). The oxidized 
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(Cu2+) and reduced (Cu+) copper exhibit different 
chemical properties. Cu+ is not stable in aqueous solution 
where it is easily oxidized to Cu2+. The standard reduction 
potential (E0) of the couple Cu
2+/ Cu+ is 0.153 V, thus 
reflecting the low likelihood that Cu2+ is reduced.  
According to the Pearson acid-base concept (HSAB), 
Cu+ usually prefers to bind soft ligands rather than 
intermediate ones as Cu2+ does. In proteins, stable Cu+ 
binding sites are usually formed by sulfur thiolate or 
thioether from Cys and Met, while Cu2+ is usually 
anchored to His imidazole or N-terminal amino group.  
Copper behaves as catalytic cofactor of many 
enzymes which exploit the copper redox activity to carry 
on many biological reactions [51]. Cytochrome-c oxidase 
(CcO), superoxide dismutase (SOD), ceruloplasmin, 
tyrosinase, peptidyl-α-monooxygenase and dopamine 
beta-monooxygenase are some examples of human 
copper enzymes. 
Despite that, redox activity of copper may also 
originate highly toxic species. In fact, Cu2+, similarly to 
Fe3+, may also catalytically favour the formation of 
reactive oxygen species (ROS), which in turn cause high 
oxidative stress in our body. The reaction, known as 
Haber–Weiss reaction generates hydroxyl radicals from 
hydrogen peroxide and superoxide [52]. 
  
              
                                          [1]                                         
Importantly Haber–Weiss reaction is 
thermodynamically unfavorable in biologic systems and it 
require Fe3+ (or Cu2+) to proceed. The resulting metal-
catalyzed reaction, including the Fenton reaction, is now 
believed to be the major mechanism by which ROS are 
produced in biological systems [53]. 
  
              
                                                    [2]                 
Fenton Reaction               
               [3]  
It is believed that abnormal and uncontrolled 
concentrations of Cu2+ inside the cell, might be 
responsible of cellular oxidative damage. In fact ROS 
generated by Cu2+ and Fe3+ may in turn lead toxic cellular 
events such as DNA damage, protein and lipid oxidation. 
For these reasons our body, possesses complex pathways 
which beside to ensure copper intake, distribution, 
utilization and excretion are able to contrast its toxicity. 
2.1 Copper homeostasis 
Copper is required for the proper function of many 
enzymes whose activity is fundamental for the life of our 
organism. Copper levels in our body are strictly regulated 
by a sophisticated machinery composed by a network of 
proteins whose functions guarantee correct copper 
delivery to specific cellular targets, avoiding circulation of 
“free” copper. In fact, because of the high toxicity of 
“free” copper ions, which can participate to the 
production of ROS, it is strictly necessary that copper 
adsorption, distribution, utilization and excretion is 
regulated by specific proteins able to tightly bound 
copper ions [54-57]. The precise functioning of the 
systems regulating copper homeostasis is fundamental 
for our health and its alterations may lead to severe 
disease states [58, 59]. As this regard, eukaryotic systems 
have developed a well-organized systems which ensure a 
correct copper transportation to all the specific cellular 
targets.  
After copper intake by diet, copper is absorbed in the 
small intestine where the metal is absorbed by intestinal 
epithelial cells [51, 60]. Copper storage in the liver or 
copper excretion in bile takes place if too much copper is 
adsorbed. As shown in Fig. 1, copper translocation across 
the cellular membranes is carried out by human Ctr-1 
(hCtr-1), a high affinity copper transport protein (Figure 
1) [61-63], mainly expressed in the liver and kidney [64]. 
Ctr-transporter proteins are also found in other 
organisms, indicating a conserved function from yeast to 
higher species. Ctr-1 is a relatively small transmembrane 
protein (190 amino acids), with three transmembrane α 
helices. Although Ctr family members have a low 
sequence homology, they are all characterized by 
common features: a long N-terminal extra cellular 
domain rich in Met and His residues and a conserved 
CysHisCys motif at the end of the short C-terminal tail, in 
the cytoplasm.  
 
 Figure 1. Schematic representation of copper 
distribution inside the cell. 
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Copper transportation inside the cell occurs through a 
channel-like architecture formed by homo trimer hCtr-1 
structures [65]. It is still not clear which protein residues 
are involved in channel relay and how the channel is 
controlled. However, there are strong evidences that Cu+, 
rather than Cu2+ is bound to Ctr-1 [66-68]. The 
mechanisms by which Cu
+
 is transferred from 
extracellular proteins (e.g ceruplasmin, 
metalloreductase, amino acids) to Ctr-1 is not 
understood yet. It has been recently proposed that Cu+ is 
specifically transferred to hCtr-1 by the following 
mechanisms [61]: (i) the N-terminus of hCtr-1 possesses 
an high affinity site for Cu+ bound molecules, or (ii) a 
stable metalloreductase-hCtr-1 complex is formed. 
Ctr-1 possesses Cu+ binding domains at both N- and 
C-terminus. At the N-terminus, the extracellular domain 
of hCtr-1 is able to coordinate two Cu+ ions. Each binding 
sites is constituted by three Met thioether groups [65, 
69]. Recent investigations on model peptides 
encompassing the first 14 residues of the extracellular 
hCtr-1 domain, indicate that His residues might be 
involved in copper acquisition from plasma proteins as 
well. In addition, they might play a key role in Cu2+ 
reduction to Cu+ [70]. On the other hand, the Cu+ binding 
domain at the C-terminal intracellular domain of Ctr-1 is 
constituted by Cys clusters [71]. 
Once Cu+ is delivered inside the cell, it is handled by 
precise copper chaperones which guarantee its 
transportation to various subcellular compartments (e.g. 
Golgi apparatus, mytochondria) for subsequent 
incorporation into copper enzymes (Figure 1).  
Copper is transported to the Golgi apparatus by two 
components system, Atox1 and copper transporting 
adenylpyrophosphatase (ATPase), ATP7A and ATP7B [72-
74]. In the cytoplasm, Atox1 chaperone binds Cu+ and 
transfers it to ATPase. Subsequently both ATP7A and 
ATP7B deliver copper ions to the Golgi apparatus. Human 
Atox1, also known as Hah1, is a 68 amino acids protein 
displaying a ferrodoxin-like fold [75]. The Cu+ binding site 
is located in the first loop and encompasses –MTCGGC–
residues (MXCXGC motif) [75]. Ternary complexes are 
formed, with Cu+ coordinated to sulfur atoms from two 
Cys and from exogenous thiols [75, 76].  
ATP7A and ATP7B are transmembrane proteins (TPs) 
able to pump copper(I) to the Golgi organelle [77]. The 
metal ion passage across the cell membranes is made 
possible by the energy release occurring during ATP 
hydrolysis. The N-terminal cytosolic tail of ATPase 
contains six Cu+ binding domains, showing positive 
cooperativity in metal coordination and forming tetra-
thiolate clusters [54-56].  
Beside pumping copper into the Golgi network, 
ATP7A and ATP7B function as fine regulators of copper 
adsorption and excretion in the human body [54-56, 78, 
79]. If copper levels inside the cells are too elevate, they 
are capable to translocate from the Golgi apparatus to 
the cellular membrane and to pump copper(I) ions into 
the extracellular space. ATP7A also regulates the 
transport of diet ingested copper from the intestine to 
the blood, thus guaranteeing copper delivery to all the 
other tissues [80]. ATP7B is also localized at the biliary 
pole of hepatocytes, where it facilitates copper excretion 
into the bile [81]. As it will be discussed in the next 
section, mutations or deletions in the ATP7A and ATP7B 
genes yield to severe disease states, known as Menkes 
(MD) and Wilson’s diseases (WD), respectively [82, 83]. 
Copper is delivered to CcO, in the mitochondrial inner 
membrane (MIM), by six copper chaperones: Cox17, 
Cox19, Cox23, Sco1, Sco2 and Cox11 [54, 56, 57]. The 
first three proteins are soluble proteins, while the other 
are MIM proteins. All these copper chaperones are 
strictly required for ensuring the proper copper transport 
to each copper sites of CcO. In fact, CcO contains three 
copper ions, two are located at the binuclear site (CuA) in 
the Cox1 domain and the remaining one is located at the 
mononuclear site (CuB) in the Cox2 domain. Cox11 is 
responsible for the delivery of copper to the CuB site of 
CcO [82], while the other five chaperones are necessary 
for copper transport to CuA site. The transport of copper 
from the cytoplasm to each site of CcO is quite complex 
and each metal chaperone needs the assistance of all the 
other; the exact mechanisms are still not completely 
understood. 
Superoxide dismutase (SOD) is another important 
metalloenzyme which requires metal ions for its catalytic 
activity. Two main isoforms of SOD have been identified 
according to the metal ion content: CuZn-SOD and Mn-
SOD.  CuZn-SOD is widely distributed in the cytoplasm, 
nucleus, and intermembrane space of mitochondria, 
while Mn-SOD is found only in the mitochondrial  
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matrix [84]. Both proteins catalyze the dismutation of 
superoxide to hydrogen peroxide thus reducing the 
superoxide produced during the respiratory chain. The 
chaperone responsible for carrying copper to CuZn-SOD 
is Ccs [85, 86].  
In addition to chaperones which transport copper to 
any specific cellular destinations, copper inside the 
cytoplasm is also handled by metallothioneins (MT) 
which protect cells from copper toxicity [87].  
Finally, albumin and ceruloplasmin are the two 
proteins that bind copper in blood. Ceruloplasmin is the 
major copper carrier, being responsible to transport 90% 
of copper. Human serum albumin is able to transport 
many metal ions such Cu2+, Ca2+, Zn2+, Ni2+. The high 
affinity Cu2+ binding site is at the N-terminus –AspAlaHis– 
(ATCUN motif), where the metal ion is bound to the His 
imidazole, the Asp-1 amino group and one or both the 
amido nitrogens of the peptide backbone between Asp 
and His. In the presence of ascorbate, Cu2+ bound to 
albumin is reduced to Cu+ which in turn is easily 
reoxidezed to Cu2+ by molecular oxygen [88, 89].  
The small percentage of copper (5-15%), which is not 
covalently bound to ceruloplasmin is usually referred as 
free copper pool even if it is loosely bound to albumin 
and other small molecules. In order to avoid copper 
toxicity, the free copper pool should be maintained to 
low levels since many evidence indicates that the larger 
is the free copper pool, the greater damage is produced.  
2.2 Sources and disturbance of copper overload 
Copper overload causes morphological and metabolic 
alterations in human tissues and, if untreated, can 
ultimately lead to death. The main sources of copper 
accumulation originates from genetic and environmental 
factors. In addition, copper poisoning has been observed 
in kidney dialysis patients due to use of contaminated 
water or leaching from dialysis membranes [90]. 
Obviously any accidental or intentional copper ingestion 
has severe consequences for our health. Finally copper 
toxicity is associated with neurodegenerative diseases 
and other disorders of aging, characterized by altered 
copper homeostasis [91].  
2.2.1 Genetic basis for copper toxicity 
As briefly discussed in the previous section, copper 
transport in our body is tightly regulated by a complex 
network of proteins whose impairment result in harmful 
cellular copper levels [58, 59, 92]. Ingested copper is 
primarily absorbed in the small intestine. From the 
intestine, copper first enters in the liver. Copper is then 
delivered to endogenous enzymes, incorporated into 
ceruloplasmin and secreted into the blood. Excess of 
copper are secreted in the bile. As schematized in Figure 
2, ATP7A and ATP7B play an important role in the 
physiological regulation and distribution of copper in the 
body. The inactivation of ATPase copper transporting 
proteins, disturbs the correct copper efflux from cells, 
giving rise to extensive copper accumulation in the 
intestine (ATP7A inactivation) or in the liver (ATP7B 
inactivation).  
Mutations in ATP7B gene are associated to WD which 
is an inherited disorder characterized by high copper 
levels mainly in the liver and in the brain [93, 94]. The 
major symptoms of patients suffering from WD are 
severe hepatic injuries, such as hepatitis and cirrhosis, 
and neurological disorders [94, 95].  
  
Figure 2. Schematic representation of the role of ATPases 
in the regulation and distribution of ingested copper 
Although ATP7B is expressed in several tissues, it 
plays a major role in hepatocytes, where it (i) transports 
copper into the Golgi network and (ii) sequesters excess 
copper into vesicles. Both processes are essential for 
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cellular life: the former ensures copper incorporation 
into copper-dependent enzymes (e.g. ceruloplasmin) [95, 
96], the latter allows copper excretion outside the 
cytosol guarantying safe copper levels inside the cell [97]. 
Mutations of the ATP7B gene alter the expression and 
the function of ATP7B, thus affecting both copper 
excretion into the bile and copper transport to the Golgi 
organelle. The results are that high copper levels 
accumulates inside the tissues causing oxidative damage 
to proteins, DNA, membranes [98] and triggering toxic 
metabolic responses [93]. 
As for ATP7B, ATP7A is involved in copper excretion 
outside the cytoplasm as well. In particular it is mainly 
involved in copper export from intestinal epithelium. In 
addition ATP7A is required for copper delivery to copper 
dependent enzymes [99, 100], including tyrosinase [101], 
lysyl oxidase [102] and peptidyl-α-monooxygenase [103]. 
Mutations on ATP7A gene cause the MD which is 
associated with the loss of the functional activity of 
ATP7A. In MD, copper accumulates in the intestinal cells 
and cannot be absorbed to the other cellular tissues 
leading to copper deficiency and reduced activity of 
essential cuproenzyme such as CcO (in the 
mitochondria), tyrosinase, and Cu/Zn SOD (in the cytosol) 
[104-106]. MD is also characterized by additional copper 
accumulation in cells located between the blood-brain 
barrier and choroid plexus, indicating that copper 
transport from blood vessels to neurons is impaired as 
well [105].  
MD is associated with a huge number (357) of 
mutations in the ATP7A gene, including insertions and 
deletions (22%), non-sense (18%), missense (17%), 
partial deletions (17%), and splice-site mutations (16%) 
[104, 107, 108]. MD is a X-linked recessive disorder which 
mainly occurs in males. MD is clinically classified 
according to the disease severity in classical MD, mild 
MD and occipital horn syndrome (OHS) which is the 
mildest and a rare form of MD. Severe neurological 
degeneration, abnormal hair, hypothermia, and 
connective tissue disorders, gait abnormalities and 
muscle hypotonia are the characteristic clinical features 
of MD and OHS.  
Beyond WD and MD, which are the most known 
inherited diseases caused by abnormal copper transport 
in our body, other disorders may additionally be 
originated by copper accumulation. For examples Indian 
Childhood cirrhosis (ICC) [109], Endemic Tyrolean 
infantile cirrhosis (ETIC) [110] and Idiopathic copper 
toxicosis (ICT) [111] are severe diseases characterized by 
copper deposits in the liver. All of them are now very 
rare but they had a great incidence in the last century in 
the rural area of India and Austria. The data collected so 
far, strongly indicate that these hepatic copper toxicosis 
are caused by a synergy of genetic deficiency in copper 
metabolism and excess dietary copper intake arising 
from contaminated water and/or utensils. 
2.2.2 Environmental copper toxicity 
Copper is commonly found in the environment and it is 
largely used in many industrial and agricultural processes 
(see above). Unlike organic pesticides, copper does not 
degrade, but rather enters a complex biogeochemical 
cycle [112]. Disposal of copper-containing waste water 
causes accumulation of copper near river banks. In 
addition the amount of copper released during the 
combustion of fossil fuels may accumulate in the airs and 
successively end up in the soils when it rains. 
For these reasons, people working in, or living in the 
proximity of industries settings handling high level of 
copper compounds, such as mines, landfills, waste water 
disposals, metal production plants, phosphate fertilizer 
plants, wood treatment plants, may undergo to 
environmental copper overload.  
In presence of excessive copper levels, our body can 
absorb copper through the skin, by inhalation and by 
ingestion. Copper exposure by inhalation is very rare and 
it is mainly due to breathing fumes or dust deriving from 
any processes involving copper and its compounds. The 
Occupational Safety and Health Administration (OSHA) 
has set a limit of 0.1 mg/m3 of copper fumes and 1 
mg/m3 of copper dusts and mists in workroom air during 
an 8-hour work shift. Higher copper inhalation can lead 
to nose, mouth, and eyes irritations, headaches, nausea, 
and diarrhea.  
On the other hand, drinking copper contaminated 
water or eating acid foods cooked in uncoated copper 
cookware are the most likely routes of excessive copper 
intake. The Environmental Protection Agency has set a 
copper maximum level of 1.3 mg/l (1.3 ppm) in drinking 
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water [113]. Although, water usually contains very low 
copper concentrations, it may happen that it dissolves 
copper from plumbing fixtures, especially when it stays 
for long time in pipes. Another important issue is that 
copper is handled differently by the body when ingested 
by food or consumed in drinking water or mineral 
supplement [114]. Food copper is processed by the liver 
(Figure 2), which regulates copper excess and prevent its 
release into the free copper pool in the blood. On the 
other hand, inorganic copper present in water or mineral 
supplements, is immediately transferred to the free 
copper pool, bypassing liver metabolism.  
Recent studies on Alzheimer’s Disease (AD) rabbit 
model indicate that very low copper amount in distilled 
water (0.12 ppm) dramatically increase amyloid plaques 
and decrease cognitive performance in cholesterol fed 
animals [115], thus suggesting that the allowed copper 
levels present in drinking water may worsen cognitive 
decline in patients affected by AD. Compared to age-
matched controls, higher free copper levels are present 
in the blood of AD patients [116]. In addition lower 
cognitive ability is usually associated with higher levels of 
copper [117].  
Beyond AD, other neurodegenerative diseases (e.g. 
Parkinson’s Disease, Prion Disease, Huntington’s disease, 
amyotrophic lateral) are characterized by the presence of 
high amount of copper in the brain amyloid plaques [118, 
119] thus suggesting a similar toxic role played by copper 
in all these disorders. To support the role of copper in 
accelerating general cognitive ability, it has been shown 
that copper intake by vitamin/mineral supplement pills 
together with consumption of high fat diet, enormously 
affects cognition performance which is generally lost at 
over three times the rate normally expected [120].  
 
3. COPPER CHELATORS IN MEDICINE 
3.1 Chelators in the treatment of Wilson’s disease 
The most widely known chelators for copper in chelation 
therapy are those used for the treatment of WD. Among 
a number of copper chelators developed and tested, the 
three most important ones are D-penicillamine (D-pen), 
Trentine (Triethylenetetramine, Trien) and ammonium 
tetrathiomolibdate (TTM), whose structures are reported 
in Figure 3. 
HO
SH
SH
BAL
HS
COOH
NH2
D-pen
HNNH
H2NNH2
Trien
HOOC SH
HOOC SH
HO3S
SH
SH
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2 NH4
+
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Figure 3. Copper chelators for the treatment of WD.  
Indeed, the very first chelator used for WD was 
dimercaprol (2,3-dimercaptopropanol, British anti-
Lewisite, BAL, Figure 3), originally developed during the 
World War II as an antidote for lewisite, a chemical 
warfare agent, and later employed to treat metal 
intoxications [121]. It was replaced by D-pen (less toxic 
and orally available) still the most used, although Trien 
revealed to be better tolerated [122]; TTM showed a 
remarkable efficacy in the treatment of patients with 
neurological symptoms [123]; unfortunately is not yet 
commercially available. 
D-penicillamine: The study of D-pen in the treatment 
of WD originated from the observation that patients 
administered with penicillin excreted penicillamine in the 
urine as a metabolite, therefore suggesting that the 
latter compound could be bioavailable [124]. Its capacity 
to remove copper is remarkable [125], although its 
hydrophilicity probably prevents the compound to 
permeate the blood-brain-barrier (BBB). For these 
reasons, several more lypophilic derivatives of D-pen 
have been prepared and reported in the literature [126], 
in the attempt to increase the BBB permeability of the 
chelators and their cell uptake. 
The clinical practice for the administration of D-pen 
has been reported [127]. D-pen is capable to mobilize 
copper from inside the cells and promotes its urinary 
excretion [128]. In mouse liver, D-pen was found to 
increase the expression of MT, which binds copper 
forming a non-toxic adduct [129]. On the other hand, it 
has been shown that, in rat models of WD, the level of 
MT and of the related mRNA is increased by excessive 
copper in hepatocytes, and reduced upon treatment with 
D-pen [130]. Remarkably, the administration of D-pen 
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combined with a deficiency in vitamin B6 levels were 
reported to cause neurological worsening [131]: for 
these reasons, vitamin B6 is routinely administered 
together with D-pen. Side effects such as fever, rash, 
renal toxicity [132], ANCA-vasculitis [133], and 
dermatologic toxicity have been reported [134]. For 
these reasons, it has been also suggested that D-pen 
should not be used as the initial therapy in WD [135, 
136]. The administration of D-pen needs to be 
discontinued in 20-30% of patients [137, 138] and it has 
to be followed by a different treatment to avoid rapid 
progression of fatal hepatitis [139]. 
Triethylenetetramine: Trien has been introduced in 
clinical practice with the purpose of having a different 
treatment for patients intolerant to D-pen [122]. Trien is 
a hydrophilic and orally available chelator, capable to 
bind copper in the blood and to promote its urinary 
excretion, even though it is less efficient than D-pen 
[140]. The use of D-pen and Trien as initial treatments in 
WD was shown to worsen the neurological symptoms 
that likely originates from a temporary increase of 
protein-unbound copper, especially due to copper 
mobilization from the liver [141, 142]. An increase of the 
albumin level in cerebrospinal fluid (CSF) compared to 
serum has been observed as a possible effect of 
perturbation of BBB [143]. Therefore, it has been 
suggested that by monitoring this ratio a basis to guide 
the modulation of the chelation therapy can be obtained. 
The clinical practice for the administration of Trien 
has been described [127]. The side effects of Trien are 
milder and less frequent [122] with respect to D-pen and 
Trien proved as efficient as D-pen in pediatric patients 
[137]. 
Ammonium tetrathiomolibdate: The diammonium 
salt of the MoS4
2- anion has been studied with the 
specific purpose of developing a new compound for the 
treatment of WD which could replace D-pen and Trien 
[144, 145]. Its efficacy in reducing copper levels in the 
body have been first observed in ruminants of Australia 
and New Zealand as the consequence of the presence of 
high levels of molybdenum in the soil [146]. TTM forms 
of a ternary complex with copper ions and proteins, 
making copper not available to the cells [147]; its 
biological activity starts in the gastrointestinal tract (see 
further). TTM has been found to be a good alternative 
treatment for neurologically affected WD patients [123], 
and its use in the initial treatment of the disease in 
combination with zinc administration proved to be 
effective [145]. Its recommended doses and clinical 
practice have been reported [123]. Remarkably, TTM is 
able to starve tumor cells of essential copper and it has 
been proposed as a new anticancer agent [148]. 
Sulfurated polydentate chelators: A series of 
potentially efficient chelators have been developed by 
Delangle and coworkers [149], with the aim to prepare 
ligands that possess a higher specificity for certain tissues 
than D-pen, Trien and TTM which actually act as systemic 
chelators. In particular, they developed chelators for Cu+ 
rather than for Cu2+, with the purpose of binding 
intracellular copper which actually is in the reduced 
form. These chelators contain sulfur, especially in the 
form of a free thiol, in order to stabilize copper in the +1 
oxidation state (Figure 4). 
The Px series of chelators consists of a family of cyclic 
peptides containing Cys (and Met) [150-152], which have 
been initially devised on the basis of the known MXCXXC 
peptide sequence of the copper chaperone Atox1 and 
ATPases ATP7A and ATP7B [153, 154]. In particular, the 
cyclic peptide Pc (Figure 4, top left) was designed from 
the actual copper binding sequence MTCSGCS in Atox1 of 
yeast [154], and bears the XPGX fragment to rigidify the 
structure [150]. Not only this peptide mimics very well 
the binding loop of Atox1, but the dissociation constant 
of its Cu+ complex is 10-17.4 M, a value very close to that 
of the chaperone [155]. The very high selectivity of Pc for 
Cu+ versus Zn2+ (ca. 10 orders of magnitude) prompted 
the design of other cyclic peptides (P1, P2 and P3, Figure 
4) which maintained the same Cu/Zn selectivity [151]. 
These peptide contain two Cys residues on one side of 
the molecule (copper binding face), while the other face 
is available for grafting specific groups (see P3, Figure 4) 
with the purpose to target receptors on the surface of 
the hepatic cells [152, 156]. In the prochelator P3 the two 
cysteines form a disulfide bridge that can be reduced 
under the reducing intracellular conditions (e.g. by GSH) 
[152], so that the thiol groups becomes available for Cu+ 
complexation. The opposite face contain four lysine-N-
acetylgalactosamine groups, with the purpose to target 
ASGP-R, a hepatic lectin expressed exclusively on the 
surface of hepatocytes [157, 158]). Indeed, not only the 
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P3 ligand is capable to target hepatocytes (by virtue of 
the “cluster glycoside effect” [159]) and penetrate the 
cell membrane, but fluorescence measurements (using a 
fluorescent copper probe) showed that P3 is capable to 
reduce the intracellular level of available copper [152]. 
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Figure 4. Sulfurated polydentate chelators. 
A few interesting examples of tripodal Cys-rich 
chelators have been reported (HnL
x, Figure 4) [160, 161], 
which have been suggested to act as potential Cu
+
 
chelators in vivo. Because the very stable Cu(I)-MT 
complexes showed that in these adducts a Cu(I)S3 
coordination environment is present [162], 
nitrilotriacetic acid has been used as a platform to 
produce the Cys-containing ligands H3L
1, H3L
2 and H6L
3. 
While  L1 and L2 expectedly form very stable 
mononuclear and polynuclear Cu+ complexes and are 
very selective for Cu+ versus Zn2+, the ligand L3 gives 
polynuclear Cu+ complexes of lower stability as the 
consequence of the presence of three negative 
carboxylate groups that originate a mutual electrostatic 
repulsion. 
Two more hydrophilic and less toxic BAL analogs have 
been developed and used for heavy metal intoxication, 
namely DMSA (meso-2,3-dimercaptosuccinic acid) and 
DMPS (D,L-2,3-dimercapto-1-propanesulfonic acid) 
(Figure 3) [163-165]. In particular, DMSA has been used 
to treat WD patients in China [166], where Trien is not 
commercially available. Finally methanobactin, a 
naturally occurring nine amino acid polypeptide, found in 
methanotrophs bacteria where it serves several 
functions involving copper (and thus termed a 
“chalkophore”), has been tested as a copper chelator in 
rat models of WD, showing the mobilization of copper 
from the liver to the bile [167, 168]. 
3.2 Chelators in the treatment of Alzheimer’s disease 
Alzheimer's disease (AD) is characterized by the 
progressive formation of amyloid plaques. However, it is 
still not clear whether these plaques are the cause or the 
consequence of the disease, and even what mechanisms 
determine their formation. However, it is established 
that some metals of biological interest, such as Fe(III), Zn 
(II) and Cu (II) can interact with soluble and aggregated 
forms of Aβ peptide, also influencing the process of 
fibrillization. Although the toxicity of both the oligomers 
or the plaques and the corresponding complexes is a 
controversial issue [169, 170], a line of research, aimed 
at treating AD, is addressed to the study of the action of 
copper chelators to remove the metal and/or to 
redistribute it into the body. 
Clioquinol (CQ) (5-chloro-7-iodo-8-hydroxyquinoline, 
CQ, also known as PBT1, Figure 5) is an aromatic chelator 
which coordinates metal ions through its (N,O-) donor set 
[171]. CQ has been used in the past as an antibiotic 
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Biofutura Pharma product. All the products were used without any
further purification.
A previous described method was used in the preparation of 0.1 M
carbonate free KOH solution [11]. Ligand solutions were acidified
with stoichiometric equivalents of HCl. FeIII solution was prepared by
dissolving the required amount of FeCl3 in pure double distilled water
to which a stoichiometric amount of HCl was previously added to pre-
vent hydrolysis. This solution was standardized by spectrophotometric
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Scheme 1. Chemical structures and acronyms of studied ligands.
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2.1. Reagents
Kojic acid, benzylamine hydrochloride, piperazine
hydrochloride, NaOH, KOH, FeCl3, methanol, ethanol and
were purchased from Aldrich, and N-benzylmethylami
Aesar product. Formaldehyde was purchased from M
Fluka, and KCl and ZnO from Carlo Erba (Milan, Italy).ethylamine
isopropanol
was an Alfa
, HCl from
feral was a
2.2. Synthesis
All the ligands were prepared from 6-alkylation of
with an aldehyde and a primary amine or an inorganic b
on desired presence or absence of amine group on that al
The particular operations are reported in the following
ligand. For each ligand preparation, a KA (1.00 g, 7.1 m
in ethanol (25 mL) was used. All the reactions were fo
using aCH2Cl2:MeOH (12:1)mixture as eluent. The synth
were fully characterized by different standard instrumental techniques.
NMR spectra were recorded on a Bruker AVANCE III spectrometer at
300 MHz and 400 MHz for 1H NMR and 13C NMR respectively. Chemical
shifts (δ) are reported in ppm related to tetramethylsilane (TMS). Infra-
red spectra were recorded by using KBr pellets on a Jasco FT-IR 410
spectrometer. The electrospray ionization mass spectra (ESI-MS) were
obtained on a 500 MS LC Ion Trap (Varian Inc., Palo Alto, CA, USA)
mass spectrometer equipped with an ESI ion source, operated in the
positive and negative ion modes. The elemental analyses were
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.86
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ethanolic solution. The solution was left under stirring for 3.5 h in a
water bath at 40/50 °C. Solventwas removed under vacuum. Red impu-
rities were removed from the white precipitate by several double
distilled cold water washings, filtrations and dryings under vacuum.
Recrystallization yielded the pure final product (0.84 g, 57%).
Mp = 126–128 °C. Elemental analysis found (calc. for C21H21NO8): C,
59.43 (60.72); H, 5.58 (5.10); N, 3.42 (3.37). FT-IR (KBr, 4000–
400 cm−1): two types of νas(CH2) 2960 and 2925, two types of
νs(CH2) 2888 and 2851, ν(C_O) 1644, δ(CH2) 1454, ν(C\N)tertiary amine
H)ar (benzyl)
), 6.295(2H,S),
MHz, MeOD):
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.
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Scheme 2. Chemical structures and acronyms of studied ligands.
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Although some of the compounds gave unsatisfactory a
for which found values differ by more than ±0.5% fro
crystal structures of all of these compounds were determ
diffraction (XRD) technique or their structures were supp
troscopic (FT-IR, 13C-NMR and ESI-MS) analyses.
2.2.1. 6,6′-(Methylazanediyl)bis(methylene)bis(5-hyd
(hydroxymethyl)-4H-pyran-4-one), L4
Methylamine hydrochloride (0.260 g, 3.8 mmol), prev
ized with NaOH (3.8 mmol), was added to a solution con
dehyde (580 μL, 7.1 mmol) in ethanol (2 mL). The mixt
for 30 min at room temperature, then added drop wi
ethanolic solution described above. The solution was left
for 1.5 h in awater bath at 40/50 °C. Solventwas removed
Addition of CH3CN yielded a white precipitate that w
washed with cold CH3CN, and dried under vacuum for 6
zation afforded the pure product as a white solid (1.09
Mp = 150–152 °C. Elemental analysis found (calc. for
52.76 (53.10); H, 5.48 (5.05);
N, 4.20 (4.13). FT-IR (KBr, 4000–400 cm−1): ν
νas(CH2) 2923, νd(CH3) 2888, νs(CH2) 2853, ν(C_O)
1460, ν(C\O\C)cyclic 1218, π(C\H)ar (kojic) 854.1H-N
MeOD): δ 6.380(2H, s), 4.350(4H, s), 3.763(4H, s), 2.4
NMR (400 MHz, MeOD): δ 145.30 (C), 148.03 (C), 169
(C), 110.09 (CH), 43.11 (CH2), 54.37 (CH2), 61.23 (CH
MH−(338.2), [M + Cl]−(374.2).
2.2.2. 6,6′-(Benzylazanediyl)bis(methylene)bis(5-hydr
(hydroxymethyl)-4H-pyran-4-one), L5
Benzylamine hydrochloride (0.51 g, 3.5 mmol), prev
ized with NaOH (3.5 mmol), was added to a solution of
(633 μL, 7.8 mmol) in ethanol (2 mL). The mixture w
30 min at room temperature and then added drop wit of ±0.4%.
lysis values,
alc. values,
ed by X-ray
ted by spec-
y-2-
sly neutral-
ing formal-
was stirred
to the kojic
der stirring
der vacuum.
filtered off,
Recrystalli-
92% yield).
H17NO8): C,
CH3) 2963,
65, δ(CH2)
(400 MHz,
3H, s). 13C-
(C), 179.95
ESI-MS(–):
y-2-
sly neutral-
maldehyde
stirred for
to the kojic
1360, ν(C\O\C)cyclic 1223, π(C\H)ar (kojic) 858, π(C\
747 and 701. 1H-NMR (300 MHz, MeOD): δ 7.203(5H,Ph
4.306(4H, s), 3.792(4H, s), 3.751(2H, s). 13C-NMR (300
δ 139.10(C), 144.86(C), 149.24(C), 169.68(C), 176.27(C
128.59(CH), 129.32(CH), 130.16(CH), 52.26(CH2)
61.21(CH2). ESI-MS(–): MH−(414.2), [M + Cl]−(450.2)
2.2.3. 6,6′-(Piperazine-1,4-diylbis(methylene))bis(5-h
(hydroxymethyl)-4H-pyran-4-one), L6
Piperazine (0.305 g, 3.5 mmol)was added to a solutio
hyde (580 μL, 7.1 mmol) in ethanol (2 mL). Themixture
30 min at room temperature and then added drop w
ethanolic solution. The solution was left under stirring
which a fine white precipitate appeared. Upon refrige
the reaction mixture was filtered off, washed with
and dried under vacuum for 6 h. Recrystallization affo
product 1.35 g, 97%). Mp N 350 °C. Elemental analysis f
C18H22N2O8): C, 54.18 (54.82); H, 6.07 (5.62); N, 7.17
(KBr, 4000–400 cm−1): two types of νas(CH2) 2951 a
types of νs(CH2) 2880 and 2839, ν(C_O) 1653,
ν(C\O\C)cyclic 1244, π(C\H)ar (kojic) 867, π(C\H)
824.1H-NMR (300 MHz, MeOD + KOD): δ 6.120(2H,S)
3.530(4H, s), 2.490(8H, s). 13C-NMR (400 MHz, MeO
148.782 (C), 154.936 (C), 165.674 (C), 183.262 (C),
53.455 (CH2), 55.127 (CH2), 61.801 (CH2). ESI-MS(–): M
2.2.3.1. Synthesis of L6 crystal. L6 (15 mg) was dissolv
water (12 mL), aided by drop wise addition of HCl 0.01
isopropanol (4 mL) was added and the solution was l
30 min and then filtered into a crystallization device to re
impurities. The solution was left stand at room temper
to evaporate. Evaporation of the solvents was controlle
of a plastic film. After three weeks, parallelepiped co
appeared suitable for XRD.
2.2.4. 2-((Benzyl(methyl)amino)methyl)-3-hydroxy-6-(hydr
4H-pyran-4-one, L7
N-Benzylmethylamine (967 μL, 7.8 mmol) was added t
of formaldehyde (633 μL, 7.8 mmol) in ethanol (2 mL). T
was stirred for 30 min at room temperature and then a
wise to the kojic ethanolic solution described above. The s
left under stirring for 5 h. Solvent was removed under vac
white precipitate was formed. Upon refrigeration for 2 h it
off washedwith cold ethanol and dried under vacuum for 6 h
= 1
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the pure final product (4.61 g, 68%). Mp = 207-208 °C. Elemental anal-
ysis found (calc. for C14H14O8): C, 54.20 (55.70); H, 5.03 (4.55). FT-IR
(KBr, 4000–400 cm−1) νas(CH3) 2983, νas(CH2) 2940, νd(CH3) 2879,
νs(CH2) 2850, ν(C_O) 1653, δ(CH2) 1463, ν(C\O\C)cyclic 1265,
π(C\H)ar (kojic) 857. 1H-NMR (300 MHz, D2O + KOD, pH = 6):
6.560(2H, s), 4.530 (4H, s), 1.660 (3H, d).
2.2.5.1. Synthesis of L8 crystal. L8 (10 mg) was dissolved in EtOH
(10 mL) undermoderate heating (35 °C) and stirred until a clear color-
s filtered into a
to control the
piped colorless
tals, successive
uitable crystals
dies were car-
ous publication
3 × 10−4 to
ies of complex
ation, and 1:1,
otentiometric–
or protonation
e 400–800 nm
path lengths.
zed using the
roTOF-Q spec-
ed with an ESI
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iment parame-
gas: nitrogen;
ollision energy
mode and cali-
nik, Germany).
. Compass Data
d to determine
peaks allowed
S experiments,
on the quadru-
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d to the mass
Fig. 1. Centro-symmetrical H2L62+ ion in the crystal of ligand L6. In
H-bonding interactions are depicted in dotted lines.
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Elemental analysis found (calc. for C15H17NO4.): C, 65.12 (
(6.22); N, 5.11 (5.09). FT-IR (KBr, 4000–400 cm−1) νas(
types of νas(CH2) 2951 and 2938, νd(CH3) 2884, νs(CH2)
1662, δ(CH3) 1496, δ(CH2) 1465, ν(C\N)tertiary amine 136
cyclic 1244, π(C\H)ar (kojic) 853, π(C\H)ar (benzyl)
1H-NMR (300 MHz, D2O + KOD, pH = 12): δ 7.351(5H
S), 4.417(2H, s), 3.684(2H, s), 3.601(2H, s), 2.249(3H, s).
2.2.4.1. Synthesis of L7 crystal. L7 (30 mg) was dissolved i
(1:1) mixture (16 mL). After 30 min stirring, a clear co
was obtained. The solution was filtered into a crystal
and coveredwith a plasticfilm to control the evaporation
In one week, parallelepiped colorless crystals were col
analysis.
2.2.5. 2-2′-Ethanediylbis(3-hydroxy-6-(hydroxymethy
one), L8
Synthesis of L8 was carried out according to liter
[12]. 6.2 g of kojic acid and an equivalent amount of
dissolved in (100 mL) ethanol. The reaction, catalyzed
trated ammonium hydroxide (1 mL), was heated for
60 °C. Then the solvent was left to evaporate and the b
was washedwith cold ethyl alcohol. Recrystallization froFig. 2. View in the ab plane of the H-bonded 3D network of the crystal o
B) Chloride ions and water molecules are removed and the total accessoxymethyl)-
o a solution
he mixture
dded drop
olution was
uum until a
was filtered
. Recrystal-
37–139 °C.
.44); H, 6.14
) 2989, two
31, ν(C_O)
(C\O\C)-
7 and 701.
), 6.331(1H,
H2O/MeOH
ess solution
tion device
he solvents.
ed for XRD
H-pyran-4-
re methods
hyde were
of concen-
ee hours at
precipitate
thanol yield
less solution was obtained. Afterwards, the solution wa
crystallization device and covered with a plastic film
evaporation of the solvent. In one week, small parallele
crystals appeared. In order to improve the size of the crys
filtrations of the mother liquors were performed until s
for XRD purposes were collected.
2.3. Potentiometric–Spectrophotometric measurements
Protonation and complex-formation equilibrium stu
ried out under the same conditions described in a previ
[7]. The operating ligand concentrations ranged from
3 × 10−3 M according to the examined ligand. The stud
formation were carried using constant ligand concentr
1:2, and 1:3 metal/ligand molar ratios. Combined p
spectrophotometric measurements were performed f
equilibria in the 200–400 nm spectral range and in th
spectral range for FeIII complexes, using 0.2 and 1 cm
Protonation and complex formation data were analy
Hyperquad program [13].
2.4. ESI-MS analysis of complexes
ESI-MS spectra were carried out on a Bruker mic
trometer (Bruker Daltonik, Bremen, Germany) equipp
source. Samples were dissolved in water and methan
1:1) and the final pH was ~7. The ligand concentration
and the ligand to metal molar ratio was 1:10. The exper
ters were as follows: scan range: m/z 100–1600; drying
and temperature: 200 °C, ion source voltage 4500 V, c
10 eV. The instrument was operating in the positive ion
brated externally with Tunemix™mixture (Bruker Dalto
Analyte solutionswere inserted at a flow rate of 3 μl/min
Analysis (Bruker Daltonik, Germany) program was use
the formulae of the complexes. The distance between
calculating the charge of the analyzed ions. In the MS/M
the ion corresponding to signal atm/z 392 was selected
pole and subsequently fragmented in the collision cell. A
as a collision gas. The obtained fragments were directe
tra-molecularf L6. A) Chloride ions and water molecules are hosted in the corresponding channels throughout the c axis.
ible voids are plotted in green space fill.
analyzer and registered as anMS/MS spectrum. The collision energywas
10 eV.
2.5. Crystal structure determination
Measured crystals L6, L7 and L8 were prepared under inert condi-
tions immersed in perfluoropolyether as protecting oil formanipulation.
Suitable crystals were mounted on MiTeGen Micromounts™ and these
ed
diff
d c
In addition, one red parallelepiped crystal obtained from the synthe-
sis of one Fe/L6 complex was mounted on a MiTeGen Micromount™
and this sample was used for data collection. Data was collected at the
ESRF synchrotron ID14-1 beamline (λ = 0.9340 Å, 100 K). Previous at-
tempts to determine the structure of these iron compound using con-
ventional X-ray diffraction facilities were unsuccessful provided the
poor diffraction power of the crystal samples. Only a tentative model
for the iron(III) compound Fe2(L6)3 can be proposed due to the limited
resolution achieved in the experiment. Constraints were used to model
nd. The diffuse
was removed
Fig. 3. Overlapped view of the two non-equivalent molecules within the asymmetric unit in the crystal of ligand L7. Molecule 1 is depicted in darker line whereas molecule 2 is
depicted in lighter line. Numbering scheme is also provided. Intra-molecular H-bonding interactions are omitted for clarity.
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SMART APEX [L6 (293 K), L7 (296 K) and L8 (100 K)]
The data were processed with APEX2 [14] program an
absorption using SADABS [15]. The structures were solve
dro
are
dr
fixe
l di
me
wer
ata
re
r the structural
llog
. C
on
6 0
up P21/c) con-
ter molecules.
the acid mole-
cule, thus L6 is centro-symmetric (Fig. 1).
formation. The
cular H-bonds
e O keto–kojic
This latter fea-
ompounds [9].methods, which revealed the position of all non-hy
These atomswere refined on F2 by a full-matrix least-squ
using anisotropic displacement parameters [16]. All hy
were located in difference Fourier maps and included as
tions riding on attached atoms with isotropic therma
parameters 1.2 times those of the respective atom. Geo
tions were carried out with PLATON [17] and drawings
with PLATON and MERCURY [18]. Additional crystal d
information about the X-ray structural analyses a
Supplementarymaterial S1 to S3. Crystallographic data fo
analysis have been deposited with the Cambridge Crysta
Centre, CCDC 914446–914448 from L6 to L8, respectively
information may be obtained free of charge on applicati
Union Road, Cambridge CB2 1EZ, UK (fax: 44 1223 33
deposit@ccdc.cam.ac.uk or http://www.ccdc.cam.ac.uk).Fig. 4. Fragment of one zig-zag 1D chain in the crystal of ligand L7. Note
one inter-molecular interactions. Likewise, the O keto–kojic group alsowith Bruker
ractometer.
orrected for
d by direct
gen atoms.
s procedure
ogen atoms
d contribu-
splacement
tric calcula-
e produced
and more
shown in
the aromatic rings and the piperazine moiety of L6 liga
scattering contribution from solvent and data noise
using the SQUEEZE procedure in PLATON [17].
3. Results and discussion
3.1. Crystal structure of ligands L6, L7, L8
3.1.1. Crystal structure of the ligand L6: (H2L6)Cl2·2H2O
The crystal of ligand L6 (monoclinic system, space gro
sists of one dichlorhydrate acid molecule and two wa
Note that an inversion center is located in the middle ofraphic Data
opies of this
to CCDC, 12
33; e-mail:
The molecule shows the most stable trans-e, e-con
kojic acid moieties are stabilized by two intra-mole
involving the OH phenol-like groups as donors and th
groups as acceptors [O14\H⋯O12 (2.742(2) Å, 113.3°)].
ture has also been observed in closely related kojic-like cthat the OH phenol-like group is involved in a bifurcated interaction acting as H-donors for one intra- and
acts as double H-acceptor from one intra- and one inter-molecular interactions.
The crystal of L6 is a 3D network built thanks to the invo
H2O and H2L62+ and Cl− ions in H-bonding interactions
S1.3). In particular, chloride ions and water molecules are
cavities that extend along the c axis and kept inside due t
bonding interactions involving all the donors from L6 aci
The total accessible void calculated by PLATON [17] is f
18.8% of the crystal volume (Fig. 2).
3.1.2. Crystal structure of the ligand L7: (L7)2
ce g
allo
he
molecules are not equivalent mainly deals with the different torsion
angles defined by the benzyl moiety [molecule 1: bN12–C14–C15–C16
85.78° or molecule 2: bN32–C34–C35–C36 108.05°] (see Fig. 3).
As already described for compound L6, each L7 molecule exhibits
one intra-molecular H-bond that, again, involve the OH phenol-like
group as donor and the O keto–kojic group as acceptor [molecule 1:
O1\H⋯O4 (2.757(2) Å, 112.8°) or molecule 2: O21\H⋯O24 (2.764(2)
Å, 112.6°)].Moreover, the independent twomoleculeswithin the asym-
metric unit are associated by one inter-molecular H-bonding interac-
f molecules.
les are further
ding zig-zag 1D
4 (2.654(2) Å,
l H-bonds (see
ophobic inter-
itecture of the
system, space
ganic molecule
lized in three
27C 0.283(6)].
Fig. 5. Asymmetric unit in the crystal of ligand L8. Intra-molecular H-bonding interactions
are plotted. Only one of the disordered positions of the hydroxyl-methyl arm is depicted
for clarity.
Table 1
Protonation constants of the ligands at 25 °C, 0.1 M KCl ionic strength, obtained from
potentiometric titration curves using the Hyperquad program [13].
L4 L5 L6 L7 L8
logK1 9.19(3) 9.01(2) 8.52(4) 8.49(1) 9.49(3)
logK2 7.51(3) 7.61(2) 7.81(2) 6.02(2) 6.69(5)
logK3 4.38(5) 3.35(2) 5.49(5) – –
logK4 – – 1.97(5) – –
Fig. 7. Speciation curves of ligand L7, with the overlapping trends of the heights of UV
bands at 276 nm (△) and 322 nm (◊), obtained by spectral decomposition of the spectra
in Fig. 6 with the Specpeak program (19).
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The asymmetric unit of the crystal comprises two cryst
independent molecules of ligand L7. The reason why tFig. 6. Spectra collected during the potentiometric titration of ligand L7
lines) spectra are collected in the pH range relative to thefirst deprotonatio
lines) spectra in the pH range relative to the second deprotonation.lvement of
(see Table
located in
o hydrogen
d molecule.
ound to be
roup P21/c.
graphically
two former
tion [O28\H⋯N12 (2.901(2) Å, 169.0°)] building pairs o
In the crystal, the aforementioned pairs of molecu
associated by rather strong inter-molecular H-bonds buil
chains [O1\H⋯O24 (2.700(2) Å, 153.2°) and O21\H⋯O
152.6°)] (Fig. 4).
Adjacent chains connect to each other by additiona
Table S2.3) leading to corrugated ribbons. Finally, hydr
actions connect close ribbons to accomplish the 3D arch
crystal.
3.1.3. Crystal structure of the ligand L8
The crystal of ligand L8 crystallizes in the triclinic
group P-1. The asymmetric unit consists of just one or
(Fig. 5).
One of the hydroxyl-methyl arms in L8 is deloca
different positions [O27A 0.393(12), O27B 0.325(14), O. Blue (darker
n, pink (lighter Fig. 8. Chemical shifts of CH3 (blue squares), CH2(B) (green triangles) and CH2(K) (red
crosses) of L7 ligand as a function of pH.
The mean planes of the two kojic moieties define a dihedral angle of
85.02°. This value, and therefore the orientation of the kojic moieties
within the organic molecule, is similar to that described for a related
bis–kojic derivatives of ortho-vanillin [9]. In accordance to the above-
described L6 and L7 ligands, in L8 can also be observed in the corre-
sponding intra-molecular interactions that involve the OH phenol-like
group and the O keto–kojic group [O26\H⋯O25 (2.774(2) Å, 111.63°)
and O36\H⋯O35 (2.756(2) Å, 112.35°)].
The crystal packing of L8 resembles to that of compound L7. Thus,
ule
5 (
ent
to
ho
een
ctr
etr
ds a
The ligands L4 and L5 are characterized by three protonation con-
stants, corresponding to the two kojic phenolates and to the nitrogen
atom in the linker; L6 by four protonation constants relative to the
two kojic units and to the two nitrogen atoms in the piperazine ring;
L7 by two protonation constants attributable to the kojic phenolate
and the nitrogen atom; L8 by the two protonation constants relative
to the two kojic phenolates. The parentmolecule kojic acid is character-
ized by a logK value of 7.70, and the protonation constant of a nitrogen
atom in a tertiary amine can be roughly estimated from literature
hanolamine to
he L− and LH
315 nm (ε =
), respectively,
ligands, based
osed. This dis-
ng only a kojic
inker. Analysis
g the potentio-
lly protonated
ies LH of kojic
, now shifted
tensity of this
Table 2
Chemical shifts of H3, CH2(K), CH2(B) and CH3 protons in the species LH2+, LH and L− of
ligand L7, calculated with the HyperNMR program [20].
Species H3 CH2(K) CH2(B) CH3
LH2+ 6.51 4.49 4.49 2.98
LH 6.41 4.03 4.00 2.60
L- 6.35 3.71 3.72 2.27
Table 3
Chemical shifts of in the species LH3+, LH2, LH− and L2− of ligands L4 and L5, calculated
with the HyperNMR program [20].
L4 L5
Species H3 CH2(N) CH3 H3 CH2(N) CH(Bn)
LH3+ 6.57 4.61 3.11 6.50 4.65 4.61
LH2 6.49 3.87 2.55 6.41 3.98 3.92
LH− 6.39 3.93 2.58 6.32 3.95 3.90
L2− 6.39 3.76 2.31 6.29 3.90 3.73
Table 4
Complex formation constants of the five ligands with FeIII at 25 °C, 0.1 M KCl ionic
strength, obtained from potentiometric–spectrophotometric data using the Hyperquad
program [13]. Charges are omitted for simplicity.
L4 L5 L6 L7 L8
FeLH3 – – 25.25(3) – –
FeLH2 22.21(3) 21.9(2) – – –
FeLH – – – – 18.4(3)
Fe2L2 – – – – 41.11(4)
Fe2L2H-1 – – – – 38.97(2)
Fe2L3H4 69.1(1) – 70.3(3) – –
Fe2L3H3 66.10(4) 67.2(2) 66.2(1) – –
Fe2L3H2 61.6(2) 64.1(2) 61.2(2) – –
Fe2L3H 56.19(1) 59.9(1) – – –
Fe2L3 49.75(1) 53.5(1) 49.4(2) – 55.08(4)
FeL2H2 – – – 33.0(1) –
FeL2H – – – 28.2(2) –
FeL2 – – – 22.6(2) –
FeL2H−1 – – – 15.7(1) –
FeL3 27.1(1)
pFe 18.1 19.3 17.7 16.7 20.0
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inter-molecular H-bonding interactions [O(26)\H⋯O2
147.5°) and O36\H⋯O35 (2.754(2) Å, 154.6°)]. Adjac
further connected by H-bonds (see Table S3.3) leading
ribbons. Again, the 3D framework is reached by hydrop
tions between neighboring ribbons.
3.2. Protonation equilibria
The protonation equilibria of the five ligands have b
potentiometry, UV spectrophotometry and 1H NMR spe
protonation constants evaluated from the potentiom
curves at 25 °C and 0.1 M ionic strength for thefive ligan
in Table 1.Schems kinked by
2.653(2) Å,
chains are
corrugated
bic interac-
studied by
oscopy. The
ic titration
re reported
data that range from a value of logK = 8.05 for triet
10.70 for triethylamine. As previously reported [7], t
species of kojic acid are characterized by UV bands at
5900 M−1 cm−1) and 270 nm (ε = 8700 M−1 cm−1
with sharp isosbestic points at 242 nm and 290 nm.
In the following the protonation sequences of the five
on the spectrophotometric and 1H NMR results, are prop
cussion starts with the simpler L7 compound, presenti
phenol group and a protonable nitrogen atom on the l
of Fig. 6 (spectra a), in which the spectra collected durin
metric titration are presented, shows the band of the fu
form LH2+ quite similar to that of the protonated spec
acid, differing only in the wavelength of the maximum
from 270 to 276 nm (ε = 8850 M−1 cm−1). The ine 3. Deprotonation sequence of ligand L4.
band decreases at about one half of its height during the first deproton-
ation (blue spectra), with the contemporary appearance of a new band
at 322 nm, with sharp isosbestic points at 242 nm and 290 nm. During
the second deprotonation (red curves) a further decrease in the inten-
sity of the band at 276 nm and an increase in that at 322 nm take
place. The band at 322 nm too is shifted to higher wavelengths and its
ε value at themaximum is slightly higher than that of the corresponding
band of fully deprotonated kojic acid. The trends of the peak intensity
after decomposition of the spectra in the Gaussian band-components
n Fig. 7.
of protons H3,
hese chemical
nations, more
itrogen atom.
pecies LH2+, LH
re reported in
s, about of the
deprotonation,
eme, in which
y the nitrogen
corresponding
at of kojic acid
atom), implies
es such as the
te O− and the
roup and the
ost by phenolic
ally shared in a
tio
ll t
n s
spe
spe
an
y d
out
nm
e H3, CH2(N),
protons in L5
quence in the
d above for L7.
in which a pro-
nitrogen atom
strong upfield
d that of H3 in
e on the kojic
terized both by
e kojic moiety,
proton, while
unaffected; in
xperienced by
shared proton,
. This sequence
g on the linker,
8.52, logK2 =
eneral mecha-
for L4 and L5,
. The low L6
pectra. Further-
stants lead to a
s, without any
pon the depro-
Ligand L8 is characterized by two protonation constants almost
equal to those of L1, and a trend of UV spectra and NMR chemical
shifts similar to that previously reported for L1 ligand was observed.
3.3. Iron complexes
The complex formation equilibria of all the five ligands with FeIII
have been studied by combined potentiometric–spectrophotometric
techniques. In fact, being FeIII almost completely complexed when
Fig. 9. Spectra collected in pH range 0.8–2.4, from solutions containing L4 = 3.44 ×
10−4 M and FeIII = 1.72 × 10−4 M, using 1 cm path length.
Fig. 10. Trend of the band absorbances at 468 nm (A) and 545 nm (B) reported as a
function of pH, after decomposition of the spectra in Fig. 9.
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A similar trend is presented by the chemical shifts
CH2(K), and CH2(B) and CH3 reported in Fig. 8. All t
shifts present an upfield shift during the two deproto
marked for the three proton groups proximal to the n
The chemical shifts of all the kind of protons in the s
and L−, calculated with the HyperNMR program [20], a
Table 2.
The variations of both UV bands and chemical shift
same order ofmagnitude during the first and the second
could lead to the hypothesis of a micro-dissociation sch
the first proton is lost in comparable measure both b
atom and by the phenolic group. The logK2 value (6.02)
to the first deprotonation step, ~1.7 units lower than th
(and much lower than that of a tertiary amine nitrogen
a particular stabilization of the monoprotonated speci
formation of a hydrogen bond between the phenola
charged NH+ nitrogen, or between the phenolic g
deprotonated nitrogen. Actually, whether the proton is l
group or by nitrogen atom, the remaining proton is equ
hydrogen bonding between these groups. Such a situa
explain the observed experimental trends in which a
NMR signals feel in an equal effect on both deprotonatio
Ligands L4 and L5 were characterized by the UV
maximum at about 275 nm for the fully protonated
values almost double with respect to those of kojic acid
during the first deprotonation step, this band slightl
both ligands, with the appearance of a new band at ab
the following steps a more marked decrease of the 275
an increase of the 328 nm band were observed.
Characteristic variations of the chemical shifts of th
and CH3 protons in L4, and H3, CH2(N), and CH(Bn)
are observed (Table 3), which allow to propose a se
deprotonations of these ligands similar to that describe
Hence, the first deprotonation leads to a neutral species
ton is shared through hydrogen bonding between the
and one of the two kojic phenol groups, inducing the
shift of the groups neighboring to the nitrogen atom, an
the kojic ring. The second deprotonation, taking plac
moiety not involved in the hydrogen bonding, is charac
a strong spectral variation of the UV bands related to th
and by an upfield shift of the NMR signals of the H3
those of the CH2(N), CH3 and CH(Bn) protons remain
the last step, mainly in L4, a further upfield shift is e
hydrogen atoms neighbor to nitrogen for the loss of the
and a further strong spectral variation of the UV bands
is briefly sketched in Scheme 3.
Concerning the ligandL6 containing thepiperazine rin
it is characterized by four protonation constants, logK1 =
7.81, logK3 = 5.49, and logK4 = 1.97. Presumably the g
nism of deprotonation could be similar to that observed
with the involvement of a further basic nitrogen atom
water solubility avoided the acquisition of reliableNMR s
more, the small differences between the protonation con
continuous variation with pH of the UV absorbance band
clear inflection. All these facts prevented to speculate u
tonation mechanism.n may well
he UV and
teps.
ctra with a
cies, with ε
d ligand L7;
ecreased in
328 nm; in
band and
mixing reagents before the base potentiometric titrations, the estima-
tion of reliable complex formation constants from potentiometric data
alone was prevented. Therefore the complex formation equilibria have
been studied both in strong acidic solutions (pH 0–2) on sets of solu-
tions at increasing concentrations of HCl until the disappearance of the
bands of complexed iron, and in thepH range 2–10. Simultaneousfitting
of potentiometric and spectrophotometric data allowed obtaining the
stability constants for the complexes of ligands L4–L8with FeIII, reported
in Table 4.
The three ligands L4, L5, and L6 show a similar behavior; the visible
spectra collected in strong acidic solutions at different metal/ligand
ratios (1/1, 1/2, 1/3) display the 1:1 complex which at increasing pH
soon disappears giving a Fe2L3Hx complex stable in the 2–4 pH range.
Actually, the shape of the spectra in this pH range is similar for all the
three solutions at different metal/ligand ratios, and this is indicative
that a unique species is formed. The ratios of the absorbance values in
the three solutions clearly indicate the formation of a Fe2L3 complex.
This has been confirmed by a Job plot performed at pH 2.9, which
Fig. 11. Speciation plots calculated on the basis of stability constants reported in Table 4, using a ligand concentration 1 × 10−3 M and FeIII concentration 5 × 10−4 M.
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results in two straight lines intersecting at the ligand mole fraction 0.6.
The spectra collected in acidic solutions for the 1:2 ligand/metal molar
ratios for ligand L4 are reported in Fig. 9 as an example.
The spectra were decomposed in four Gaussian bands, with the
program Specpeak [19]. The absorption of the bands at 468 nm and
545 nm are reported as a function of pH in Fig. 10.
The speciation plots shown in Fig. 11, calculated on the basis of
stability constants reported in Table 4, allow some considerations: at
very acidic pH (~1) a FeLH2 complex with the two ligands L4 and L5 is
III e t
e s
lex
, ea
mp
dia
and
ona
pK
nat
rog
LH3
e s
ub
s
f th
st t
th t
Fe2
roto
el
jic
FeL
liga
rdin
on
y lo
and it was evidenced only by spectral analysis. Already at these low pH
values a Fe2L2 complex is formedwith the two iron atoms joined by the
two ligands. This complex is further stabilized by the loss at pH 2.1 of a
proton from a coordinated water molecule, presumably a μwater join-
ing the two iron atoms. At pH≈4 a Fe2L3 complex is formed in which
each iron atom is completely surrounded by six oxygen atoms from
three kojic units.
The ESI-MS spectra, collected at pH ~7, with a 10:1 metal excess,
allows revealing further complexes not lighted by the other solution
III omplexes with
ls a [L42Fe2]2+
s to [L42Fe2]2+
rmation of this
ring ionization
o free ligand is
lex formation.
d m/z 478.045.
2Fe2]2+, while
52Fe2]2+. Such
ojic acid mole-
he peak corre-
ng to signal at
ethylene-kojic.
e2]2+ complex
xes with L6 is
t m/z 448.052
intensity peak
ally character-
ned using the
nds containing
h FeIII allowed
2:3 Fe:L com-
unprotonated
peciation plots
forms FeL2Hx
Fig. 12. ESI-MS spectra of the system L4-FeIII in a ratio 1:10 at pH 7.
n at
229L. Toso et al. / Journal of Inorganic Biochemistry 127 (2013) 220–231formed, in which presumably Fe is coordinated by th
atoms of a kojic unit, being the nitrogen atom and th
unit till protonated. At increasing pH a Fe2L3H3 comp
which the two iron atoms are joined by the three ligands
the two metal ions through its kojic moieties; the co
formed only by the ligand L4 is presumably an interme
two ligands join the two metal ions, and the third lig
one iron atom with a kojic unit, the second one till prot
pH increase induces progressive deprotonations with
and 6.4 for L4 and 3.1, 4.2 and 6.4 for L5. These deproto
reasonably attributed to the loss of protons from the nit
the linker.
A similar behavior is presented by L6, in which a Fe
initially formed, with iron coordinated by a kojic unit, th
unit and the two piperazine nitrogen till protonated. S
Fe2L3H4 complex is formed, in which the two iron atom
by the three ligands through both kojic units, with four o
azine nitrogen atoms till protonated. Afterwards, the fir
are lost with pK values 4.1 and 5.0, and the two last wi
5.9. After several attempts to crystallize the compound
parallelepiped crystal was obtained and read with Sync
but the collected data only allowed seeing a rough mod
plex (See Supplementary Information).
Ligand L7, which does not contain a second ko
FeL2Hx and FeL3 complexes, similarly to kojic acid. The
complex, protonated on the nitrogen atoms of both
these protons and a third one, presumably from a coo
molecule at pK's 4.8, 5.6 and 6.9.
As far as the ligand L81 is concerned, its complexati
starts with the formation of a FeLH complex at extremel
1 L8, differently from L4-L7 complexes, does not contain nitroge
analogous to the previously studied L1 ligand [7].wo oxygen
econd kojic
appears, in
ch bonding
lex Fe2L3H4
te in which
binds only
ted. Further
's ~ 4.5, 5.4
ions can be
en atoms in
complex is
econd kojic
sequently a
are bridged
e six piper-
wo protons
he same pK
(L6)3 a red
n radiation
of the com-
unit, forms
2H2 starting
nds, looses
ated water
mechanism
w pH (0–1)
equilibrium techniques. The ESI-MS spectrum of Fe c
L4 is illustrated in Fig. 12. The signal atm/z 393.004 revea
complex formation. The peak at m/z 315.991 correspond
complex without one methylene-kojic acid molecule. Fo
complex is probably due to cleavage of the N\C bond du
of the [L42Fe2]2+ complex. The signal corresponding t
not present.
The ESI-MS spectrum in Fig. 13 displays the L5 comp
The main peaks appear at m/z 392.026, m/z 469.040 an
The peak at m/z 469.040 corresponds to complex [L5
peak at m/z 478.045 represents its hydrated form [L
type of complex is stable even without one methylene k
cule, since the peak at m/z 392.026 is very intense. T
sponding to the free ligand is not present.
MS/MS fragmentation of the complex correspondi
m/z 392.025 (Fig. 14) results in loss of another m
Signal atm/z 315.014 agrees with stoichiometry of [L52F
without two methylene kojic acid molecules.
The representative ESI-MS spectrum of FeIII comple
presented in Fig. 15. The high intensity of the peak a
corresponds to the [L62Fe2]2+ complex, while the low
atm/z 457.053 represents [L62Fe2 + H2O]2+ complex.
4. Conclusions
Five new ligands have been synthesized, structur
ized and their protonation scheme has been explai
information of UV and 1H NMR spectra. For all the liga
two kojic units, the complex formation equilibria wit
concluding about the formation of variously protonated
plex as the major species in the whole pH range; the
Fe2L3 complex is the unique species at pH 7.4 (see s
in Fig. 11). Ligand L7, containing only a kojic unit,
oms, and it is
complexes and, in a lower amount, a FeL3 complex. The prevailing spe-
cies at pH 7.4 is FeL2H−1, stabilized by the deprotonation of a coordinat-
ed water molecule.
The pFe values reported in Table 4 can be used to evaluate and to
compare the chelating ability of the various ligands. These data give ev-
idence of a strong chelating ability of L8 ligand. The remaining ligands
L4–L6, containing nitrogen atoms in the linker, show a minor chelating
efficiency, pFe ranging from 19.3 for L5 to 17.7 for L6. Interaction of iron
with L7 ligand, having only a coordinating kojic unit, is characterized by
koj
e s
ole
ire
wo
zed
t p
om
The excellent chelating properties recommend further toxicological and
pharmacological research on these new promising ligands.
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Description of the Fe2(L6)3 crystal 
 
The collected data from X-ray diffraction experiments were not enough to successfully complete 
the crystal structure determination. However, the available data were processed to obtain a rough 
model, with the crystal being solved in the trigonal system, space group R3. In the model, three 
different complex molecules are observed: (i) a tentative model of the Fe2(L6)3 complex, (ii) one 
tentative model of a related Fe(Kj)3 complex and (iii) one iron centre surrounded by 6 oxygen 
atoms.  
 
In the model of the Fe2(L6)3 complex, one of the two kojic moieties within the L6 ligands is 
incomplete. Thus, those kojic moieties tied to the Fe2 atom do not have the alcoholic groups and 
show a residual peak (represented as a carbon) close to the keto group (see SMFigure 1). These 
differences between the expected and the observed formula of the L6 ligands have been attributed 
to limitations in the experimental data which did not allow further refinements. In contrast, the 
stoichiometry of the complex and the metal surrounding are well defined. The two Fe3+ ions are 
surrounded by 6 oxygen atoms provided by three different L6 ligands. The complex molecule 
Fe2(L6)3 occupies a special crystallographic position (3-fold rotation axis) what determines the 
coordination bond distances [Fe1-O6 2.1228(2) Å, Fe1-O8 1.9793(1) Å and Fe2-025 2.0181(1) Å, 
Fe2-O26 1.8738(1) Å] and the values of the trans-angles [O6-Fe1-O8 172.25º and O25-Fe2-O26 
176.67º] (see SMFigure 1). Note that the largest coordination bonds correspond to Fe–O(keto) 
bonds whereas the smallest ones are Fe–O(hydroxy). A fairly similar configuration was reported for 
the Fe(Kj)3 complex [1], which showed average bond distances of 2.070 and 1.974 Å for Fe–
O(keto) and Fe–O(hydroxy) bonds, respectively. 
 
Concerning the two other iron complexes present in the crystal, only speculations can be done. 
During the crystallization process, the solution experimented color changes from colorless to 
yellow. This fact was tentatively attributed to a slight degradation of the ligand L6 in the presence 
of light. This is in accordance to the existence in the crystal of one complex molecule that contains 
kind of individual kojic units and iron(III). This compound could be the previously reported Fe(Kj)3 
complex [1] or any Fe(Kj)3–like related complex. Again, residual peaks were found around the kojic 
moieties that could not be unequivocally assigned. These residues are shown in SMFigure 2 as 
extra-alcoholic groups in the kojic moieties. The other complex molecule present in the crystal (one 
Fe3+ ion surrounded by six oxygens) is most probably, for neutrality reasons, another Fe(Kj)3-like 
unit. However, the idea of an hexaaquo cation of iron(III) cannot be dismissed because it is still 
possible that some counteranion is present in the crystal but it could not be seen in the model due to 
the above refinement problems.  
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Aluminium related diseases
Attention is devoted to the role of chelating agents in the treatment of aluminium related disease
of the efforts that have drastically reduced the occurrence of aluminium dialysis diseases, they s
cause of great medical concern. The use of chelating agents for iron and aluminium in
applications has found increasing attention in the last thirty years. With the aim of designin
we synthesized a series of kojic acid derivatives containing two kojic units joined by differen
advantage of these molecules is that they are cheap and easy to produce. Previous works on co
equilibria of a first group of these ligands with iron and aluminium highlighted extremely goodChelation therapy gave evidence of the ability to scavenge iron from inside cells. On these bases a second set of bis-kojic ligands,
d size, has been
ria studied by
culations and 1H
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presented [1,2]. Aluminiumwa
seventies of the last centurywhose linkers between the kojic chelating moieties are differentiated both in terms of type an
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ligands is presented. The in vivo studies show that these new bis-kojic derivatives induce faste
main organs as compared with the monomeric analog.
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chelation was recommended when patients did not clin
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aluminium chelator introduced in clinical practice that re
bone aluminium deposit but also aluminium burden in th
The acute neurological complications, which may be de
Deferoxamine therapy for aluminium bone diseases
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applications, in medicine, in
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to decrease
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then introduced [15].
The aluminium chelation therapy has been founded on
iron. Actually, massive research efforts due to the worldw
iron overload diseases have lead to significant imp
iron chelation. Evidence has been given for the utility,
dependent pathologies, of the knowledge acquired on
agents [16,17].
With the aim of designing new ligands that form
complexes, which satisfy the chemical and biological re
iche, Cittadella
fax: +39 070
an effective chelating agent such as selectivity, lipophilicity and
bioavailability, our group has synthesized some derivatives of kojic
acid, and studied their complex formation equilibria with FeIII and AlIII,
as well as those with the parent ligand kojic acid (Scheme 1).
In previousworks, the formation of MeL, MeL2, andMeL3 complexes
of AlIII and FeIII with kojic acid was remarked, and of diverse protonated
species of Me2L2 andMeL2 complexes with L1 [18], andwith the related
compounds in which vanillin and o-vanillin (L2 and L3) substituents
were inserted on the linker [19]. The found pFe values (23.1 for L1,
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to which a stoichiometric amount of HCl was previously added to
prevent hydrolysis. This solution was standardized by EDTA titration.
2.2. Synthesis
The synthesis of the ligands in Scheme 1 has been previously
reported [21].
aided by drop
l (3 mL) was
added and the solution was left stirring for 30 min and then filtered
s. The solution
acetone acts as
parallelepiped
n (XRD). It is
also possible to obtain single crystals of L4 without acetone diffusion,
ver, the quality
ot be obtained.
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nd. The studies
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low complex formation rate with Al(III), a suitable procedure was used:
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Scheme 1. Chemical structures and acronyms of studied ligands.
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comparable with that of deferiprone (20.7), and the
ligands are easily and cheap to produce were very en
have recently synthesized a new set of bis-kojic lig
different linkers connecting the two kojic coordinating
been designed for improving the interaction between
and the metal ions.
In this paper we will report the study on the com
equilibria of ligands L4–L8 as well as the structure cha
L4 by X-ray diffraction. The in vivo efficacy of the liga
and L8 as potential sequestering agents was also studie
herein, namely for the Ga-67 mobilization in mice prev
with the radiotracer 67Ga-citrate, as an animal model of
2. Experimental
2.1. Reagents
All the products, NaOH, KOH, and AlCl3 purchased fro
from Fluka, KCl from Carlo Erba (Milan, Italy), were
further purification. An already described method was
carbonate free KOH solution [20]. Ligand solutions were
stoichiometric equivalents of HCl. AlIII solution was p
dis
(2–7 min) and
drift parameterdissolving the required amount of AlCl3 in pure double(26.6) and
that these
raging. We
2.2.1. Synthesis of the L4 crystal
L4 (15 mg) was dissolved in distilled water (3 mL),
wise addition of HCl 0.01 M. Afterwards, isopropanoieties have
kojic units
formation
erization of
into a crystallization device to remove possible impuritie
was placed into an acetone chamber diffusion, where
antisolvent in crystallization process. After three weeks,
colorless crystals appeared suitable for X-ray diffractios L4, L5, L7
d reported
sly injected
overload.
Aldrich, HCl
ed without
leaving the solution to stand at room temperature. Howe
of the crystals is lower, hence good quality data could n
2.3. Potentiometric measurements
Potentiometric measurements of the complex form
were carried out under the same conditions described
publication [18]. The operating ligand concentration
3× 10−4 to 3 × 10−3M according to the examined liga
of complex formationwere carried using constant ligand
and 1:1, 1:2, and 1:3metal/ligandmolar ratios. To take inidified with
repared by
tilled water
the titrations started 1 h after the mixing of the reage
times between two subsequent additions were used
the achievement of the equilibriumwas checked using a
of 1 mV/min [18]. Complex formation data were analyzed using the
Hyperquad program [22].
2.4. 1H NMR measurements
NMR spectra were recorded on a Bruker AVANCE III spectrometer at
300MHz for 1H NMRmeasurements. Chemical shifts (δ) are reported in
ppm related to tetramethylsilane (TMS). The concentrations of the
ligands ranged from 4 mM for L6 to 10 mM for L4, according to their
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ices [36] were
calculated at the optimized geometries. The programs GaussView 5
and Molden 5.0 [37] were used to investigate the charge distributions
and molecular orbital shapes. Calculations were carried out on a 64 bit
E4 workstation equipped with four quad-core AMDOpteron processors
and 16Gb of RAM and running the Ubuntu 12.04 Linux OS and on a 64
bit IBM x3755 server equipped with four 12-core processors and 64 Gb
of RAM running the SuSE 10.2 OS.
In order to estimate some pharmacokinetic parameters related
with the ADME (absorption, distribution, metabolism and excretion)
lar descriptors
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ar structure of
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Fig. 1.Molecular structure of L4.
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2.5. ESI-MS analysis of complexes
ESI-MS spectra were carried out on a Bruke
spectrometer (Bruker Daltonics, Bremen, Germany) equ
ESI source. Samples were dissolved in water and methan
final pH was ~7. The ligand concentration was ~10−5M
to metal molar ratio was 1:10. The experimental param
follows: scan range 100–1600 m/z, drying gas nitrogen
200 °C, ion source voltage 4500V, in-source collision ene
instrument operated in the positive ion mode and
externally with Tunemix™ mixture (Bruker Daltoni
Analyte solutions were introduced at a flow rate 3 μl
Data Analysis (Bruker Daltonics, Germany) software
determine the formulae of the complexes. The stoich
complexes was unambiguously confirmed by distri
isotopic peaks and MS/MS analysis. The distance betwe
peaks allowed calculating the charge of the analyzed ion
2.6. Crystal structure determination
Measured crystal was prepared under inert condition
perfluoropolyether as protecting oil for manipulation. S
were mounted on MiTeGen Micromounts™ and these
used for data collection. Data were collected with Bruke
(100 K) diffractometer. The data were processed wit
program and corrected for absorption using SADA
structures were solved by direct methods, which reveal
of all non-hydrogen atoms. These atoms were refined o
matrix least-squares procedure using anisotropic displac
eters [25]. All hydrogen atoms were located in differenc
and included as fixed contributions riding on at
with isotropic thermal displacement parameters 1.2 t
the respective atom. Geometric calculations were car
PLATON [26] and drawings were produced with
MERCURY [27]. Additional crystal data and more info
the X-ray structural analyses are shown in Suppleme
Crystallographic data for the structural analysis have b
with the Cambridge Crystallographic Data Centre, CCDC
of this information may be obtained free of charge on
CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: 44
e-mail: deposit@ccdc.cam.ac.uk or http://www.ccdc.cam
2.7. Theoretical calculations
Theoretical calculations were carried out on the ligan
their neutral and N-protonated forms (see Results and d
on the complexes [Al2(L4−)3]3+ and [Al2(L6)3]6+ with t
(Rev. A.02) commercial suite of programs [28] at Den
Theory (DFT) level, adopting the mPW1PW91 (mPW1P
by Adamo and Barone [29]. Schäfer, Horn, and Ahlrichs
polarization all-electron basis sets [30] were used for
were extracted from the Basis Set Exchange Database [3
compound, the optimized geometries were verified
calculations of harmonic vibrational frequencies comput
Mulliken natural charges [33–35], and Wiberg bond inddied.
icroTOF-Q
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the compounds which were energy minimized with M
then re-imported by Maestro to run QikProp job. From
out-put file the following set of properties was predicte
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moles/L is the concentration of the solute in saturated
apparent Caco-2 cell permeability in nm/s, the bind
serum albumin, the Human oral absorption in gastro-int
2.8. Biodistribution studies
67Ga-citrate injection solution was prepared by dil
citrate from MDS Nordion with saline to obtain a fin
concentration of 5–10MBq/100μL. Biodistribution studie
out in groups of 3 female CD1mice (randomly bred, Cha
CRIFFA, Barcelona, Spain) weighing ca. 25 g. Mice were
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each ligand in 100 μL DMSO (L4, L5, L7) or saline (L8
bioassayed due to its low solubility in water (neutral pH
Animals weremaintained on normal diet ad libitum and
by cervical dislocation at 1 h and 24 h post-admin
administered radioactive dose and the radioactivity
animals were measured by a dose calibrator (Curiemete
Japan). The difference between the radioactivitymeasure
after the injection and in the sacrificed animal, taking in
radioactive decay was assumed to be due to whole b
Tissue samples of main organs were then removed for
gamma counter (Berthold LB2111, Berthold Technolog
Biodistribution results were expressed as percent of in
per total organ (% I.A./organ) and presented as mean va
blood, bone and muscle, total activity was calculated
previously reported, that these organs constitute 7, 10
total weight, respectively. Statistical analysis of the
was done with GraphPad Prism and the level of signifi
at 0.05.
3. Results and discussion
3.1. Crystal structure of ligand L4
Ligand L4 crystallizes in the orthorhombic system, space group Pbca.
The asymmetric unit consists of just one acidmolecule (Fig. 1). The kojic
acid moieties are stabilized by two intra-molecular H-bonding
interactions involving the OH phenol-like groups as donors and the O
keto-kojic groups as acceptors [O9\H⋯O7 (2.744(2) Å, 112.4°) and
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longer linker than that of the previously studied L1, L2 and L3 ligands
[19,21] form only one kind of complex of Al2L3 stoichiometry, variously
protonated on the nitrogen atoms on the linker. As regard L4 and L5
ligands, the startingAl2L3H3 species is the fully coordinated 2:3 complex
with all the three protonated nitrogen atoms. L5, characterized by the
piperazine ring in the linker, forms a starting Al2L3H4 complex, in
which one piperazine is protonated on both nitrogen atoms, while the
other two only on a single one. These protons are lost at increasing pK
values, with the same basicity order as in the free ligands L5b L4b L6.
kojic acidwith
AlL3 complex
ith kojic acid.
. These protons
lues being 5.52
r stability than
ty of formation
r. With respect
es prevents the
rison of these
asis of the pAl
Fig. 2. Left: 3D architecture of the crystal of L4 with inter-molecular interactions (H-atoms omitted); right: detail of inter-molecular π,π-stacking interactions. Intra- and inter-molecular
interactions are shown.
AlIII at 25 °C, 0.1M
measurements.
L8
) 9.49 (2)
2) 16.18 (1)
Al2L2 31.99 (1)
Al2L2H−1 27.10 (3)
Al2L2H−2 21.71 (1)
Al2L3H4 59.28 (4) 62.3 (1)
Al2L3H3 55.36 (5) 53.6 (1) 57.9 (3)
Al2L3H2 50.73 (5) 49.86 (8) 52.11 (2)
Al2L3H 45.00 (5) 45.41 (7) 45.49 (1)
Al2L3 37.4 (2) 37.9 (1) 37.73 (4)
AlL2H2 27.53 (2)
AlL2H 22.01 (4)
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in closely related kojic-like compounds [19,21].
In the crystal of L4, adjacent acid molecules are link
with one OH-alcohol group and the quaternary N-atom
donor and H-acceptor, respectively [O4\H⋯N12 (2.782
These interactions build chains that extend along the b
extra-stabilized by inter-molecular C\H⋯π interaction
the alcohol group and one kojic moiety [C3\H3A⋯Cg2 (
Neighboring chains are further connected by inter-
H(phenol-like)⋯O(alcohol) H-bonding interactions res
framework. Here the two kojicmoietieswithin L4 are acti
[O9\H⋯O22 (2.854(2) Å, 164.7°) and O17\H⋯O4 (2.662
The 3D architecture is accomplished by rather strong i
π,π-stacking [Cg2⋯Cg2 3.375Å, α=0°, β=γ=16.13°]
interactions [(alcohol)O22\H⋯O3(keto-kojic) (2.801(
(Fig. 2).
Interestingly, only one of the kojic moieties is in
referred π,π-stacking interactions. This mainly de
different torsion angles defined by the kojic moieties
[kojic#1: bN12\C11\C10\C8 107.42° or kojic#2:
C15\C16 95.61°].
3.2. Potentiometric and 1H NMR results
The complex formation equilibria of all the five lig
have been studied by potentiometric techniques (t
are provided in as supplementary material). At pH N
occurred, so the Hyperquad analysis was performed only
precipitation. Themodels and the relative complex form
are reported in Table 1, together with the protona
previously determined [21]. L4, L5 and L6 that are characterized by a AlL2 16.37 (3)
AlL3 21.39 (4)
pAl 11.2 11.6 11.8 9.9 14.4
C(19)\C(20).1 Cg2= centroid of the ring kojic#2: O(23)\C(15)\C(16)\C(18)\n observed
ia H-bonds
eing the H-
Å, 176.8°)].
s which are
hat involve
4Å, 160°)].1
lecular O\
g in a 2D
implicated
Å, 148.5°)].
r-molecular
H-bonding
Å, 173.6°)]
lved in the
with the
the crystal
12\C14\
L7 complexation scheme resembles that of the parent
formation of AlL2Hx complexes and, subsequently, an
formed at higher pH than the corresponding complex w
AlL2H2 is protonated on the nitrogen atom on the linkers
are lost easier than in free ligand (pK=6.0), their pK va
and 5.64.
The last ligand L8 forms Al2L2 complexes of highe
those found with the analogous L1 ligand; the possibili
of Al2L3 complexes is counteracted by the too short linke
to L1 complexes, the stronger stability of Al2L2 complex
formation of AlL2 complexes. Estimation and compa
ligands as aluminium chelators can be done on the b
values, reported in Table 1.
Table 1
Protonation and complex formation constants of the five ligands with
KCl ionic strength, obtained from potentiometric–spectrophotometric
Species L4 L5 L6 L7
LH 9.19 (3) 9.01 (2) 8.52 (4) 8.49 (1
LH2 16.70 (3) 16.62 (2) 16.66 (2) 14.51 (
LH3 21.08 (5) 19.97 (2) 22.15 (5)
LH4 24.12 (5)
These pAl values, almost similar for L4, L5 and L6, in the range 11.1–
11.8, characterize these ligands as less strong than L1, L2 and L3, with a
shorter connecting chain between the two kojic moieties and with pAl
values 12.8, 11.9 and 13.9, respectively. The potentiometric results are
substantiated by the 1H NMR spectra collected from solutions at
different Al:L molar ratios and at variable pH from 1 to 10, whose
behavior can be rationalized taking into account the speciation plots
reported in Fig. 3.
As an example some illustrative 1H NMR spectra collected on the
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• no spectra of free ligand is present at pH N 3.80 for the NMR spectra
collected on solutions at 2:3 Al:L4 molar ratios, differently from
what happens in the spectra collected at 1:3 and 1:2 molar ratios.
This strongly supports the existence of the unique Al2L3Hx complex
determined by potentiometric titrations;
• the signal of pyrone H3 in the complex is downfield shifted with
respect to that in the free ligand, indicative of a deshielding action of
aluminium complexation on the ring protons, while, the signal of
CH3 in the complex is not affected by that effect. On the contrary,
plex formation
s any eventual
come by some
of the nitrogen
the free ligand,
ith oxygen of
protons of the
us shielding of
expected, the
s.
t pH~7, with a
indicated by
S spectrum of
corresponds to
.055 reveals a
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speciation plot of L4 and its aluminium complexes at
ratio. As the most representative protons of the system
H3 pyrone proton (6.6–7.4 ppm) and CH3 on nitroge
3.2 ppm) are reported in Fig. 4A. The bands at 6.60 pp
3.15 ppm (CH3) of free ligand are the only ones observ
At pH 2.85 two new bands of the complexed ligand
7.08 ppm of H3 proton, and the other at 2.94 ppm of
pH 3.41 the intensity of these two bands increases w
those of free ligand, which completely disappear at pH
pH 7 precipitation of the complex occurs. At basic pH
dissolution of complex takes place with formation of fre
the soluble aluminium species Al(OH)4−.
Some considerations can be done on these behaviors
• the slow exchange of ligand between its free and co
determines the appearance of separate NMR signa
alone related to complexed ligand is observed,
existence of only one kind of complex;Fig. 3. Speciation plots of the systems AlIII–Ligands calculatedwith the staber with the
e same 2:3
e signals of
atom (2.3–
H3) and at
till pD 1.83.
ear, one at
3 group. At
respect to
. Just before
ues (N10.5)
gand and of
lexed form
One signal
icating the
there is a small shielding effect after starting the com
with respect to that in the free ligand. Thus, if there i
minor deshielding effect of the AlIII, it might be over
shielding effect due to an increase (ca. 0.4) on basicity
protons in the complexed formswith respect to that in
due to the absence of hydrogen-bonding interaction w
OH chelating group;
• the stepwise deprotonation processes of ammonium
aluminium complex seems responsible for a continuo
the CH3 signal, because of its adjacent positioning; as
H3 signal is minimally affected by these deprotonation
3.3. ESI-MS results
The ESI-MS spectra, collected for samples prepared a
10:1 metal excess, reveal further complexes not
potentiometry and 1H NMR spectroscopy. The ESI-M
AlIII–L4 is presented in Fig. 5. The signal at m/z 364.047
[L42Al2]2+ complex formation, while the peak at 373ility constants in Table 1, at [L]=1.5×10−3M and [AlIII]=5×10−4M (1/3 plots) and 1.5×10−3M (1/1 plots).
hydrated [L42Al2+H2O]2+ complex. The peak corresponding to the free
ligand is not present.
The ESI-MS spectrum in Fig. 6 displays the L5 complex formation
with AlIII ions. The main peaks appear atm/z 416.128,m/z 432.101,m/z
440.086, m/z449.092 and m/z 458.093. The first peak at m/z 416.128
corresponds to the protonated free ligand. The peak at m/z 432.101 is
indicative of the species [L53Al2]3+, visible also in experiments with
higher metal ion excess. The peak at m/z 440.086 corresponds to the
species [L52Al2]2+. The most abundant peak at m/z 449.092 and
to the mono-
Al2+2H2O]2+,
xes with L6 is
99 corresponds
tensity, at m/z
ted [L62Al2 +
respectively.
) calculations
ty to help the
lectrochemical
n recent years,
ely recognized
information at
Fig. 4. A) 1H NMR signals of H3 and of CH3 of L4 at 2:3 aluminium
B) speciation plot of L4 at the same experimental condition.
Fig. 5
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hydrated [L52Al2+H2O]2+ and bi-hydrated species [L52
respectively.
The representative ESI-MS spectrum of AlIII comple
presented in Fig. 7. The highest intense peak atm/z 419.0
to the [L62Al2]2+ complex, while those with lower in
428.103 and m/z 437.097, represent the mono-hydra
H2O]2+ and bi-hydrated [L62Al2+2H2O]2+ complexes,
3.4. QM-calculations
During the past decades, quantum-mechanical (QM
have gained an increasing interest due to their abili
investigations on the structural, spectroscopic, and e
features of inorganic and organometallic compounds. I
density functional theory (DFT) [40–42] has been wid
as a theoretical tool capable of providing very accurate
an acceptable computational cost.
alculations to
lexes featuring
bis[3-hydroxy-
[(4-hydroxy-3-
xyl methyl)-
een extended
s separated by
orm binuclear
computationalRecently, some of the authors exploited DFT c
investigate the relative stabilities of AlIII and FeIII comp
the 2,2′-[(2-hydroxy-3-methoxyphenyl)methanediyl]
6-(hydroxyl methyl)-4H-pyran-4-one] and 2,2′-
methoxyphenyl)methanediyl] bis[3-hydroxy-6-(hydro
4H-pyran-4-one] ligands [19].
Prompted by these results, DFT calculations have b
to the ligands L4 and L6, featuring two kojic residue
spacers capable of providing them the ability to f
monomeric complexes. With the aim to validate the
ligand ratio;. ESI-MS spectrum of AlIII–L4 complexes.
set-up, the metric parameters optimized for the neutral form of L4
have been compared with the corresponding ones determined by
X-ray diffraction (see above). In agreement with diffractometric
data, the hydroxyl groups of the kojic units are involved in H-
bonding interactions with the adjacent carbonyl groups (O\H⋯O
2.587 Å, 121.7°). The localization of Kohn–Sham (KS) HOMO
(Highest-Occupied Molecular Orbital) on the quaternary N atom
accounts both for its basicity in solution and for its ability to
participate to inter-molecular H-bonding interactions.
ac
rm
om
y o
occurred through a proton transfer from the nitrogen atom to one of the
two kojic oxygen donor atoms. The resulting optimized structure is
stabilized by an O\H⋯O hydrogen bond linking the two kojic residues.
On the contrary, in the case of L6, optimized with the piperazine spacer
disposed in a chair configuration, such stabilization did not occur and
therefore the optimization of the N-protonated species is feasible. The
optimized structure of L6 displays metric parameters close to those
previously calculated for related systems [19]. In particular, the two
C\O distances of each donor groups show significantly different
ifferentWiberg
ctively).
oxygen atoms
/HOMO-2 and
Fig. 6. ESI-MS spectrum of AlIII–L5 complexes.
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both ligands have been studied in their N-protonated fo
L6, respectively), with the deprotonated oxygen donor at
to the kojic acid moieties. In the case of L4−, the geometrFig. 7idic media,
s (L4− and
s belonging
ptimization
distances (1.217 and 1.262Å, respectively), reflected in d
bond indices [36] (average value 1.681 and 1.373, respe
Filledmolecular orbitals can be found localized on the
of the kojic residues. In particular, the couples HOMO-3. ESI-MS spectrum of AlIII–L6 complexes.
HOMO-1/HOMO exhibit large contributions from the symmetric and
antisymmetric combinations of the 2p oxygen atomic orbitals laying
on the plane of the 4H-pyran-4-one ring and perpendicularly to it,
respectively (Fig. 8), which feature remarkable negative natural charges
(−0.575 and−0.769 e), being therefore available to coordinate the AlIII
centers.
Based on potentiometric and 1H-NMRmeasurements, the complexes
featuring 2:3metal:ligand ratioswere also optimized for the two ligands.
In the binuclear cation [Al2(L4−)2]3+ (corresponding to the Al2L3H3
ab
Å.
oxy
nds
anc
av
distances of 1.257(1) and 1.291(6) Å and Al\O distances of 1.897(9)
and 1.95(1) Å [average 1.92(3) Å]. The complex is stabilized by three
hydrogen bonds established between the N\H group of the protonated
spacers and the hydroxyl groups of the hydroxymethyl substituents of
each 4H-pyrane ring.
The structure of [Al2(L6)3]6+ shows very similar structural features.
The different nature of the spacer between the two kojic residues in
each ligand unit results in a larger separation between the two AlIII
centers (8.091Å) and also in this case the two C\O bonds within each
(2) Å; average
on the metal
[Al2(L4−)2]3+
larized nature
t on the global
, L7 and L8, as
ied their effect
ed 67Ga-citrate
adiotracer. The
its distribution
5 μmol of each
Fig. 8. Drawings of the isosurfaces of Kohn–Sham HOMO (A), HOMO-1 (B), HOMO-2 (C) and HOMO-3 (D) calculated for L6. Contour value 0.05 e.
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the optimised Al⋯Al distance was calculated to be 6.084
coordinated in a distorted octahedral fashion by the
from three deprotonated kojic acid units of different liga
In each kojic unit, the two optimized C\O dist
corresponding Al\O are statistically different, withe and clearance
on with that of
0 as well as in
iron-chelating
same animal
n.
stration of the
he radioactive
f radioactivity
odifications on
nhancement of
of radioactivity
that induced a
he distribution
induce slower
s, at 1 h after
el of plasmaticFig. 9. Drawing of the optimized structure of the complex [Al2(L4−ove pH 3.9)
Each AlIII is
gen atoms
(Fig. 9).
es and the
erage C\O
donor unit feature different distances [1.260(4) and 1.31
Al\O distance 1.93(3) Å].
Finally, an examination of the net positive charge
centers calculated at NBO level (1.999 and 2.003 e for
and [Al2(L6)3]6+, respectively) testifies for the very po
of Al\O bonds in both compounds, which is independen
charges of the two complexes.
3.5. Biodistribution studies
To evaluate the efficacy of the new ligands L4, L5
chelating agents for mobilization of metal ions, we stud
on the usual biodistribution profile of the well-establish
in female mice after intravenous administration of the r
tissue distribution of this radiotracer was compared to
with simultaneous intraperitoneal administration of 0.
ligand solution.
The effect of this series of chelators on the 67Ga uptak
on the major organs and on the excretion, in comparis
the 67Ga-citrate, can be overviewed graphically in Fig. 1
Table 2. The influence of the commercially available
drug, deferiprone (DFP), previously evaluated in the
model [43], was also included in this graphic presentatio
Analysis of these results shows that the co-admini
ligands interferes in the usual tissue distribution of t
metal in mice enhancing the overall excretion rate o
from whole animal body. The four ligands can induce m
the 67Ga biodistribution pattern with the same trend, e
its total excretion. No significant differences in the rate
elimination were found, except by administration of L7
slower excretion. The most important differences in t
profile are related with the blood clearance. L7 and L8
clearance from blood than the other two compound
administration, which may be attributed to a highest lev)3]3+.
protein binding. Consequently highly irrigated organs like the heart,
lungs and kidneys also present the highest radioactivity levels.
This improvement in the elimination rate of the radiotracer makes
evident the ability of the ligands to coordinate in vivo with gallium,
suggesting their potential as decorporating agent of this metal.
However, high levels of radioactivity are retained in the muscle and
bone tissues which are similar to those of the radiotracer. Comparison
of our data with those of DFP indicates that the drug is able to induce
the fastest clearance from organs like muscle and bone and total
d
om
po
hel
on
the calculated pAl values (Table 1) it can be anticipated that L4 and L5
present an identical gallium chelating capacity (pAl= 11.2–11.6) while
L7 and L8 present the lowest (pAl= 9.9) and the highest (pAl= 14.4)
values, respectively (DFP presents the highest value (pAl = 16.0) [43],
due to its different N-heterocyclic nature). Interestingly, an identical
trend was found for the total metal excretion at 24h. Further differences
on the biodistribution profile could also be partially rationalized on the
basis of the predicted values for some of the pharmacokinetic properties
for ligands and complexes, namely lipophilicity, membrane crossing
lculated ligand
rationalization
d DFP present
lecular weight,
(HAS), gastro-
on membrane
Fig. 10. Biodistribution data in themost relevant organs, expressed as % I.A./organ for 67Ga-citrate (i.v. injection) and 67Ga-citratewith simultaneous intraperitoneal injection of the ligands
L4, L5, L7, L8 and DFP [43], at 1 and 24 h after intravenous administration in female mice (n=3–5).
rgan 1 h and 24 h, after
24h
120 L. Toso et al. / Journal of Inorganic Biochemistry 130 (2014) 112–121excretion.
Some rationalization of these bioassays can be aide
parameters, namely the metal chelating ability of the c
the pharmacokinetic properties of the ligands and corres
complexes. Since it is known that the Al(III) and Ga(III) c
of analogous hard ligands follows a parallel trend [43,44],
Table 2
Biodistribution data at the most relevant organs, expressed as % I.A./o
intravenous administration in female mice (n=3).
Organs I.A./organ (%)
L4 L5
1 h 24 h 1hBlood 5.0± 0.8 0.9± 0.5 6.6± 2.6
Liver 1.3± 0.4⁎ 1.4± 0.4 2.2± 0.3
Intestine 8.4± 0.8 3.0± 0.7 8.0± 1.5
Spleen 0.07±0.01 0.06±0.03 0.11±0.06
Heart 0.20±0.02 0.08±0.05 0.28±0.05
Lung 0.44±0.03 0.14±0.03 0.6± 0.2
Kidney 0.97±0.03 0.8± 0.1 1.0± 0.1
Muscle 20.0± 4.6 5.10±0.04 16.4± 1.1
Bone 13.0± 0.8 21.9± 2.5 10.5± 1.0⁎
Stomach 0.97±0.05 0.7± 0.3 0.8± 0.1
Brain 0.06±0.01 0.02±0.01 0.05±0.01
Excretion 14.5± 1.3 53.3± 4.8 14.2± 2.4
⁎ p b 0.05.by different
pounds and
nding metal
ating ability
the basis of
ability, binding with serum proteins. However, the ca
descriptors (see Table 3) [38,39] did not allow a good
match. In particular, although the monochelators L7 an
quite good similarities on some estimated properties (mo
lipophilicity, interaction with human serum albumin
intestinal (GI) absorption), considerable differences found
for 67Ga-citrate with simultaneous intraperitoneal injection of the ligands L4, L5, L7, L8 at
L7 L8
24 h 1h 24h 1 h1.0± 0.4 10.1± 2.6⁎ 1.2± 0.6 15.0± 4.6⁎ 0.6± 0.1
1.2± 0.2 2.9± 0.8 2.1± 0.3 4.6± 0.4⁎ 1.4± 0.5
3.3± 0.2 11.1± 0.7⁎ 3.0± 0.2 8.2± 1.8 3.1± 1.3
0.05± 0.02 0.2± 0.06 0.06± 0.01 0.22± 0.09⁎ 0.08±0.04
0.06± 0.01 0.4± 0.1⁎ 0.07± 0.03 0.4± 0.2⁎ 0.06±0.03
0.09± 0.05 1.3± 0.5⁎ 0.2± 0.1 1.0± 0.3 0.18±0.08
0.5± 0.1 1.2± 0.2 1.5± 0.2 1.47± 0.04⁎ 0.9± 0.1
3.4± 1.1 20.7± 1.4 7.2± 1.0 20.6± 2.4 5.9± 0.4
16.1± 1.6⁎ 13.2± 0.6 25.2± 2.6 10.7± 0.2 21.9± 1.4
0.6± 0.1 0.72± 0.01 0.4± 0.1 0.7± 0.1 0.45±0.05
0.02± 0.01 0.13± 0.04 0.02± 0.00 0.12± 0.05 0.02±0.01
53.9± 2.9 4.4± 0.1⁎ 48.0± 4.0 14.3± 4.8 57.4± 5.6
permeability and chelating capacity may have account for L7
with the lowest metal excretion capability and concomit
retention in bone, intestine andmuscles, in opposition to DFP
containing two kojic units (L4, L5 and L8) present a sim
behavior at 1 h (despite the slowest blood clearance indu
while at 24 h, L8 appears as the most efficient metal mobil
eventually due to both the higher chelating affinity and mo
efflux properties of its smaller metal complex.
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The complex formation equilibria of aluminiumIII
ligands recently synthesized and structurally character
studied by potentiometry and 1H NMR spectra. C
supporting information has been obtained from ESI-M
and quantum-mechanical calculations. The complex fo
libria of L4, L5 and L6 with AlIII are characterized by the
2:3 Al:L complex variously protonated, as the major
whole pH range. L7 is characterized by the formation
Al:L complexes, as the parent ligand kojic acid. Instead,
Al:L complex which is stabilized at high pH values by th
mixed hydroxo complexes. The pAl values of these lig
allow to remark the very good chelating qualities of lig
superior to that of the analogous L1 ligand (12.8). The rem
L4–L6, containing nitrogen atoms in the linker, show a m
efficiency, the pAl ranging from 11.1 for L4 to 11.8 for L6
contains only one kojic residue is characterized by the lo
The high efficiency of this family of ligands with respec
parent kojic acid is strongly determined by the comple
of the second kojic unit through the formation of dinucl
complexes in which each of the two aluminium ions
by two or three kojic chelating moieties. Studies in mice
high in vivo metal sequestering power of the bischelators
with the correspondingmonochelator. The excellent chela
recommend further toxicological and pharmacological re
new promising ligands.
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Abstract: This work reports the 
synthesis, characterization and study of 
complex formation equilibria of the 
new ligand 6,6'-(2-
(diethylamino)ethylazanediyl)bis(meth
ylene)bis(5-hydroxy-2-hydroxymethyl-
4H-pyran-4-one) with Fe
III
, Al
III
, Cu
II
 
and Zn
II
. On the basis of previous 
encouraging results with tetradentate 
bis-kojic acid chelators, this ligand was 
designed to improve the 
pharmacokinetic properties: increase 
the solubility, neutral at physiological 
pH 7.4, and enhancement of membrane 
crossing ability. Fe
III
 and Al
III
 
complexation gave evidence of high 
metal-sequestering capacity of L9. 
Cellular assays showed that the ligand 
is capable of crossing cellular 
membranes and it does not present 
toxic effects. Complex formation 
equilibria with the essential metal ions 
Cu
II
 and Zn
II
 have 
been furthermore 
studied to evaluate 
disturbances of this 
chelator on the 
homeostatic 
equilibria of these 
essential metal ions. 
The variety of used techniques 
(potentiometry, UV-vis 
spectrophotometry, 1D and 2D NMR 
spectroscopy, ESI-MS, quantum 
mechanical calculations and X-ray 
diffraction) allowed to obtain the 
structural characterization of the ligand, 
and of its iron and zinc complexes, 
along with an exhaustive picture of the 
protonation and complex formation 
solution equilibria.  
 
Keywords: Kojic acid • FeIII and 
Al
III• CuII and ZnII • Solution 
equilibria
 
Introduction 
In the frame of our research on chelating agents for iron and 
aluminium,[1] a set of kojic acid (KA) derivatives were synthesized 
and the complex formation equilibria with these two trivalent metal 
ions were fully characterized.[2] The principal features of these 
ligands (Scheme 1) are i) the presence of two coordinating groups 
associated with two kojic units, heterocycles containing a pair of O-
donor atoms due to a carbonyl and a vicinal hydroxyl group, which 
allow the ligands acting as tetradentate chelators (except KA and 
L7); ii) the formation of binuclear Fe2L2 and Fe2L3 complexes of 
high stability; iii) the remarkable increase of iron binding affinity 
compared with the parent KA.  
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Scheme 1. Chemical structures of ligands KA, L1-L8. 
Literature search on iron chelating agents shows a preponderant 
interest, on one side, towards bidentate and tridentate chelators, 
apparently due to the better adequacy of their characteristics to the 
requirements of an oral drug (permeability, molecular mass, etc); on 
the other side, towards the not orally active hexadentate chelators, 
which form the most stable complexes. Archetypes of these ligands 
are those in clinical use for the treatment of iron overload in 
thalassemic patients, bidentate Deferiprone, tridentate Deferasirox, 
and hexadentate Desferal. Minor attention has been devoted towards 
tetradentate chelators, presumably because denticity two and three 
allow the formation of octahedral mononuclear complexes FeL3 and 
FeL2. However, by mimicking the natural rhodotorulic acid, a bis-
hydroxamate siderophore,[3] a number of tetradentate ligands have 
been proposed to date as potential FeIII chelators, namely bis-
hydroxamates,
[3] bisphosphonates,[4] bis(3-hydroxy-4-pyridinone),[5] 
and a bis-(kojic acid) derivatives, similar to L1 and L8 (Scheme 1), 
recently proposed by Zhu et al.[6] The molecular weight of these 
ligands is generally below the limit of 500 g/mol suggested by 
Lipinski’s rule of five and pFe values are in the range 18–21. In 
order to completely fulfill the hexacoordination of ferric ion, the 
denticity of these ligands requires formation of polynuclear species, 
invariably found in these systems. In particular, the most common 
polynuclear complex is the dimer Fe2L3, with a charge depending on 
the ligand structure. The tetradentate chelators we proposed display 
the following features: 
1. The length of the linker and the molecular conformation do not 
allow that the ligand acts as a tetradentate ligand toward a single 
FeIII ion; nevertheless, in all cases the tetradentate nature of the 
ligand favors the formation of dinuclear complexes Fe2L2 or 
Fe2L3. In particular the complex of stoichiometry FeL2 found 
with L1 and L8, of exceptionally higher stability than that of the 
corresponding FeL2 complexes with KA and L7, should be 
better hypothesized as Fe2L4. This complex should be 
structurally thought as a central Fe2L2, further coordinated by 
one ligand on each iron through one KA moiety, satisfying its 
octahedral coordination. 
2. The formation of Fe2L2 or Fe2L3 complexes seems dictated by 
the length of the linker. Linker constituted by a free or 
substituted methylene group (L1, L2, L3 and L8) allows two 
ligands bridging the two iron atoms, while a longer chain 
permits the formation of a helicate, in which three ligands 
completely satisfy FeIII octahedral coordination. Similar Fe2L3 
complexes are formed by the natural siderophores rhodotorulic 
acid and synthetic analogues.[3] 
3. The possible conformations related to the length of the linker are 
shown in Scheme 2: conformation 1, accessible when the length 
of the linker allows the tetradentate chelation on the same iron 
ion by the same ligand (bis(3-hydroxy-4-pyridinone)-IDA 
derivative);[5] conformation 2, which is obtained with linkers too 
short with respect to the above requirements, but long enough to 
allow the formation of a helicate in which the three ligands 
completely satisfy the hexacoordination of the two iron atoms 
(L4, L5, and L6); conformation 3, in which a too short linker 
does not allow the formation of the above helicate (L1, L8).  
 
 
Scheme 2. Conformation of iron complexes with tetradentate chelators. 
 
4. These tetradentate chelators join the advantages of being small 
enough to allow membrane permeability (MW < 500 g/mol) and 
requiring, for complete iron hexacoordination, an amount 1.5 
times that of chelatable iron, i.e. between the value 1 for 
hexadentate chelators and 2 and 3 for tridentate and bidentate 
chelators, respectively.  
We have synthesized a new ligand, 6,6'-(2-
(diethylamino)ethylazanediyl)bis(methylene)bis(5-hydroxy-2-
 3 
hydroxymethyl-4H-pyran-4-one), termed L9a (Scheme 3), similar to 
L4 and L5, and bearing a diethylaminoethyl group on the nitrogen 
atom in the linker, instead of methyl or benzyl groups, with the aim 
of improving the solubility and having a neutral molecule at pH 7.4. 
In the present work the characterization of this new ligand and of its 
FeIII and AlIII complexes is presented. The study of the complex 
formation equilibria with the essential metal ions CuII and ZnII, 
whose homeostatic equilibria could be perturbed by iron and 
aluminium chelation, is furthermore reported.  
 
Scheme 3. Chemical structure of ligand L9 
 
With the aim of estimating the possible perturbations of the 
homeostasis of essential metal ions induced by an iron chelator, the 
total amounts of these metal ions in the body, and that of the ligand, 
should be evaluated, and some assumptions made: a beta 
thalassemic patient of 60 Kg, who receives 45 blood units annually, 
has a transfusion iron intake of about 9 g iron/year, corresponding to 
0.4 mg Fe/Kg body weight/day; a further gut absorption 0.07 mg 
Fe/Kg body weight/day can be assumed, for a total of 0.47 mg 
Fe/Kg body weight/day that corresponds to 8.4 mol Fe/Kg body 
weight/day. To reach a steady situation between assumed iron 
(transfusion + ingestion) and excreted iron, the necessary amount of 
chelating agent should be provided (at least 8.4 mol chelator/Kg 
body weight/day in the case of Desferal that forms a 1:1 complex, 
twice in the case of Desferasirox that forms a 1:2 complex and three 
times in the case of Deferiprone that forms a 1:3 complex). A survey 
of clinical doses shows that a large excess (4-10 times) is used. On 
the other hand, zinc and copper concentrations are evaluated as 1.5 
× 10-5 M.[7] In fact, the total zinc concentration circulating in plasma 
has been assumed according the “Report of the Task Group on 
Reference Man”,[8] and in the case of copper, according to Linder et 
al..[9] These estimates are the necessary bases to evaluate how a 
given iron chelator can affect copper and zinc homeostasis once the 
complex formation stability constants are known for all the involved 
metal ions.  
Results and Discussion 
Synthesis and crystal structure of the ligand L9: The synthesis of 
ligand L9 follows a methodology similar to that recently reported,[2c] 
involving a multicomponent condensation of a non-enolizable 
aldehyde, a primary amine and a cyclic enol, to afford an 
aminoalkylated product (Mannich type reaction). The iminium 
intermediate of the reaction between the amine and aldehyde 
carbonyl is the acceptor of the reaction with the enol carbon. In 
particular, L9 was prepared by 2-alkylation of two kojic acid (KA) 
                                                 
aL9 is a diprotic acid. In the formulae we will represent L9 as LH2, and L
2- for its 
completely deprotonated form. 
units with a double imine backbone, due to reaction of two 
formaldehyde equivalents with the primary amine (N,N-diethyl-
ethylenediamine), resulting the formation of the N-functionalized 
dimeric KA derivative. Since the bearing tertiary amine of the 
primary amine reactant molecule could act as base catalyst of the 
reaction there was no need of extra base addition. 
The crystallization of L9 from water solutions yielded colourless 
crystals of stoichiometry L9•2H2O belonging to the P21/c space 
group. In the lattice L9 exists as a zwitterion crystallized in 
dihydrate form (Figure 1).  
 
Figure 1. Asymmetric unit in the crystal of L9•2H2O ligand. Intramolecular H-
bonding interaction in the zwitterion L9 and the stabilizing role of the O2-water 
molecule are plotted in dashed lines. Ellipsoides are drown at 50 % probability level. 
 
The H-onium atom comes from the O8(phenolate) group and 
was located in the difference Fourier map on the N20 tail/terminal 
atom of the ethylenediamine arm. The N+–H group further 
cooperates in the intermolecular interaction, N20–
H20···O8(phenolate) (2.675(3) Å, 167.3°). Hence the ‘onium H20-
atom’ falls inside of a distorted tetrahedral surrounding (NC2O). All 
C=C and C–O bond distances in kojic rings of L9 are equivalent and 
have usual values (Table S1.2). Shortest C–C bond distances than 
typical C(sp2)–C(sp2) distance and longest C=O bond lengths than 
typical C(sp2)=O in 4-H-pyran-4-one rings bring out the aromaticity 
of a typical benzene ring system although enables π-electronic 
delocalisation that ensures its planarity. L9 zwitterion adopts a 
folded conformation with the two kojic moieties piled one upon 
another as a consequence of a week π,π-stacking interaction between 
them (that is featured by a short ring-ring centroid-centroid distance 
= 3.50 Å but with an open interplanar dihedral angle of 20.44º). This 
conformation is further stabilized by two water mediated hydrogen 
bonding interactions, connecting the O2-H bonds to the 
O7(phenolate) and O17(hydroxyl) acceptor atoms. To enable such 
water mediated interactions and minimize steric hindrances related 
to the hydroxylmethyl moieties, the kojic rings are rotated nearly 
180º to each other. 
In the crystal lattice of L9, pairs of adjacent zwitterions are 
symmetrically connected by intermolecular H-bonds which involve 
hydroxylmethyl and keto kojic groups (Table S1.3, Figure2-left). 
Likewise adjacent of zwitterionic pairs are associated by additional 
intermolecular H-bonding interactions where water molecules (O1) 
and keto-kojic groups, as well as the phenol and hydroxylmethyl 
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groups, are involved, building a 3D H-bonded network (Figure 2-
right). 
 
Figure 2. Pair of molecules of L9 connected through symmetrical H-bonding 
interactions (left), 3D network of L9 in the ac plane (right). 
 
Protonation equilibria: The protonation equilibria of the ligand 
have been studied by potentiometry, UV-vis spectrophotometry and 
1H-NMR spectroscopy. The protonation constants were evaluated by 
potentiometric titration at 25 °C and 0.1 M KCl ionic strength, and 
by 1H-NMR spectroscopy for the very acidic log β4. These values 
are reported in Table 1, and the corresponding distribution curves 
are shown in Figure 3. 
 
Table 1. Protonation constants evaluated from the potentiometric 
titration at 25 °C and 0.1 M KCl ionic strength. 
Species log β log K 
LH- 10.81(1) 10.81 
LH2 19.04(2) 8.23 
LH3
+ 25.99(2) 6.95 
LH4
2+ 26.50(4)* 0.512 
2 This value has been evaluated from 1H-NMR spectra at variable pH. 
 
Figure 3. Speciation plot of ligand L9 calculated with the protonation constants in 
Table 1. 
 
Ligand L9 is characterized by four protonation constants, 
corresponding to the two kojic phenolates and the two nitrogen 
atoms in the linker. A protonation sequence of the ligand, based on 
the spectrophotometric and 1H-NMR results, can be proposed.  
 
Figure 4. Selected absorptivity spectra collected during the spectrophotometric 
titration of L9 in the pH range 5.0 - 10.0 relative to the second and third protonation 
steps (CL9 = 3.0 × 10
−4 M, 0.2 cm optical path length) (left). Absorptivity spectra of the 
four differently protonated forms of L9 calculated on the whole set of spectra (pH 0.5-
12)[12, 31] (right). 
The results of the potentiometric-spectrophotometric titration 
presented in Figure 4 left allow some considerations:  
The spectra of L9 look similar to those of KA, with a near 
double intensity due to the presence in L9 of two KA units. In KA, 
the L- and LH species are characterized by UV bands at 315 nm ( = 
5900 M-1cm-1) and 270 nm ( = 8700 M-1cm-1), respectively, with 
sharp isosbestic points at 242 nm and 290 nm.[2a] 
The first deprotonation (pK = 0.51), which causes a negligible 
effect on the band at 270 nm, allows to undoubtedly attribute this 
deprotonation to one of the two nitrogen atoms. Actually, the band 
presented at pH 5.0, corresponding to the LH3
+ species, is quite 
similar to that of the protonated species LH of KA, and does not 
change during the first deprotonation (the maximum is shifted with 
respect to KA from 270 to 274 nm,  = 15000 M-1cm-1).  
From pH 5.0 to 10.0, the second and the third deprotonations 
take place, along with a substantial decrease of the band intensity at 
270 nm, and a concomitant increase of that at 320 nm, allowing to 
attribute these deprotonations to the phenol groups in the KA units. 
In particular, the intensity of the band at 277 nm decreases in about 
one half of its height during the second deprotonation (dashed line 
spectra), with the simultaneous increase of the new band at 322 nm, 
with sharp isosbestic points at 246 nm and 298 nm. During the third 
deprotonation (continuous line spectra) a further decrease in the 
intensity of the band at 276 nm and an increase in the intensity of 
that at 322 nm take place. The band at 322 nm also shows a slight 
red shift and its  value is about twice that of the corresponding 
band of fully deprotonated KA.[2a] 
No evident spectral variations take place at pH > 10 during the 
fourth deprotonation (Figure 4 right), which can be therefore 
ascribed to the loss of a proton from the second nitrogen atom. The 
above attributions are supported by the absorptivity spectra 
calculated for the four species using the HypSpec program on the 
spectra collected from pH 0 to pH 12.[31] 
The trends of the 1H-NMR chemical shifts of the different 
protons versus pH, analyzed with the program HypNMR,[32] have 
allowed both to refine the value of log 4 (related to a log K4 = 0.51, 
not reliably determinable from potentiometric measurements) and to 
obtain the intrinsic chemical shifts of the various protons in the 
differently protonated species, reported in Table 2. 
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Table 2. a) Intrinsic chemical shifts of the different protons in L9 ligand in the 
differently protonated species, calculated with HypNMR. b) Variations of the intrinsic 
chemical shifts connected to each deprotonation step.  
O
O
H
O
H
N
N
O
O
H
O
H
O
O
A
A
B
B
C
D
E
E
F
F
G
 
a) Intrinsic chemical shift (  
Species A B C D E F G 
L2- 0.84 2.40 2.60 2.52 3.77 6.29 4.37 
LH- 1.20 3.12 3.20 2.96 3.74 6.17 4.26 
LH2 1.22 3.15 3.28 2.99 3.79 6.27 4.31 
LH3
+ 1.26 3.26 3.35 3.09 3.86 6.36 4.35 
LH4
2+ 1.13 3.15 3.50 3.47 4.28 6.34 4.29 
 
 
 
b) Variation of  
Deprotonation A B C D E F G 
LH-L2- 0.36 0.72 0.60 0.44 -0.03 -0.12 -0.11 
LH2LH
- 0.02 0.03 0.08 0.03 0.05 0.10 0.05 
LH3
+LH2 0.04 0.11 0.07 0.10 0.07 0.09 0.04 
LH4
2+LH3
+ -0.13 -0.11 0.15 0.38 0.42 -0.02 -0.06 
 
We also report the variations of the intrinsic chemical shifts 
during each deprotonation step (Table 2b). These last values allow 
the unambiguous assignment of the first and the forth deprotonation 
steps to the nitrogen atom on the linker and to the nitrogen atom in 
the lateral chain respectively. In fact, in the first deprotonation 
(LH4
2+ LH3
+) the most affected protons are E and D while in the 
forth the most affected protons are B and C, and, in a less extent, A 
and D.  
 
Cellular assay: Two different cellular lines (PK1 and HepG2) have 
been used both to evaluate the toxicity of L9 and its the ability to 
enter the cellular membranes. After adding L9 to cells growing 24 h 
in a complete medium, the amount of ligand entered into the cells 
was evaluated at different times.  During the first two hours, 3.6  
0.7 µmol of ligand were absorbed by PK1 cells, and 0.8  0.2 by 
HepG2 cells. After 6 h from the beginning, PK1 cells absorbed 4  2 
µmol of L9, and HepG2 cells 1.9 0.1 µmol. The final 
determination at 24 h showed an absorption of 7.4  0.6 µmol by 
PK1 cells, and 5.6  0.8 µmol by HepG2 cells. The experimental 
error evaluated on triplicate measurements on different cell cultures 
comes from the different number of cells in each culture. The used 
concentration of ligand was not toxic at all for both cellular lines, 
actually, no apoptotic cells were observed in the cells growing 
vertically. 
 
Iron complexes 
Crystal structure of Fe2L3 complex with the ligand L4: In the 
absence of crystal structure of the iron complex with L9, we have 
decided to present the structure of corresponding complex with L4 
as its surrogate, which will also allow to infer useful insights on the 
coordination geometry of this kind of tetradentate chelators. In fact 
L4 differs from L9 just for a methyl group instead of the 
diethylaminoethyl moiety as the nitrogen substituents of the linker. 
The chelating properties of L4 toward iron were previously 
presented,[2c] together with a set of analogous ligands. 
Fe2L43 crystallizes (monoclinic, C2/c) as an hydrated complex 
salt according to a formula [Fe2(2-HL)3]Cl3·nH2O. In the crystal 
structure solution only four water molecules have been localized 
meanwhile the remaining highly disordered solvent molecules have 
been removed during the structure refinement. The dinuclear cation 
complex (Figure 5) contains slightly distorted octahedral FeIII 
centres, which are bridged by three zwitterionic 2-HL
- ligands. 
Each ligand supplies O-keto and O-phenolate donors from a kojic 
moiety to a FeIII atom building a planar five-membered chelate ring. 
We can assume that the univalent anionic form of L4 tautomerizes, 
with transference of the ‘acid’ proton from one O(phenol) kojic 
group to the central N(tertiary) atom, in order to use both anionic 
kojic moieties as bidentate chelating groups for two FeIII centres. In 
this manner, the anticipated octahedral coordination of each FeIII 
atom (with 3d5 electronic configuration) is fully accomplished by 
three halves of the L4 ligand (as monoanionic groups) in a neutral 
surrounding. This coordination provides FeIII centres with a 
noticeable resistance against potential hydrolytic processes and 
polymerization reactions. The three positively charged N-
ammonium moieties of the HL4 ligands per dinuclear complex are 
compensated by the three chloride counter anions to provide the 
electro neutrality of the salt.  
The tris(kojic) moieties associated to each metal centre are 
further connected by H-bonding interactions involving O10 and O11 
water molecules and the hydroxy group from two symmetrical L4 
ligands (O4 and O24 acceptor atoms). Furthermore, the tris-chelate 
moieties exhibit fac configuration with dihedral angles between 
planar kojic rings ranging from 64.35º to 89.86º and with the 
hydroxymethyl groups pointing towards the carbon atom of the 
kojic rings in position 3. These features are in good agreement with 
other tris-chelate complexes containing KA as bidentate ligand 
reported previously.[2a] 
The helical nature of the tris-chelate moiety confers chiral 
properties and therefore Δ/Λ isomerism is expected. In the dinuclear 
structure, a mirror plane bisects the complex cation, passing through 
the N12, N32 and N52 atoms and therefore, both isomers Δ and Λ 
are present. The propeller structure is further stabilized by H-
bonding interactions between the ‘oniom’ N+–H groups (N32 and 
N52) and the ‘linker’ O10 and O11 water molecules. One of the 
most striking features of this structure is that the three chlorine 
anions and two water molecules are located endohedrally in the 
cavity build inside the complex by the three ligands and two FeIII 
centres.
Table 3. Complex formation constants of L9 with the four examined metal ions 
Fe Al Zn Cu 
Species log  Species log  Species log  Species log  
[Fe2L2H4]
6+ 60.3(1) [Al2L3H5]
5+ 76.02(2) [ZnLH]+ 18.17(2) [CuLH2]
2+ 25.38(2) 
[Fe2L3H3]
3+ 78.1(2) [Al2L3H4]
4+ 70.5(8) ZnL 10.75(3) [Cu2L2H2]
2+ 46.42(2) 
[Fe2L3H2]
2+ 72.4(2) [Al2L3H3]
3+ 65.0(1)   [Cu2L2H]
+ 39.23(5) 
Fe2L3 55.3(1)     Cu2L2 31.11(3) 
      [Cu2L2H-1]
- 20.84(4) 
      [Cu2L2H-2]
2- 10.29(3) 
pFe 17.7 pAl 10.3 pZn 7.6 pCu 9.7 
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Figure 5. Asymmetric unit in the crystal of [Fe2(2-HL)3]Cl3·nH2O complex of iron with 
L4 ligand. The stabilization of the complex conformation by H-bonding interactions is 
plotted. Ellipsoides are drown at 50 % probability level. 
 
-stacking interactions build ribbons that extend parallel to the 
b axis, involving symmetry related kojic rings (those containing O46 
atoms). These ribbons are reinforced by -OH···Cl interactions 
(Figure 6 left). Additional H-bonding interactions between water 
molecules and the remaining of O-acceptor finished the 3D array 
that exhibits an overall solvent accessible volume/cell of 1708 Å3 
(namely 26%) where the disordered water molecules are located 
(Figure 6 right). 
 
Figure 6. Detail of a ribbon generated by -stacking interactions between symmetry 
related kojic moieties (left) in the crystal structure of [Fe2(2-HL)3]Cl3·nH2O. 3D 
network in the ac plane showing voids (right). 
 
Formation equilibria of iron complexes: The complex formation 
equilibria of ligand L9 with FeIII have been studied by combined 
potentiometric-spectrophotometric techniques. The estimation of 
reliable complex formation constants from potentiometric data alone 
was not possible, since the FeIII was almost completely complexed 
when mixing reagents before the base potentiometric titrations. 
Therefore the complex formation equilibria have been studied both 
in strong acidic medium (pH 0–2) and in the pH range 2–10, using 
different sets of solutions with known amount of acid and base. The 
Evolving Factor Analysis[12] of spectra collected from pH 0 to pH 
2.5 for the 1:1, 1:2 and 1:3 iron/ligand molar ratios allowed the 
observation of a minor species with a maximum at pH ~ 2 and a 
second species whose intensity increases up to pH 4. The amount of 
the minor species in the three different solutions is proportional to 
iron concentration; furthermore the absorptivity spectrum of this 
species strictly resembles that of the 1:2 complex of FeIII with 
KA.[2a] The absorptivity of the spectra of the second species agrees 
with that expected for a Fe2L3 complex; in this case the spectra 
resemble those of FeL3 complex with KA, confirming that iron 
atoms are fully hexacoordinated. Analysis of the whole set spectra 
in the acidic range with HypSpec[31] has allowed the calculation of 
the complex formation constants for [Fe2L2H4]
6+and 
[Fe2L3H3]
3+reported in Table 3.  
The analysis of potentiometric titrations with Hyperquad,[12] 
setting constant the previously determined stability constants, 
allowed to obtain the complex formation constants of the variously 
protonated [Fe2L3Hn]
n+ complexes (Table 3). In the [Fe2L2H4]
6+ 
species the two iron atoms are each one coordinated by two KA 
units of two different ligands, both protonated on the nitrogen atoms, 
i.e. each iron atom has a coordination environment similar to that of 
iron in the 1:2 complex FeL2 with KA.
[2a] In the [Fe2L3H3]
3+ 
complex a third L9 ligand saturates iron hexa-coordination, similar 
to that found for the structure of Fe2L3 isolated with the ligand L4 
(see Supporting Information), all the ligands being protonated at the 
more basic terminal nitrogen atoms. These three protons are 
progressively lost with pK 5.7 (the first), and pK 8.5 (the remaining 
two). These values, respectively 5.1 and 2.4 pK units lower than that 
determined for pure ligand, are accounted for by the different 
charges of the molecules (-1 in the free ligand and +3 and +2 in the 
complexes respectively). 
 
 
Figure 7. Speciation plots of complexes formed by L9 with the four examined metal 
ions (Me = Fe, Al, Cu, Zn), calculated at [L] = 2 × 10-3 M and [Me] = 1 × 10-3 M using 
the complex formation constants reported in Table 3. 
 
The peaks of the complexes with iron in ESI-MS spectra, Figure 
8, confirm the previous findings. The intensity of the free ligand 
peak is one order of magnitude higher than that of the complex 
peaks. The signal at m/z 478.103 derives from the dinuclear complex 
with stoichiometry [Fe2L2]
2+, the signal at m/z 506.071 is in 
excellent agreement with the simulated signal of [Fe3L2]
2+ complex, 
and the peak at m/z 690.195 is the product of reaction between three 
ligands and two iron ions [Fe2L3H2]
2+. ESI-MS spectra further 
confirm the [Fe2L3H2]
2+ species calculated in the potentiometric 
studies. The peak at m/z 613.18 is possibly originated by the two 
ligands, two iron ions and one kojic-amine linker molecule; such a 
complex could be the product of decomposition of [Fe2L3]
2+complex 
in ESI-MS, and it suggests strong affinity of KA to the iron ions in 
the complex. It is noteworthy that dimeric complexes with water 
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molecules are not present, in opposition to what happened with 
other KA derivatives.[2b] 
 
Figure 8. ESI-MS spectra of the system L9-FeIII. 
 
Aluminium complexes 
 
Formation equilibria of aluminium complexes: The lower 
stability of aluminium with respect to the iron complexes allowed to 
evaluate the complexation model and the relative constants in Table 
3 from the potentiometric data alone. The species [Al2L3H5]
5+ , 
observed at low pH values similarly to the [Fe2L3Hn]
n+ iron 
complexes, has the three most basic nitrogen atoms protonated, as 
well as two of the least basic nitrogen atoms on the linker. These 
later two protons are lost, the first one to give [Al2L3H4]
4+ and the 
second one to give [Al2L3H3]
3+
, with the same pK 5.5, while the 
same protons are lost in the free ligand at the very acid pK 0.51. The 
strong increase of basicity of the nitrogen atom in the linker could 
be explained referring to a complex structure similar to that reported 
in Figure 5 for the FeIII-L4 complex: the involvement of two –NH+ 
groups in the linker in hydrogen bonding with two water molecules 
well accounts for the permanence of these protons up to pH 5.5. The 
1H-NMR spectra collected at the two 2:1 and 3:2 ligand/aluminium 
molar ratios and at variable pH confirm the potentiometric results 
and allow to detail them. The spectra recorded at pH ≈ 2 for both 2:1 
and 3:2 L9-Al systems do not show differences as compared to 
those of the free ligand, in agreement with the potentiometric data; 
in fact, the first species starts to form at pH above 2.5. At pH 4 the 
spectra show remarkable differences between that of the free ligand 
and that of [Al2L3H5]
5+ species. A similar behavior in terms of 
changes in the chemical shifts is found at pH 5.9, where the main 
species is [Al2L3H4]
4+. Whereas at 2:1 L9-Al ratio a remarkable 
amount of the free ligand is still visible in the spectra, no signals 
attributable to the free ligand are observed at 3:2 ratio, in agreement 
with the proposed species (Figure 9). 
The degeneracy of the two methyl proton signals (triplet) A is 
still present and the signals moved to higher fields (= -0.49 ppm). 
Methylene group B (quartet) loses its degeneracy and splits into two 
sets of broadened peaks, B' (= -0.46) and B'' (= -0.82), both 
shielded. The C protons (triplet), compared to D (triplet) (= 0.02), 
are strongly shifted to higher fields (= -0.95), and both broadened. 
Two doublets (E' and E'') originating from the non equivalent 
methylene protons E, appeared after AlIII binding. Their geminal 
protons H1 (= -0.26) and H2 (= 0.44) are now distinguishable 
and shifted in the opposite directions compared to the overlapping 
signals (Figure 9 and Figure 10). The geminal protons H1 and H2 
become magnetically non-equivalent upon coordination, whereas 
the two methylene groups from (Ar-)CH2 (E' and E'') are in the same 
chemical and magnetic environment. This behavior suggests the 
presence of a rigid but symmetric structure of these complexes. The 
singlet signals of G (= 0.27) and F (= 0.60) protons resulted 
deshielded and thus shifted down field upon AlIII interaction. Carbon 
chemical shift changes are the following: A (= -0.32), B (= 
0.43), C (= 0.55), D (= -2.26), E (= 3.24), F (= -3.20), G 
(= 0.59). 
 
 
Figure 9. Aromatic and aliphatic region of 1H 1D spectra for the free L9 ligand at pH 
4.3 (a), and for L9-AlIII system, 3:2 molar ratio, at pH 4.3 (b), at pH 5.9 (c), 7.9 (d) and 
9,1 (e), respectively. Assignments for the free ligand are shown by capital letters (a). 
The new resonances after AlIII interaction with L9 ligand are indicated by arrows and 
capital letters (b). 
 
The chemical shift table with the complete set of resonances for 
the free and AlIII bound status of L9 ligand, including carbon nuclei, 
is available as Supporting Information (Table S4). 
 
 
Figure 10. Selected aliphatic region of 2D 1H-13C spectrum for the free L9 ligand 
(orange), and L-AlIII system, 3:2 molar ratio (blue), at pH 4.3. The spectrum is similar to 
that obtained at pH 5.9. The new resonances of L9 upon AlIII interaction are indicated 
by orange arrows and capital letters. 
By raising the pH from 7.9 on, the spectra show a considerable 
increase in the complexity of the system deriving from several 
species, which can be in a dynamic equilibrium in the NMR time 
scale. In addition, at very high pH (above 8), precipitation 
phenomena, probably due to the formation of hydroxyl species and 
to hydrolysis reactions (yellowing of the solution), prevent any clear 
interpretation of the spectra. The ESI-MS spectrum of ligand-
aluminium solutions shows different peaks (Figure 11), which can 
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be attribute to [LH2 + H]
+(not present in the figure), [Al2L2]
2+, 
[Al2L2(KA-amine)]
2+,  and [Al2L3H2]
2+ species. The intensity of free 
ligand is twice stronger than the intensity of the complexes with 
metal ions. The m/z values of the molecular ions are in excellent 
agreement with the calculated masses. The complex [Al2L2(KA-
amine)]2+ confirm strong affinity of kojic acid unit to the metal ion 
and the importance of amine linker. As long as no evidence of the 
minor species [Al2L2]
+2 was given by potentiometric and 1H-NMR 
measurements,  we suggest that dinuclear complex [Al2L2]
2+. is only 
the breakdown product of [Al2L3H2]
2+. It is noteworthy that water 
complexes of our ligand with aluminum and iron  ions are not 
present in ESI-MS spectra. The reason of such a phenomenon could 
be the formation of [M2L3H2]
2+ in which the presence of water 
molecules is restricted.  
 
 
Figure 11. ESI-MS spectra of the system L9-AlIII. 
 
Copper complexes 
Formation equilibria of copper complexes: The potentiometric 
data were fitted with the model reported in Table 3, which is 
consistent with the ESI-MS results described below, except for the 
existence of a CuL complex at low pH. These data can be accounted 
for by the visible absorptivity spectra reported in Figure 12, 
calculated from spectral data with the HypSpec program[31] using 
stability constants in Table 3. It has to be remarked that the spectral 
data were collected at higher concentrations than in potentiometric 
measurements due to experimental requirements. 
 
 
 
Figure 12. Absorptivity spectra of copper complexes. 
 
These spectral data with the results from quantum mechanical 
calculations will be the basis of the structural hypothesis below 
discussed. According to ESI-MS spectrum (Figure 13), L9 forms 
copper complexes of different stoichiometry, whose presence is 
confirmed by the signals at m/z 486.106, 549.035, 577.054, 602.236, 
718.072 and 971.202 assigned to [Cu2L2H2]
2+, [Cu2LH]
+, 
[CuLH(amine)]+, and [Cu2L2H]
+, respectively. Free ligand peak (not 
shown in the figure) is present in the spectrum with intensity one 
order of magnitude higher than that of the complexes. The m/z 
values of calculated and experimental isotopic patterns are in perfect 
agreement. The species [Cu2L]
+ in which one ligand is able to 
coordinate two copper ions was not detected by potentiometric 
analysis, while complexes [Cu2L2H2]
2+  and [Cu2L2H]
+ were 
calculated in potentiometric studies. The peak at m/z 602.236 
corresponds to a complex of one copper ion, one ligand and the 
amine of the linker, while peak at m/z 718.072 represents a complex 
of one copper ion, one ligand, and the amine of the linker. Such 
complexes is probably a breakdown product of [Cu2L2H]
+ during 
the ESI-MS experiment, remarking the strong affinity of amine 
linker to the copper ion in the complex.  
 
 
Figure 13. ESI-MS spectra of the system L9-CuII. 
 
Zinc complexes 
Crystal structure of ZnL9 complex: The 1:1 complex between 
ZnII and L9 has been isolated in the compound of stoichiometry 
[ZnL(H2O)]·2.6H2O (Figure 14). In this complex, the Zn
II atom 
exhibits a trigonal bipyramidal coordination where the equatorial 
plane is defined by two O-phenolate (kojic) and the tail/terminal-
N20(ethylenediamine) atoms from dianionic form of L9 ligand 
(Table S2.2). The coordination polyhedron is accomplished by the 
O1-aqua ligand and one head-N(ethylenediamine) atom as trans-
apical donors. Hence, L9 displays a tripodal-tetradentate chelating 
role. The equatorial donor atoms (N1, O19 and O30) define an 
almost equilateral trigonal surrounding (strictly an isosceles triangle 
with O19···O30 separation (3.487 Å) > N1···(O19 or O30) ones 
(2.443 Å)). Consistently, the sum of the equatorial coordination 
angles is (359.87º) approximately 360º. Thereby the ZnII atom is 
minimally displaced (0.042 Å) from the trigonal plane toward the 
closest apical O-aqua donor as well as the ‘open’ dihedral angle 
between the kojic ring (116.68º) is close to 120º. In the complex the 
ethylenediamine chelate ring of L9 adopts a -puckered 
conformation with a small bite angle (N1-Zn1-N20) of 84.35º. 
The O-aqua and all donor atoms of L9 feature a hard base 
behaviour according to the Pearson’s criterion, whereas the ZnII 
atom is unambiguously considered a borderline Pearson’s acid[33] 
due to its relatively small ionic radius (0.74 Å) and in spite of the 
filled [Ar]3d10 electronic configuration.[34] The bipyramidal trigonal 
coordination is rather common for ZnII (by its 3d10 electronic 
configuration and ionic size) but is also related to the partial 
protonation and conformational constraints of the L9 chelating 
ligand. As indicated in the experimental section, besides the water 
molecules localised in difference Fourier maps, the crystal of the 
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complex has disordered water molecules (0.6 molecules per 
complex unit) filling voids of the lattice (Figure 15-right). 
 
 
Figure 14. Asymmetric unit in the crystal of ZnL9 complex of stoichiometry 
[ZnL(H2O)]·2.6H2O. Ellipsoides are drown at 50 % probability level. 
 
In the crystal complex molecules build ribbons by weak ,-
stacking interactions between symmetry related anti-parallel kojic 
moieties (Figure15-left). These ribbons are further stabilised by H-
bonds between the O17(hydroxymethyl) and the O15(keto) groups. 
Moreover, additional H-bonding interactions involving aqua ligands, 
hydroxymethyl groups as well as water molecules connect ribbons 
giving rise to a 3D architecture (Figure 15-right). 
 
 
Figure 15. Detail of a ribbon generated by ,-stacking interactions between kojic 
moieties (left). 3D network in the bc plane showing voids (right). 
 
Formation equilibria of zinc complexes: The analysis of 
potentiometric data for the zinc complex formation gives evidence 
of a [ZnLH]+ complex that is transformed in ZnL with a pK value of 
7.42. Taking into account the structural results, it can be 
hypothesized that in the first complex [ZnLH]+, the zinc ion is 
coordinated by the phenolate on one of the kojic moieties and by 
both nitrogen atoms, being the second phenolic group still 
protonated. This phenol group loses its proton with a pK 7.42, about 
0.8 pK units lower than the pK 8.23 in the free ligand, accounting 
for the different charges of the molecules from which the proton is 
lost (0 in the free ligand and +1 in the complex). The potentiometric 
results did not give evidence of the dinuclear complexes Zn2L2 
pointed out by ESI-MS. According to ESI-MS results, L9 ligand 
forms with zinc ions mono- and dinuclear complexes. The high 
intensity peaks at m/z 487.105, 520.059 and 603.236 are in 
agreement with [ZnL]+, [Zn3L2]
2+ and [ZnLH(amine)]+ complexes, 
respectively. As mentioned above, evidence of [ZnLH]+ complex 
was given by potentiometry. The peak at m/z 603.236 corresponds to 
a complex of one zinc ion, one ligand, and the amine of the linker. 
Such complex is surely an ESI-MS breakdown product of [Zn2L2H]
+ 
complex, not revealed by potentiometry neither by 1H NMR. Such a 
complex remarks the strong coordination between the amine group 
on linker and zinc. Two other signals at 720.071 and 821.173 m/z 
can be attributed to further breakdown products, [Zn2L(KA)]
+ and 
[Zn2L(KA)(amine)]
+ complexes with strong affinity both of KA and 
amine linker to the metal ion. The free ligand peak (not reported in 
Figure 16) is ten times more intense than signals of the complexes. 
 
 
Figure 16. ESI-MS spectra of the system L9-ZnII. 
 
NMR spectra of 1:1 ligand-zinc solutions were recorded at 
different pH values (Figure 17).The spectrum recorded at pH 2.5 
(Figure 17 a) shows that ZnII ions do not interact with the ligand, in 
agreement with potentiometric data, which show that the first 
species [ZnLH]+ appears at pH around 4 and it is visible until pH 10, 
reaching its maximum concentration at pH around 6 (Figure 7). 
 
 
Figure 17. Aromatic and aliphatic region of 1H 1D spectra of L-ZnII system, 1:1 molar 
ratio, at different pHs. Assignment of L9 free ligand is showed by capital letters (a). The 
new resonances of L9 ligand upon ZnII interaction is showed by orange, blue and green 
labels related to the three species (d).  
 
NMR measurements are consistent with this model. In fact, the 
spectrum at pH 4.7, where ZnLH species should be present at low 
concentration (less than 10%), reveals the beginning of ZnII-ligand 
interaction, with some new low intensity signals appearing in the 
spectrum (Figure17 b). By raising the pH the intensity of these 
signals increases, reaching a maximum at pH around 6.3 (Figure17 c, 
d, e), in agreement with speciation curves (Figure 7). The 1D and 
2D HSQC spectra (Figure18) confirm the remarkable differences 
between free ligand and ZnII complexes.  
Protons belonging to A, B, C, D groups show minor chemical 
shifts, which can result from a shielded environment. In particular, 
the two methyl proton signals (triplet) A, overlapped in the free 
ligand, shift to higher fields, giving the three triplets A', A'' and A'''. 
Chemical shifts differences at pH 5.9 (= bound-free (ppm) for 
proton and carbon nuclei) are A' (H= -0.26, C= -0.19), A'' 
(H= -0.41, C= 0.16) and A''' (H= -0.35, C= -0.09). The 
new resonances of methylene groups B (quartet), shifted to higher 
fields, remain in overlap, B'=B'' (H= -0.42, C= 0.47). C 
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protons (triplet) exhibit three signals, C' (H= -0.70, C= 1.28), 
C'' (H= -0.58, C= -0.43) and C''' (H= -0.70, C= -1.64). D 
protons (triplet) move slightly, whereas the corresponding carbon 
experiences a large chemical shift variation (H= -0.09, C= -
1.75). The new set of signals from B, C and D groups become 
broadened; the relative broadness of the signals in the ligand-metal 
system suggests the presence of exchange processes. 
 
 
Figure 18. 2D 1H-13C spectra for the free L9 ligand (orange), superimposed to L9-ZnII 
system, 1:1 molar ratio (blue), at pH 5.9. The new resonances of L9 after ZnII 
interaction are also indicated. 
 
The two nonequivalent methylene protons E (their pairs of 
geminal protons H1 and H2 are overlapped in the free ligand), after 
ZnII binding, appear separated in three set of doublets of doublets 
with a distinguishable NMR resonance, E' (H2= 0.36, H1= -
0.35, C= 3.88), E'' (H2= 0.28, H1= -0.25, C= 2.89) and 
E''' (H2= 0.57, H1= 0.07, C= 3.94). ZnII addition results in a 
deshielded environment of G and F groups. Their signals are 
downfield shifted, appearing as a new set of three signals 
characterized by the chemical shift changes G' (H= 0.09, C= 
0.48), G'' (H= 0.34, C= 0.70), G''' (H= 0.15, C= 0.45); F' 
(H= 0.30, C= -1.69), F'' (H= 0.39, C= -0.75), and F''' 
(H= 0.30, C= -1.69). 
In conclusion, 1D and 2D NMR spectra recorded in the pH 
range 5.15 - 6.30, where ZnLH is the predominant species, show for 
this system three main signals of comparable intensity, instead of 
the single one of the free ligand. Since the only species evidenced 
by potentiometric measurements is ZnLH, the presence of at least 
three species detectable in the NMR timescale has to be attributed to 
coordination isomers of ZnLH species in a dynamic equilibrium. 
AROESY experiment[b] performed with a mixing time of 200 ms, at 
298 K, confirmed the three isomers in a dynamic exchange (Table 
S4). 
Variable temperature NMR spectra of L-ZnII system, at 1:1 
molar ratio and pH 6.3, were obtained in the range 296-332 K and 
are shown in Figure 19. The coalescence of three sets of isomer 
peaks is clearly observed. 
                                                 
[b] ROESY (the rotating frame NOESY) is commonly used to monitor exchange 
processes: protons exchanging on the NMR time scale can be observed as off-
diagonal signals. 
 
Figure 19. Selected VT-NMR spectra of L-ZnII system, 1:1 molar ratio, at pH 6.3. 
 
According to speciation curves (Figure 7), two species exist at 
pH 7.5 ([ZnLH]+ 60% and ZnL 40%), the spectra of L-Zn system 
present a more complex situation, probably complicated by the 
presence of different species in equilibrium among them (Figure17 
g). At higher pH (above 8.8) precipitation phenomena occur 
probably from the formation of zinc hydroxy species (Figure17 h, i). 
The spectra therefore resemble those of the free ligand, even if some 
shifts of the NMR signals are noticed. In particular, the loss of 
degeneracy for the two geminal methylene protons H1 and H2 for E, 
together with some shifts for B, G and F groups, have to be 
remarked. This fact is indicative of an equilibrium of metal ion 
between hydroxyl and L9 species. 
 
Theoretical Calculations: DFT calculations have been exploited 
successfully on a plethora of chemical systems, ranking from simple 
organic compounds to complex species involving transition or main 
group metals.[35] In recent works, some of the authors reported on 
the application of QM calculations at DFT level on iron and 
aluminium complexes of ligands containing the Kojic units. In 
particular, the relative stabilities of AlIII and FeIII complexes 
featuring the 2,2′-[(2-hydroxy-3-methoxyphenyl)methanediyl]bis[3-
hydroxy-6-(hydroxylmethyl)-4H-pyran-4-one] and 2,2′-[(4-
hydroxy-3-methoxyphenyl)methanediyl] bis[3-hydroxy-6-(hydroxyl 
methyl)-4H-pyran-4-one] ligands were investigated.[2b] The results 
reported previously prompted for a DFT investigation on the species 
discussed in this work.  
The structure of the ligand L9 was optimized starting from the 
structural data discussed above. The pattern of the metric parameters 
optimized for L9·H2O is in good agreement with the structural data, 
and confirms the role of the water molecule in the conformation and 
the stability of the species as an inner zwitterion. Not only the bond 
distances are correctly optimized, but also non-bonding interaction 
are well-reproduced by the adopted computational set-up. In 
particular, the O···C shortest distance between atoms belonging to 
the two planar Kojic rings, was optimised at 3.230 Å (experimental 
value 3.317 Å, see below). The N···O distance between the nitrogen 
atom of the diethylaminoethyl arm and the C–O group of one of the 
two Kojic moieties (N20···O8 in Figure 1), whose interaction is 
mediated by an hydrogen bond, is well reproduced [calcd. 2.726; 
structural value 2.675(3) Å], although the optimized structure 
describes the system as a N···H–O group rather than a N–H···O one 
(N-H-O angle: calcd. 156.90°).  
While the stoichiometry and the stability of the differently 
protonated species of iron and aluminium species are clearly 
understood on the grounds of mass spectrometry and UV-vis 
spectroscopy, the nature of copper and zinc species is less clearly 
defined, and therefore theoretical calculations have been carried out 
 11 
to shed a light on the structural features of the possible species 
present in solution. 
 
 
Figure 20. Optimized geometry at DFT level of Cu(L)(H2O) (a) and of the isomer of 
[Cu(LH)(H2O)2]
+ featuring the L9 protonated at the terminal diethylamino group (b). 
Hydrogen atoms have been omitted for clarity. 
 
The geometry of the ligand prevents the saturation of the 
coordination of CuII, hence differently hydrated forms have been 
studied. The neutral complex with stoichiometry CuL(H2O), 
featuring both Kojic moieties deprotonated, was optimized in the 
doublet ground state starting from the structural data collected for 
the corresponding Zn complex (see above), where both Kojic units 
interact with the same metal center. In CuL(H2O) the copper ion 
shows a distorted trigonal bipyramidal coordination geometry 
(Figure 20a), achieved by the two unprotonated nitrogen atoms (Cu-
N 2.239 and 2.233 Å), by two carbonyl groups of the Kojic donors 
(Cu-O 1.907 and 1.937 Å), and by a water molecule, strongly 
interacting with a free oxygen atom of one Kojic ring (Owater···OKojic 
2.717 Å; O-H···O 162.37°). It is worth noting that in this complex 
the copper also shows a short distance with the carbon atom of a 
carbonyl donor (C···Cu 2.569 Å), analogously to what found in 
different CuII complexes featuring phenolic donors in strained 
conformations.[36] A second water molecule in compound 
CuL(H2O)2 does not lead to a variation in the coordination sphere of 
the metal ion, but interacts with the first water molecules and one of 
the oxygen atoms of the Kojic rings through hydrogen bonds.[c] 
Protonation of a free Kojic oxygen provides the complex with 
stoichiometry [Cu(LH)(H2O)]
+. In this species, the central metal ion 
preserves the coordination geometry described above for CuL(H2O), 
with only small variations in the pattern of bond lengths and angles 
(Cu-N 2.309 and 2.191; Cu-Okojic 1.908 and 1.964; Cu-Owater2.046). 
A second isomer of the same cationic complex, less stable than the 
former by about 7 kcal mol–1, can be obtained by protonation at the 
nitrogen atom on the diethylaminoethyl arm, which is the least 
acidic site in the free ligand according to spectroscopic, 
potentiometric, and NMR measurements discussed above (see 
Figure 3). In this case, the Cu center shows a distorted square-planar 
coordination, achieved by two trans-disposed carbonyl groups (Cu-
O 1.907 and 1.882 Å), the available nitrogen donor of the spacer 
                                                 
[c] The bridging interaction of the second water molecule is thermodynamically favored, 
and is calculated to involves a |rH°| = 19.1 kcal mol
–1 (Table S5.1 in Supporting 
Information). 
 
(Cu-N 2.173 Å), and the water molecule (Cu-O 2.000 Å; N-Cu-O, 
86.41 and 89.85°; OKojic-Cu-Owater 103.40 and 85.037°; OKojic-Cu-
OKojic 164.15 °). The addition of a second water molecule to the 
latter complex yields the species [Cu(LH)(H2O)2]
+(rH° = 19.3 kcal 
mol–1 at 298.15 K) showing the copper ion in a trigonal bipyramidal 
coordination (Figure 20b), the axial positions being occupied by the 
two carbonyl groups of the kojic donors (Cu-O, 1.916 and 1.899 Å; 
OKojic-Cu-OKojic 172.74 °), and the equatorial ones by the free N 
donor atom (Cu-N 2.172 Å) and the two water molecules (Cu-O 
2.139 and 2.206 Å). Such a species provides a conceivable model 
for the CuLH2 species detected in solution at acidic pH values. 
Finally, an attempt was made to optimize a dimeric species, 
identified in alkaline solutions (Figure 7). In the neutral complex 
Cu2L2 optimised in its triplet ground state,
[d] the aminic nitrogen 
atoms and two Kojic carbonyl groups bridge the two copper ions, 
whose coordination is completed by the phenolic oxygen atoms of 
the remaining Kojic units to give a pseudo-trigonal bipyramidal 
coordination at the metal centers (Figure 21). Hence, each copper 
ion is coordinated by two aminic nitrogen donor atoms (average Cu–
N, 2.145 Å), by one carbonyl group of a Kojic ring (average Cu–O, 
1.937 Å) and two bridging carbonyl groups (average Cu–O, 2.117 
Å) as a part of an elongated Cu2O2 diamond core, where the two 
metal centers do not interact directly significantly (Cu···Cu distance 
3.344 Å; Wiberg bond index 0.013). 
 
 
Figure 21. Optimized geometry at DFT level of the complex Cu2L2. Hydrogen atoms 
have been omitted for clarity. 
 
DFT calculations have been also applied on the Zn species 
deriving from the L9 ligand. The structural parameters from the 
crystal structure of the compound ZnL(H2O) (see above) were used 
to model the mononuclear complex. The optimized structure show 
metric parameters very close to the experimental ones [Calcd. Zn-
N1 2.357, Zn-N20 2.106, Zn-O1 2.111, Zn-O8 1.968Å, Zn-O16 
1.931Å; exp. Zn-N1 2.263(3), Zn-N20 2.091(3), Zn-O1 2.115(3), 
Zn-O8 1.973(3), Zn-O16 1.927(3) Å; see Figure 14 for numbering 
scheme]. Accordingly, the ZnII ion shows a trigonal bipyramidal 
coordination, only slightly distorted with respect to that established 
by single crystal X-ray diffraction. Calculations have been extended 
to the species ZnL, not including a water molecule in the 
                                                 
[d]The triplet state is calculated to be more stable than the singlet state by about 19.1 
kcal mol–1 in the total electronic energy (Table S5.1). 
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coordination sphere of the metal ion.[e] In ZnL, the metal ion is 
tetrahedrically coordinated and shows, as expected, bond distances 
slightly shorter than those calculated for Zn(L)(H2O) (Zn–OKojic, 
1.894 and 1.895; Zn–N 2.114 and 2.138 Å]. Protonation of the L9 
ligand in the Zn complex leads to the cationic species 
[Zn(LH)(H2O)]
+. As discussed above for the copper isologue, 
protonation can be theoretically achieved by protonation on the 
terminal diethylamino N pendant or by O-protonation on a free 
Kojic oxygen. In the former case, the ZnII ion shows a tetrahedral 
coordination by the water molecule (Zn–O 2.117 Å), two carbonyl 
groups (Zn–O 1.862 and 1.898 Å) and the amino group of the spacer 
(Zn–N 2.172 Å). In the latter case, the coordination of the 
corresponding neutral species is preserved, with only a modest 
increase in the distance between the metal ion and the oxygen atom 
of the ring featuring the protonated group (Zn-N1 2.391, Zn-N20 
2.097, Zn-O1 2.073, Zn-O8 2.004, Zn-O16, 1.943 Å). Notably, a 
comparison in the total electronic energy of the two isomers (see 
ESI) shows that the second isomer, at least in the gas phase, is more 
stable than the N-protonated isomer by about 33 kcal mol1, in 
concordance with what it was observed for the corresponding 
copper species. 
The stability of such L-protonated species supports the 
hypothesis that these could represent structural models of the 
species ZnLH identified in solution (Table 3 and Figure 7). 
Conclusion 
The results presented herein, involving several solid state and 
solution techniques for the study of complex formation between a 
new amine-bearing bis-kojic acid and four metal ions, highlight the 
different coordination schemes adopted towards two trivalent hard 
metal ions (iron and aluminium) and two borderline divalent ions 
(copper and zinc). For the complexes with the hard metal ions, only 
chelation with both hydroxypyrone (O,O)-donor atoms is implied in 
the coordination, whereas for complexes with the borderline 
divalent ions, the nitrogen atoms of both the linker and the side-
chain amine groups, together with oxygen atoms of phenolate 
groups, are involved in metal coordination, the carbonyl oxygen 
atoms being not involved. The detailed knowledge of speciation of 
L9, free and bonded to the four target metal ions, is of great value 
for giving a picture of its bioavailability and behavior in chelation 
treatments.  
One of the main requirements of a metal chelator for clinical use 
is the selectivity toward the target metal ion, which takes into 
account the contemporary physiological presence of a number of 
essential metal ionsf.  
As a general rule, the used doses of iron chelators in clinical 
treatments, planned to reach a steady state between assumed and 
excreted iron, are five-ten times higher than the necessary 
stoichiometric amount. This excess, intended to overcome the 
                                                 
[e]A comparison of the total electronic energies of [ZnL] and [Zn(L)(H2O)] (Table S5.1) 
shows that the reaction enthalpy at room temperature of the process [ZnL] + 
H2O → [Zn(L)(H2O)] is favoured by 24.9 kcal mol
–1. 
 
f A ligand can be surely considered selective toward a given metal ion Me when the 
corresponding pMe value is at least 4 units greater than that with any other metal 
ion; i.e. an excess concentration of a competitive metal ion 103 times greater 
than that of the target metal ion interferes less than 10% with Me chelation. 
quantity of chelator not bioavailable (because of incomplete 
absorption, metabolism, etc.), surely perturbs the homeostatic 
equilibria of essential metal ions. Actually, even with Zn2+ that is 
the metal ion that forms the less stable complexes, an extremely low 
excess concentration of L9 (10-6 M), is able to chelate zinc (10-6 M) 
at 66% that in this complexed form is ready to be excreted. It is 
therefore to be remarked that while on one hand selectivity assures 
that iron chelation is not perturbed by the presence of essential metal 
ions, on the other hand the required excess of chelating agent can 
surely constitute a problem for the homeostatic equilibria of 
essential metal ions. This last point in our opinion has been 
undervalued in chelation therapy, whereas it deserves particular 
attention mainly in long life iron overload treatments.  
Experimental Section 
Reagents: Kojic acid, N,N-diethyl-ethylenediamine, NaOH, KOH, FeCl3, ZnCl2, 
CuCl2
.H2O, AlCl3, methyl alcohol, and ethyl alcohol were purchased from Aldrich, 
formaldehyde from Merck, HCl from Fluka, KCl from Carlo Erba (Milan, Italy), and 
Desferal from Biofutura Pharma. All the reagents were used without any further 
purification. Carbonate free 0.1 M KOH solution was prepared as previously 
described.[10] The metal ion standard solutions were prepared by dissolving the required 
amount of chloride salts in pure double distilled water to which stoichiometric amounts 
of HCl were previously added to prevent hydrolysis. All metal solutions were 
standardized by EDTA titration, except the iron solution, which was standardized by 
spectrophotometric analysis as Desferal complex. 
Synthesis of ligand, 6,6'-(2-(diethylamino)ethylazanediyl)bis(methylene)bis(5-
hydroxy-2-(hydroxymethyl)-4H-pyran-4-one): N,N-diethyl-ethylenediamine (0.98 
mL, 7 mmol) and aqueous formaldehyde (36%, 2.6 mL, 15.5 mmol) were mixed with 
ethyl alcohol (96%, 20 mL) for 30 min; this solution was added drop wise to a solution 
of kojic acid (2.0 g, 14.1 mmol) in ethyl alcohol(96%, 30 mL) and then the reaction 
mixture was stirred at room temperature for 5h (reaction followed by TLC, using as 
eluent a 6:0.7 CH2Cl2/MeOH solution). The mixture was then evaporated in a rotavapor 
under vacuum. Addition of ethyl alcohol (99.5%), followed by refrigeration for 2 h, lead 
to formation of a light yellow precipitate, which upon filtration and washing with cold 
ethyl alcohol, afforded the pure final product (2.00 g, 67% yield); M.p. 142-143°C;1H-
NMR (D2O): δ 6.35 (s,2H), 4.39 (s, 4H), 3.88 (s, 4H), 3.38 (s, 2H), 3.26 (s, 4H), 3.10 (s, 
2H), 1.32 (s, 6H); ESI-MS: 425.2 (MH+). Elemental analysis (%) calculated for 
C20H28N2O8: C 54.29; H 6.83, N 6.33; found: C 54.00, H 7.16, N 6.34. 
Analysis of the synthesized ligand: Elemental data were obtained using a Fisons 
EA1108 CHNS/O within the limit of ±0.4%. NMR spectra were recorded on a Bruker 
AVANCE III 300 MHz spectrometer. Chemical shifts (δ) were reported in ppm from 
the internal reference 3-trimethylsilyl-propionic acid-d4 sodium salt (DSS) The mass 
spectra (ESI-MS) were obtained by a 500 MS LC Ion Trap (Varian Inc., Palo Alto, CA, 
USA) mass spectrometer equipped with an ESI ion source, operating in the positive and 
negative ion modes. 
Spectrophotometric-potentiometric measurements: Protonation and complex-
formation equilibrium studies were carried out at the same conditions previous 
described.[11] The operating ligand concentrations ranged from 3 × 10-4 to 3 × 10-3 M. 
Complex formation studies were performed using constant ligand concentration, and 1:1, 
1:2 and 1:3 metal/ligand molar ratios. Combined potentiometric-spectrophotometric 
measurements were performed for protonation equilibria in the 200-400 nm spectral 
range and in the 400-800 nm range for FeIII complexation, using 0.2 and 1 cm path 
lengths, respectively. Protonation and complex formation data were analyzed using the 
Hyperquad program.[12] 
ESI-MS analysis of complexes: All MS experiments were performed on a Bruker 
microTOF-Q spectrometer (BrukerDaltonik, Bremen, Germany), equipped with an 
Apollo II electrospray ionization source with an ion funnel. The instrument parameters 
were: scan range m/z 250- 2000, dry gas – nitrogen, temperature 200 °C, ion source 
voltage 4500 V, collision energy 10 eV, analyte aqueous solutions (70 μL) were 
introduced at a flow rate of 3 μL/min. The ligand was incubated with the inorganic salts 
(AlCl3, Fe(NO3)3, CuCl2 and ZnCl2) at equimolar concentrations (1 × 10
-4 M) for 10 h at 
room temperature before the measurements. The instrument was calibrated externally 
with the Tunemix (tm) mixture (Bruker Daltonik, Germany) in the quadratic regression 
mode. The mass spectrometer was operated in the positive ion mode. Each spectrum 
was obtained with more than 100 individual scans. The overall charge of the analyzed 
ion was calculated on the base of distance between isotopic peaks. The formulae of the 
complexes were determined by application of the Compass Data Analysis (Bruker 
Daltonik, Germany) program. 
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NMR spectroscopy: NMR experiments were performed on a Bruker AscendTM 400 
MHz spectrometer equipped with a 5 mm automated tuning and matching broad band 
probe (BBFO) with z-gradients. The samples used for NMR experiments were 5 mM 
D2O solutions. All NMR experiments were carried out at 298 °K in 5 mm NMR tubes. 
The solution pH, corrected for the deuterium isotopic effect, was adjusted with diluted 
DCl and NaOD on a pH meter Crison micro TT 2050 with an electrode Mettler Toledo 
InLab 422. The pD values measured for the D2O solutions were converted to the pH 
values using the deuterium isotopic correction pH = pD–0.4.[13] The concentration of 
zinc or aluminium ions was achieved by using a stock acidic deuterated aqueous 
solution of zinc and aluminum chloride. The metal ions were added to L9 ligand 
solutions and the pH was then set to the right value just before the acquisition of spectra. 
2-D 1H-13C heteronuclear correlation spectra (HSQC) were acquired by using a phase-
sensitive sequence employing Echo-Antiecho-TPPI gradient selection with a 
heteronuclear coupling constant JXH = 145 Hz, and shaped pulses for all 180° pulses on 
f2 channel with decoupling during acquisition; sensitivity improvement and gradients in 
back-inept were also used.[14] Relaxation delays of 2 s and 90° pulses of about 10 μs 
were applied in all experiments. Solvent suppression for 1D 1H, 2D 1H-1H TOCSY 
(total correlation spectroscopy) and 1H-1H ROESY (rotating-frame overhauser effect 
spectroscopy) experiments was achieved by using excitation sculpting with gradients. 
The spin-lock mixing time of TOCSY experiment was obtained with MLEV17.[15] 1H-
1H TOCSYs were performed by using mixing times of 60 ms. A combination of 1D, 2D 
TOCSY, HSQC and ROESY experiments was employed to assign the signals of both 
free and metal-bound ligand at different pH values. All NMR data were processed with 
TopSpin (Bruker Instruments) software and analyzed by Sparky 3.11[16] and MestRe 
Nova 6.0.2 (Mestrelab Research S.L.) programs. 
Crystal structure determination: Measured crystals were prepared under inert 
conditions immersed in perfluoropolyether as protecting oil for manipulation. Suitable 
crystals were mounted on MiTeGen MicromountsTM and these samples were used for 
data collection. Data were collected with a Bruker D8 Venture diffractometer. Data 
were processed with APEX[17] and corrected for absorption using SADABS.[18] The 
structures were solved by direct methods,[19] which revealed the position of all non-
hydrogen atoms. These atoms were refined on F2 by a full-matrix least-squares 
procedure using anisotropic displacement parameters.[19] All hydrogen atoms were 
located in difference Fourier maps and included as fixed contributions riding on 
attached atoms with isotropic thermal displacement parameters 1.2 times those of the 
respective atom. Geometric calculations were carried out with Mercury[20] and 
PLATON[21] programs, and drawings were produced with Olex2[22] and Mercury.[20] The 
solvent masking procedure as implemented in Olex2 was used to remove the electronic 
contribution of highly disordered solvent molecules from the refinement of ZnL 
complex with L9. One void was found in the unit cell and it is postulated to contain 1.2 
molecules of water.  In the case of Fe2L3 iron complex with L4ligand, although four 
water molecules were localized in difference Fourier maps, the voids in the unit cell 
contain disordered solvent at partial occupancy. A satisfactory disorder model for the 
solvent was not found, and therefore the Olex2 [21] solvent mask routine was used to 
mask out the disordered density. Additional crystal data and more information about the 
X-ray structural analyses are reported in S1, S2 and S3 as Supporting Information. 
Crystallographic data for the structural analysis have been deposited with the 
Cambridge Crystallographic Data Centre, CCDC 984048-984050 for ligand L9, zinc 
complex with L9 and iron complex with L4, respectively. Copies of this information 
may be obtained free of charge on application to CCDC, 12 Union Road, Cambridge 
CB2 1EZ, UK (fax: 44 1223 336 033; e-mail: deposit@ccdc.cam.ac.uk or www: 
http://www.ccdc.cam.ac.uk). 
Quantum chemical calculation: Density Functional Theory (DFT) calculations were 
performed on L9·H2O, H2O, and also copper and zinc complexes with stoichiometry 
CuL(H2O), CuL(H2O)2, [Cu(LH)(H2O)]
+, [Cu(LH)(H2O)2]
+, [Cu(LH)(H2O)3]
+, Cu2L2, 
ZnL, ZnL(H2O), and [Zn(LH)(H2O)]
+. All calculations were carried out with the 
commercial package of software Gaussian09[23] with the mPW1PW[24] hybrid functional 
and the full-electron Ahlrichs double- [25] with polarization functions 
(pVDZ) for all atomic species. NBO populations[26] and Wiberg bond indices[27] were 
calculated at the optimized geometries, which were verified by harmonic frequency 
calculations. Frequency calculations were exploited to derive the thermodynamic data 
summarized in Table S5.1 in Supporting Information. Reaction enthalpies rH° at 
298.15 K were obtained from total electronic energies E0 as rH° = fH
°
products –
fH
°
reagents =(E0 + Hcorr)products – (E0 + Hcorr)reagents = (E0 + Hcorr).
[28] The results of the 
calculations were examined with GaussView 5[29] and Molden 5.0[30] programs. 
Cellular assays: The human cell line HepG2 (ICLC HTL95005), was furnished by the 
“Istituto Nazionale per la Ricerca sul Cancro” (ICLC, Genova), and kidney proximal 
cell line (LLC-PK1) from the American Type Culture Collection. The used culture 
medium was a mixture of minimal essential medium with Earle's balanced salt solution 
(MEM EBSS), 10% fetal bovine serum (FBS), 100 units/mL penicillin, 100 µg/mL 
streptomycin, 2 mM L-Glutamine, 1% non-essential amino acids. Confluent cells were 
isolated using trypsin/EDTA and samples of 2-3 × 104 cells/cm2 HepG2 were plated at 
37°C, 5% CO2. After 24 h of growth with complete medium, L9 was added to the 
samples and its concentration was spectrophotometrically evaluated at different times (0, 
2, 6 and 24 h). The analytical determination of L9 has been performed on its maximum 
of absorbance in the cell growing medium at 316 nm. 
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